{
    "url": "https://www.sec.gov/Archives/edgar/data/1867066/000141057824000347/derm-20231231x10k.htm",
    "report_type": "10-K",
    "context": [
        {
            "id": 0,
            "context": "Item 1. Business\nOVERVIEW We are a commercial-stage pharmaceutical company founded in October 2014 that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Our current portfolio includes seven branded and two authorized generic prescription drugs for dermatological conditions that are marketed in the U.S. We are managed by experienced life science executives with a track record of creating value for their stakeholders and bringing novel medicines to the market, enabling patients to experience increased quality of life, and enabling physicians and other licensed medical professionals to provide better care for their patients. We aim to acquire rights to future products by licensing or otherwise acquiring an ownership interest in, funding the research and development of, and eventually commercializing, these products through our field sales organization. Since inception, we have made significant investments to build out our commercial product portfolios, which we believe, coupled with our experienced dermatology sales leadership team and our seasoned field sales force, will position our business for growth. We are a majority-owned subsidiary of Fortress.",
            "type": "paragraph"
        },
        {
            "id": 1,
            "context": "2023 Highlights and Events On December 27, 2023, we entered into a Credit Agreement (the \u201cCredit Agreement\u201d) with SWK Funding LLC (\u201cSWK\u201d). The Credit Agreement provides for a term loan facility (the \u201cCredit Facility\u201d) in the original principal amount of up to $20.0 million. On the closing date, we drew $15.0 million. The remaining $5.0 million may be drawn upon our request within 12 months after the closing date. Loans under the Credit Facility (the \u201cTerm Loans\u201d) mature on December 27, 2027 unless the Credit Facility is otherwise terminated pursuant to the terms of the Credit Agreement and bear interest at a rate per annum equal to the three-month term Secured Overnight Financing Rate (\u201cSOFR\u201d) (subject to a SOFR floor of 5%) plus 7.75%. The interest rate resets quarterly. Interest payments begin in February 2024 and are paid quarterly. Beginning in February 2026, we are required to repay the outstanding principal of the Term Loans quarterly in an amount equal to 7.5% of the principal amount of funded Term Loans. If our total revenue, measured on a trailing twelve-month basis, is greater than $70 million as of December 31, 2025, principal repayment is not required until February 2027, at which point we are required to repay a portion of the outstanding principal of the Term Loans quarterly in an amount equal to 15% of the principal amount of funded Term Loans.",
            "type": "paragraph"
        },
        {
            "id": 2,
            "context": "On August 31, 2023, we entered into a license agreement (the \u201cNew License Agreement\u201d) with Maruho Co., Ltd., a Japanese company specializing in dermatology (\u201cMaruho\u201d), whereby we granted an exclusive license to Maruho to develop and commercialize Qbrexza\u00ae for the treatment of primary axillary hyperhidrosis in South Korea, Taiwan, Hong Kong, Macau, Thailand, Indonesia, Malaysia, Philippines, Singapore, Vietnam, Brunei, Cambodia, Myanmar and Laos (the \u201cTerritory\u201d). Under the terms of the New License Agreement, Maruho paid us $19.0 million as a non-refundable upfront payment. Maruho is also obligated to make royalty payments to us related to sales of the product in the Territory equal to the corresponding rate payable by us to Dermira under the asset purchase agreement between us and Dermira.",
            "type": "paragraph"
        },
        {
            "id": 3,
            "context": "In July 2023, we announced positive topline data from our two DFD-29 Phase 3 clinical trials for the treatment of papulopustular rosacea. The Phase 3 clinical trials achieved the co-primary and all secondary endpoints, the subjects completed the 16-week treatment and the drug was well-tolerated. DFD-29 demonstrated statistical superiority over both the standard of care, Oracea\u00ae capsules, and placebo for Investigator\u2019s Global Assessment treatment success and the reduction in the total inflammatory lesion count in both studies. We summitted a New Drug Application (\u201cNDA\u201d) under Section 505(b)(2) of the United States Federal Food, Drug and Cosmetic Act (\u201cFDCA\u201d) with the U.S. Food and Drug Administration (the \u201cFDA\u201d) for DFD-29 on January 4, 2024, paying a $4.0 million filing fee, and expect potential approval from the FDA in the second half of 2024. On March 18, 2024, we announced the FDA accepted the Company\u2019s NDA with a Prescription Drug User Fee Act goal date of November 4, 2024.",
            "type": "paragraph"
        },
        {
            "id": 4,
            "context": "CORPORATE INFORMATION Journey Medical Corporation was incorporated in Delaware in 2014. Our executive offices are located at 9237 E Via de Ventura Blvd. Suite 105, Scottsdale, AZ 85258. Our telephone number is 480-434-6670, and our e-mail address is info@jmcderm.com or ir@jmcderm.com.",
            "type": "paragraph"
        },
        {
            "id": 5,
            "context": "6\n\n| \u25cf | Qbrexza\u00ae (a medicated cloth towelette for the treatment of primary axillary hyperhidrosis), acquired and launched in May 2021; |\n| \u25cf | Accutane\u00ae (an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne), licensed in July 2020 and launched in March 2021; |\n| \u25cf | Amzeeq\u00ae (minocycline) topical foam, 4% (a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and children nine years and older), acquired and launched in January 2022; |\n| \u25cf | Zilxi\u00ae (minocycline) topical foam, 1.5% (a topical minocycline treatment for inflammatory lesions of rosacea in adults), acquired and launched in January 2022; |\n| \u25cf | Exelderm\u00ae Cream and Solution (a broad-spectrum antifungal intended for topical use), acquired and launched in October 2018; |\n| \u25cf | Targadox\u00ae (an oral doxycycline drug for adjunctive therapy for severe acne), licensed in March 2015 and launched in October 2016; and |\n| \u25cf | Luxamend\u00ae (a water-based emulsion formulated to provide an optimally moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis), acquired in 2021 and launched in 2023. |\n| \u25cf | sulconazole nitrate cream and solution, 1% antifungal agents indicated for the treatment of tinea cruris and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis,* and for the treatment of tinea versicolor. *Efficacy for this organism in the organ system was studied in fewer than 10 infections. EXELDERM\u00ae Cream is also indicated for the treatment of tinea pedis (athlete\u2019s foot). Effectiveness of EXELDERM\u00ae Solution has not been proven in tinea pedis. These products were launched in January 2020; and |\n| \u25cf | doxycycline hyclate immediate release 50mg tablets, indicated as adjunctive therapy for severe acne to reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of doxycycline hyclate and other antibacterial drugs, launched in May 2018. |",
            "type": "table"
        },
        {
            "id": 6,
            "context": "Our Products and Relevant Disease StatesExcessive Underarm Sweating and the Current Standard of CareExcessive underarm sweating, commonly referred to as primary axillary hyperhidrosis (\u201cPAH\u201d), is a rare disorder characterized by excessive sweating in the armpits. The exact cause of PAH is not known, and the disorder affects males and females equally. When excessive sweating occurs as part of some other disorder, it is said to be secondary hyperhidrosis, which is a more commonly encountered condition than is primary hyperhidrosis. According to a 2016 article published in the Archives of Dermatological Research, there are approximately 10 million people who suffer from PAH in the United States. The symptoms of PAH typically begin during childhood or puberty and may often, although not always, persist throughout a person\u2019s life. Affected individuals may experience a heightened reaction to certain stimuli that can cause sweating such as anxiety, pain, exercise, tension, caffeine, and/or nicotine. The symptoms of this disorder develop due to overactivity of certain sweat glands, and incidences may be precipitated by social and/or physical stress. Some people with PAH experience relief from the symptoms during adulthood without treatment or obvious reason for the remission.Pharmacological treatment options for PAH include topical, oral and iontophoretic treatments.Qbrexza\u00ae (glycopyrronium 2.4% cloth) for the Treatment of Primary Axillary HyperhidrosisOur Qbrexza\u00ae (glycopyrronium 2.4%) product is a topical, once-daily anticholinergic cloth that was approved by the FDA in June 2018 for the treatment of PAH in adult and pediatric patients nine years of age and older. Anticholinergics are a class of pharmaceutical products that exert their effect by blocking the action of acetylcholine, a neurotransmitter that transmits signals within the nervous system that are responsible for the activation of sweat glands. Qbrexza is applied directly to the skin and is designed to block underarm sweat production by inhibiting sweat gland activation. Qbrexza has Orange Book-listed patents that extend through February of 2033.The PAH market had approximately 450,000 prescriptions in 2023 according to Symphony Health, excluding over-the-counter (\u201cOTC\u201d) clinical strength anti-perspirants.Acne and the Current Standard of CareAcne, also known as acne vulgaris, is a common skin disorder characterized by a blockage of hair follicles, which are clogged with oil and dead skin cells. According to the American Academy of Dermatology (\u201cAAD\u201d), acne is the most common skin condition in the US, affecting up to 50 million individuals annually.Approximately 85% of people between the ages of 12 and 24 experience at least a minor form of acne. The disease is classified as mild, moderate or severe based on the severity of the disease progression, which is useful in identifying an appropriate treatment regimen. Mild acne is characterized by clogged hair follicles (known as comedones) that are either exposed to air (blackheads) or closed (whiteheads), with occasional inflammatory lesions which occur primarily on the face. Moderate acne is characterized by a higher presence of inflammatory lesions known as papules and pustules across the face and extending to the trunk. Severe acne is characterized by painful, deep lesions called nodules across the face, with extensive involvement of the trunk frequently.Treatment options are based on the severity of disease, with certain drugs being reserved for more severe forms of the disease. Mild acne is addressed with dietary and lifestyle changes, along with OTC and prescription topical agents. Other therapies with varying degrees of success include dermabrasion and chemical peels, light therapy and hormonal therapy such as birth control pills or spironolactone. Moderate acne is treated with more aggressive therapy including topical and oral antibiotics such as tetracyclines, which are particularly effective due to their antibacterial and anti-inflammatory properties, and other topical agents including benzoyl peroxide and retinoids. Severe acne is treated with combination therapies, often including oral antibiotics. For resistant cases, physicians may use a potent drug known as isotretinoin (a vitamin A analog), which requires Risk Evaluation and Mitigation Strategy (\u201cREMS\u201d) (safety) monitoring with regard to pregnancy. The current U.S. market size for treatment of acne is considerable and estimated at approximately $3 billion annually, according to the American Medical Association.8",
            "type": "paragraph"
        },
        {
            "id": 7,
            "context": "Accutane\u00ae for the Treatment of Severe Recalcitrant Nodular AcneAccutane\u00ae (isotretinoin 10mg, 20mg, 30mg, and 40mg capsules USP) is indicated for the treatment of severe recalcitrant nodular acne. Accutane is used to treat a type of severe recalcitrant nodular acne that has not been helped by other treatments, including antibiotics. Severe recalcitrant nodular acne occurs when many red, swollen, tender lumps form in the skin. Patients with severe nodular acne are at higher risk of scarring. Accutane belongs to a class of drugs that affects all four major pathogenic processes in acne: increased sebum production, irregular follicular desquamation, propionibacterium acnes proliferation and inflammation. Accutane has achieved a strong market position and is well known in the dermatology community.The oral isotretinoin market had over 2 million prescriptions in 2023 according to Symphony Health.Targadox\u00ae for the Treatment of Severe AcneTargadox\u00ae (doxycycline hyclate immediate release 50mg tablets) is indicated as adjunctive therapy for severe acne, which is part of a class of oral antibiotics known as tetracyclines. The tetracycline class, which includes minocycline, doxycycline, sarecycline and tetracycline, is particularly effective in treatment for more severe forms of acne due to its antibacterial and anti-inflammatory properties. Targadox is gluten-free, lactose-free, animal byproduct-free, and GMO-free.The oral doxycycline market had more than 27 million prescriptions in 2023 according to Symphony Health.Amzeeq\u00ae for the Treatment of Moderate-to-Severe AcneAmzeeq\u00ae (4% minocycline foam), formerly known as FMX101, was approved by the FDA in October 2019 and became available in pharmacies nationwide in January 2020. Amzeeq is a once-daily novel topical antibiotic foam formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients nine years of age and older. Amzeeq utilizes proprietary MST\u2122 technology and is the first topical minocycline to be approved by the FDA for any condition. We believe that the combination of a well-established antibiotic in a well-tolerated, easy to use foam makes Amzeeq a very attractive treatment option for patients. The topical acne market had almost 21 million prescriptions in 2023 according to Symphony Health, presenting significant unmet needs of patients and healthcare providers to be addressed. As the first topical minocycline to be approved by the FDA for any condition, we believe that Amzeeq may provide a new treatment alternative for patients and healthcare providers who are unsatisfied with their current therapies. Amzeeq has Orange Book-listed patents that extend through September of 2037.Ximino\u00ae for the Treatment of Inflammatory Lesions of Non-Nodular Moderate to Severe AcneDuring fiscal 2022 and part of fiscal 2023, we marketed and sold Ximino\u00ae (minocycline hydrochloride extended-release 45mg, 90mg, and 135mg capsules), which is indicated for the treatment of inflammatory non-nodular lesions (pimples and red bumps) associated with moderate to severe acne. We discontinued selling Ximino in September 2023.The oral minocycline market had just under 2.7 million prescriptions in 2023 according to Symphony Health.Fungal Infections of the Skin and the Current Standard of CareFungal skin infections, collectively referred to as dermatomycoses, are common infections caused by ringworms (tinea) and include conditions such as athlete\u2019s foot, jock itch and ringworm of the body. Tinea pedis, commonly known as athlete\u2019s foot, is a form of ringworm that usually develops between the toes. Symptoms include peeling, cracking and scaly feet, blisters, and skin that is red, softened, itching, or burning. Tinea cruris, commonly known as jock itch, is a form of ringworm that affects the groin. Tinea corporis, commonly known as ringworm of the body, is a fungal infection that appears on the body in which the outer part of the sore might be raised while the skin in the middle appears normal. Fungal infections caused by ringworm cause skin rashes that present as itchy, red, raised and scaly rings. These infections are easily transmissible between people, pets or contaminated objects or surfaces but are usually not serious in nature.9",
            "type": "paragraph"
        },
        {
            "id": 8,
            "context": "Treatment options typically involve topical OTC and prescription antifungal medications. Where difficult to administer topically, oral options (such as for toenail fungus or oral thrush) or suppositories (such as for vaginal yeast infections) have proven to be more effective. OTC products typically include known antifungal ingredients such as clotrimazole, miconazole, terbinafine or ketoconazole. Prescription treatments are often reserved for more serious infection or for those in hard-to-treat areas. In conjunction with OTC or prescription medications, lifestyle adjustments, including daily washing of bedding and clothing during an infection, drying thoroughly after bathing, wearing loose clothing in affected areas and actively treating infected areas, can all contribute to disinfecting your surroundings and preventing a prolongation or recurrence of infection.Exelderm\u00ae for the Treatment of Fungal Skin InfectionsExelderm\u00ae (sulconazole nitrate 1%, cream and solution) is a broad-spectrum antifungal agent indicated for the treatment of ringworm-caused fungal infections including tinea pedis, tinea cruris, tinea corporis and tinea versicolor. The active pharmaceutical ingredient (sulconazole) acts by inhibiting fungal cell division and growth and has been shown to have broad activity against candida species, aspergillus species and dermatophytes. Exelderm cream or solution is administered externally only, whereby a small amount of cream or solution is gently massaged into the affected and surrounding areas and only requires a convenient once or twice daily application. However, when used to treat tinea pedis, for which Exelderm cream is also indicated, twice daily application is required.The topical antifungal market had more than 11 million prescriptions in 2023 according to Symphony Health.Pruritus (Itch) and the Current Standard of CarePruritus or itch is defined as an unpleasant sensation of the skin that provokes the urge to scratch. It is a characteristic feature of many skin diseases and an unusual sign of some systemic diseases. Pruritus may be localized or generalized and can occur as an acute or chronic condition. Itch can be caused by a number of conditions, including skin conditions such as dry skin, eczema, psoriasis, scabies, parasites, burns, scars, insect bites and hives. Depending on the cause of itchiness, skin may appear normal, red, rough or bumpy. Repeated scratching can cause raised thick areas of skin that might bleed or become infected.Treatment for itch may include moisturizing daily, using gentle cleansers, and bathing with lukewarm water. Long-term relief requires identifying and treating the underlying cause of itchy skin. Common treatments are prescription medicated creams and lotions, moist dressings, and oral anti-itch medicines.Anti-Itch Product for the Treatment of PruritusOur acquired anti-itch product is indicated to treat pruritis, scabies, and other skin itch conditions (\u201cAnti-itch Product\u201d). Our Anti-itch Product delivers prescription relief and is non-steroidal and antihistamine free. Topical steroids are effective against itch because they reduce inflammation that can cause itch. However, they are not recommended for long-term use. Antihistamines are also effective in treating some types of itch, but they too have drawbacks with continued use. We plan on launching our Anti-itch Product through our field sales force during the second half of 2024 or first half of 2025.Rosacea and the Current Standard of CareRosacea is a chronic, relapsing, inflammatory skin condition that most commonly presents with symptoms such as deep facial redness, acne-like inflammatory lesions (papules and pustules) and spider veins (telangiectasia). According to The National Rosacea Society, it is estimated that rosacea affects well over 16 million Americans (F1000Research 2018, 7(F1000 Faculty Rev):1885) and as many as 415 million people worldwide. Rosacea is most frequently seen in adults between 30 and 50 years of age. Surveys conducted by The National Rosacea Society report more than 90% of rosacea patients said their condition had lowered their self-confidence and self-esteem, and 41% reported that it had caused them to avoid public contact or cancel social engagements. Among rosacea patients with severe symptoms, 88% said the disorder had adversely affected their professional interactions, and 51% said they had missed work because of their condition. The rosacea market had 3.8 million prescriptions in 2023 according to Symphony Health.10",
            "type": "paragraph"
        },
        {
            "id": 9,
            "context": "The tetracycline class of antibiotics (minocycline and doxycycline) are considered to be effective options for the treatment of papulopustular rosacea, likely due to anti-inflammatory activities that are usually manifested at doses much lower than those prescribed for treatment of bacterial infections. A low dose of doxycycline (i.e., 40 mg taken once daily) as oral formulation has been approved for the treatment of only inflammatory lesions (papules and pustules) of rosacea and is available under the proprietary name Oracea\u00ae in the US. Oracea is generally considered to be the current standard of care. Minocycline, first introduced in 1971, is widely believed to be the most effective tetracycline agent due to its high lipophilicity, which is anticipated to permit greater permeation into, and accumulation in, the sebaceous follicles and layers of the epidermis. We offer two products, Zilxi and, if approved, DFD-29, that we believe provide a new treatment alternative for patients and healthcare providers who are unsatisfied with their current rosacea therapies.Zilxi\u00ae for the Treatment of Papulopustular RosaceaZilxi\u00ae (1.5% minocycline foam), was approved by the FDA in May 2020 and became available in pharmacies nationwide in October 2020. Zilxi is a once-daily novel antibiotic foam formulation of minocycline for the treatment of inflammatory lesions of rosacea in adults. Similar to Amzeeq, Zilxi leverages MST\u2122 technology and is the first minocycline product of any form to be approved by the FDA for use in rosacea. We believe the anti-inflammatory properties of minocycline delivered in our innovative foam technology make Zilxi a highly appealing treatment option for rosacea patients. Zilxi has Orange Book-listed patents that extend through October of 2030.DFD-29 for the Treatment of RosaceaDFD-29 is a low-dose minocycline (40 mg) extended release capsule formulation for oral use for the treatment of papulopustular rosacea. The rationale of selecting DFD-29 doses lower than the approved minocycline dose is based on the lower protein binding and higher lipophilicity of minocycline. In a Phase 1 PK study (DFD-29-CD-001) in 24 healthy subjects, the systemic exposure of minocycline from DFD-29 (minocycline HCl) ER capsules 40 mg was much lower than that seen with the approved antibiotic dose of minocycline, although this was not a head-to-head study. A Phase 2 study (DFD-29-CD-002) in 205 subjects with papulopustular rosacea, demonstrated that DFD-29 (40 mg) was significantly superior to placebo and Oracea\u00ae, on the co-primary endpoints of IGA treatment success and absolute inflammatory lesion count reduction. The study also showed DFD-29 was well-tolerated. DFD-29 has also shown superiority to Oracea and Placebo on the co-primary endpoints and all secondary endpoints in two phase 3 studies and was well-tolerated. The NDA was filed under Section 505(b)(2) of the FDCA, in January 2024 and is under review by the FDA.Luxamend\u00ae for Wound HealingLuxamend\u00ae is a water-based wound cream formulated for the dressing and management of superficial wounds; minor abrasions; dermal ulcers; donor sites; 1st and 2nd degree burns, including sunburns; and radiation dermatitis. Luxamend contains purified water, white mineral oil, ethylene glycol monostearate, stearic acid, propylene glycol, paraffin wax, squalane, avocado oil, trolamine/sodium alginate, triethanolamine, cetyl palmitate, sodium sulfate (anhydrous), potassium sorbate, methylparaben sodium, propylparaben sodium, sodium hexametaphosphate, sulfamic acid, and allergen-free fragrance. When applied properly to a wound, Luxamend provides an optimum moist environment for the healing process. It is approved as a prescription medical device and is supplied in a 114 gram tube. Our StrategyWe are a highly focused, pharmaceutical company dedicated to developing and commercializing therapies for the treatment of dermatologic conditions that seeks to deliver value to patients, physicians and the healthcare system, as well as to our stakeholders. Our strategic priorities include continuing to augment and grow our product portfolio and organization in order to maximize long-term value creation. This will consist of both commercial execution on our existing product portfolio, including lifecycle management, out-licensing of our current branded products and/or technologies in global markets, as well as investing in additional growth strategies through product and company acquisitions, licensing, or developing new products.An important part of our growth strategy is to identify new business development opportunities, including development stage and commercial drugs that we may acquire from other pharmaceutical companies. We are in various stages of discussion for other opportunities, both commercial and development stage, that could drive additional growth in the business. Successful development and commercialization of any future in-licensed development stage or commercial drugs will require us to navigate the many laws and regulations of governmental authorities and regulatory agencies around the world, including the FDA, relating to the manufacture, development, approval and commercialization of investigational drugs. For development stage drugs, we may require financial resources significantly in excess of our current cash on hand and amounts that we may borrow under our Credit Facility, and it may take many years for us to receive marketing approval, if ever, for any in-licensed or acquired product candidate.11",
            "type": "paragraph"
        },
        {
            "id": 10,
            "context": "| \u25cf | Commercial leadership of our management team with a track record of commercial execution. We have a highly skilled and customer-focused management team in critical leadership positions across our Company. Our senior management team has over 135 years of collective sales and marketing experience in the pharmaceutical industry and a proven track record of developing businesses and creating value. Members of our management team have developed, launched, commercialized, and managed brands generating over $3 billion in aggregate peak sales, collectively, at leading dermatology organizations. This experience includes improving business performance through organic revenue growth, maximizing operational efficiencies and through the identification, consummation and integration of licensing and acquisition opportunities. Our senior management team has extensive roots in the dermatology industry, with many of them having worked at and held senior positions with Medicis Pharmaceutical, Inc. leading up to the company\u2019s acquisition by Valeant Pharmaceuticals, Inc. (now Bausch Health Pharmaceuticals, Inc.) for $2.6 billion in 2012. Our strategic approach leverages our management team\u2019s experience with the capabilities of our field sales force to drive performance based on prescribing habits, brand preferences, promotional strategies and profit optimization while focusing on customer service excellence for our providers and their patients. |\n| \u25cf | Performance and experience of our accomplished field sales force. Our current seasoned field sales force has deep-rooted and longstanding customer relationships in their respective territories. We have strategically optimized our sales outreach to cover over 80% of dermatologists in the top 50 U.S. metropolitan statistical areas and over 70% of the overall dermatology prescribing market. We are able to leverage the experience of our field sales force to create a tailored and entrepreneurial compensation plan that incentivizes our field sales force and aligns their activities with our corporate performance and growth objectives. We intend to continue to build a team of committed, experienced employees and to engage with patients and members of the dermatology community. Additionally, we believe that consolidation in the medical dermatology industry has resulted in an enhanced opportunity for a medical dermatology-focused company to build relationships with these stakeholders and has made available a large and growing talent pool of experienced individuals who can make significant contributions to our Company. |\n| \u25cf | Specialized and differentiated access and distribution model. We have a specialized and differentiated access and distribution network of over 600 specialty pharmacies and wholesalers, where we directly sell our products, with limited distribution through traditional national wholesalers. This decentralized approach allows us to maximize our brand equity across our product portfolio through strategic relationships directly with pharmacies and allows us to provide exceptional customer service and access to patients and physicians. |\n| \u25cf | Active business development initiative. Business development plays a vital role in our growth strategy as we look to build scale. We consistently evaluate both synergistic acquisitions that leverage our existing infrastructure, as well as more transformative assets that would require building out or restructuring our field sales force. We have extensive relationships in the industry that help us stay abreast of developments in our space and continually monitor new opportunities. We believe that we are an ideal partner for development stage companies with limited or no commercial capabilities, as well as established pharmaceutical companies looking to deprioritize their dermatology portfolio. We regularly engage in discussions with an array of companies, including traditional large pharma, mid-size specialty pharma companies and smaller companies that focus on research and development, although we have not entered into any definitive agreements or arrangements. Another important part of our business development strategy is to continue to out-license our branded products and/or proprietary technologies in global markets. |",
            "type": "table"
        },
        {
            "id": 11,
            "context": "Major CustomersWe primarily sell our prescription products to specialty pharmacies, independent wholesalers, and distributors with limited sales through the traditional national wholesaler channels. Our wholesalers and distributors purchase products from us and, in turn, supply products to retail drug store chains, independent pharmacies and managed care organizations. Customers in the managed care market include health maintenance organizations, group purchasing organizations, nursing homes, clinics, pharmacy benefit management companies and mail order customers. License & Collaboration Agreements and AcquisitionsWe continue to seek to enhance our product line and develop a balanced portfolio of differentiated products through product acquisitions and in-licensing or acquiring rights to products and technologies from third parties. We intend to enter into strategic alliances and collaborative arrangements with third parties, which will give us rights to develop, manufacture, market and/or commercialize pharmaceutical products, the rights to which are primarily owned by these third parties. These alliances and arrangements can take many forms, including licensing arrangements, co-development and co-marketing agreements, co-promotion arrangements, research collaborations and joint ventures. Such alliances and arrangements will potentially enable us to share the risk of incurring all research and development expenses that do not lead to revenue-generating products. However, because profits from alliance products are shared with the counterparties to the collaborative arrangement, the gross margins on alliance products are generally lower, sometimes substantially so, than the gross margins that could be achieved had we not opted for a development partner. From time to time, we may also seek to grant licenses or sublicenses of rights to develop, sell and distribute our products to third parties in exchange for the payment of license fees and/or royalty payments.Environmental MattersOur operations are subject to substantial federal, state and local environmental laws and regulations concerning, among other matters, the generation, handling, storage, transportation, treatment and disposal of, and exposure to, hazardous substances. Violation of these laws and regulations, which may change, can lead to substantial fines and penalties. Many of our third-party operations require environmental permits and controls to prevent and limit pollution of the environment. We believe that the facilities of our third-party service providers are in substantial compliance with applicable environmental laws and regulations, and we do not believe that future compliance costs will have a material adverse effect on our business, financial condition, results of operations or cash flows.Employees and Human Capital ManagementWe currently employ 58 individuals, all of whom are full-time employees. We have 41 employees in sales and marketing, 14 employees in general and administrative positions, and 3 employees in research and development positions. Additionally, we have retained a number of expert advisors and consultants that help us navigate through different aspects of our business. We consider our relations with our employees to be good and have not experienced any work stoppages, slowdowns or other serious labor problems that have materially impeded our business operations.Our human capital management objectives include, as applicable, identifying, recruiting, retaining, incentivizing, and integrating our new and existing employees. The principal purpose of our equity incentive plan is to attract, retain, and motivate selected employees, consultants, and directors through the granting of share-based compensation awards and cash-based bonus awards.Geographic AreasAll of our product revenues are generated from operations or otherwise earned within the U.S. We are entitled to receive commercial milestones payments from Maruho, our exclusive licensing partner in Japan, based on certain net sales achievements for Rapifort\u00ae Wipes 2.5% (Qbrexza\u00ae), for the treatment of primary axillary hyperhidrosis. We also received a one-time upfront license payment totaling $19.0 million from Maruho during 2023 under the New License Agreement in which we granted Maruho exclusive rights to Qbrexza in Korea and other Asian countries.13",
            "type": "paragraph"
        },
        {
            "id": 12,
            "context": "Seasonality of BusinessOur business is affected by the standard annual insurance deductible resets, as well as the purchasing patterns and concentration of our customers; however, our business is not materially impacted by seasonality. There are no assurances that these historical trends will continue in the future.Relationship with FortressGeneralFortress is a biopharmaceutical company dedicated to acquiring, developing and commercializing pharmaceutical and biotechnology products and product candidates at its majority-owned and majority-controlled subsidiaries and joint ventures, and at entities founded by Fortress and in which it maintains significant minority ownership positions. Fortress has a talented and experienced business development team, comprised of scientists, doctors, and finance professionals, who identify, evaluate, and propose for our consideration promising products and product candidates. We have a nine-year operating history and we are a majority owned subsidiary of Fortress.Product Licensing Agreements and Asset AcquisitionsRapifort\u00ae Wipes 2.5% (Qbrexza)On August 31, 2023, we entered into the New License Agreement with Maruho, whereby we granted an exclusive license to Maruho to develop and commercialize Qbrexza\u00ae for the treatment of primary axillary hyperhidrosis in the Territory. Under the terms of the New License Agreement, in exchange for the exclusive rights to Qbrexza in the Territory, Maruho paid $19.0 million as a non-refundable upfront payment.On February 11, 2022, we announced that Maruho received marketing and manufacturing approval for Rapifort Wipes 2.5% (Qbrexza), for the treatment of primary axillary hyperhidrosis, triggering a net $2.5 million milestone payment to us. The net payment reflected a milestone payment of $10.0 million to us from our exclusive licensing partner in Maruho, offset by a $7.5 million payment to Dermira, pursuant to the terms of the asset purchase agreement between us and Dermira. In conjunction with the terms of the licensing agreement with Maruho, the milestone payment was due from Maruho within 30 days of the approval. We acquired global rights to Qbrexza from Dermira in 2021.Amzeeq, Zilxi, FCD105 and the Molecule Stabilizing Technology PlatformOn January 12, 2022, we entered into an Asset Purchase Agreement (the \u201cAPA\u201d) with Vyne Therapeutics Inc. (\u201cVyne\u201d) to acquire Vyne\u2019s Molecule Stabilizing Technology\u2122 franchise (the \u201cAcquisition\u201d) for an upfront payment of $20.0 million, with an additional $5.0 million payment due on the one-year anniversary of the closing of the Acquisition. The APA also provides for contingent net sales milestone payments: in the first calendar year in which annual sales reach each of $100 million, $200 million, $300 million, $400 million and $500 million, we will be required to make a one-time payment of $10 million, $20 million, $30 million, $40 million and $50 million, respectively, in that year only, per product, totaling up to $450.0 million. In addition, Journey will pay Vyne 10% of any upfront payment received by Journey from a licensee or sublicensee of the products in any territory outside of the United States, subject to exceptions for certain jurisdictions as detailed in the APA. There are no subsequent milestone payments or royalties beyond the aforementioned payments. The Acquisition included two FDA-approved products (Amzeeq\u00ae and Zilxi\u00ae), and a development-stage dermatology program (FCD105), along with the Molecule Stabilizing Technology proprietary platform.14",
            "type": "paragraph"
        },
        {
            "id": 13,
            "context": "DFD-29 AgreementOn June 29, 2021, we entered into a license, collaboration, and assignment agreement with Dr. Reddy\u2019s Laboratories, Ltd. (\u201cDRL\u201d) to obtain the global rights for the development and commercialization of DFD-29, a late-stage development modified release oral minocycline that is being evaluated for the treatment of inflammatory lesions of rosacea (the \u201cDFD-29 Agreement\u201d). We acquired global rights to DFD-29, including in the U.S. and Europe, except that DRL has retained certain rights to the program in select markets including Brazil, Russia, India, China and the Commonwealth of Independent States (\u201cCIS\u201d) countries. Pursuant to the DFD-29 Agreement, we agreed to make an upfront payment of $10.0 million, comprised of a $2.0 million payment upon execution and $8.0 million which was paid on September 29, 2021, 90 days following execution, with additional contingent regulatory, commercial, and corporate-based milestone payments, totaling up to $158.0 million. Royalties ranging from ten percent to twenty percent are payable on net sales of the product. Royalties are payable in each country until the last-to-expire patent in such country expires. Royalties are subject to a 50% reduction in the event that a generic competitor launches in an applicable country where we market and sell the product. We are responsible for the prosecution and enforcement of patents licensed under the DFD-29 Agreement. The DFD-29 Agreement contains customary representations, warranties, and indemnities, and title transfers to us on the date of achievement of certain regulatory milestones set forth in the agreement, after which our licenses become our acquired assets. Each party may also terminate the DFD-29 Agreement for material breach by the other party or for certain bankruptcy or insolvency related events. Additionally, we agreed to fund and oversee the Phase III clinical trials. From inception to date we have incurred approximately $23.8 million in costs associated with the development of DFD-29.The DFD-29 Agreement will remain in effect on a country-by-county basis until the expiration of the revenue percentage term in the relevant country, which period begins on the first commercial sale of a product in that country and ends upon the expiration or invalidation date of the last revenue generating patent in such country. The DFD-29 Agreement terminates in its entirety upon the expiry of the revenue percentage term in the last country covered under the DFD-29 Agreement.Qbrexza AgreementOn March 31, 2021, we executed an asset purchase agreement for Qbrexza\u00ae (the \u201cQbrexza APA\u201d) with Dermira Inc. (\u201cDermira\u201d), pursuant to which we acquired global ownership to Qbrexza (glycopyrronium), a prescription cloth towelette approved to treat primary axillary hyperhidrosis in people nine years of age and older. The transaction closed on May 14, 2021, and pursuant to the Qbrexza APA, we made an upfront $12.5 million cash payment to Dermira. We are obligated to make payments to Dermira of up to $144.0 million in the aggregate upon the achievement of certain milestones. For the first two years, we were required to pay royalties on sales ranging from the mid-thirty to the mid-twenty percent. Thereafter, we are required to pay royalties on Qbrexza net sales ranging from the lower teen digits to the upper teen digits, which are payable for a period of eight years ending in 2029, subject to certain reductions. The Qbrexza APA contains customary representations, warranties, and indemnities. Each party may also terminate the Qbrexza APA for material breach by the other party.As part of the Qbrexza APA, we were assigned an exclusive license agreement with Rose University (\u201cRose U\u201d) pursuant to which we obtained a worldwide exclusive license within a field of use including hyperhidrosis to practice, enforce and otherwise exploit certain patent rights, know-how and data related to Qbrexza. The license agreement with Rose U includes a sublicense of certain data and an assignment of certain regulatory filings which Rose U had obtained from Stiefel Laboratories (\u201cStiefel\u201d). In connection with the license agreement, we assumed Rose U\u2019s obligations to Stiefel to use commercially reasonable efforts to develop and commercialize products using the licensed patent rights, know-how and data.Pursuant to these agreements with Rose U and the related agreement with Stiefel with respect to Qbrexza, we are obligated to pay Rose U low-to-mid single-digit royalties on net product sales and low double-digit royalties on sublicense fees and certain milestone, royalty and other contingent payments received from sublicensees, to the extent such amounts are in excess of the milestone and royalty payments we are obligated to pay Rose U directly upon the events or sales triggering such payments.15",
            "type": "paragraph"
        },
        {
            "id": 14,
            "context": "We are permitted to grant sublicenses to the licensed rights and may assign the agreements upon our acquisition or that of our assets that relate to the license agreement. We may terminate the license agreement if Rose U experiences certain insolvency events or if Rose U commits a material breach of the license agreement, subject to applicable cure provisions. Rose U may terminate the license in certain circumstances if we experience certain insolvency events or if we commit a material breach of the license agreement or if we cause Rose U to be in material breach of its license agreement with Stiefel, subject in each case to applicable cure provisions. Subject to earlier termination, the license agreement remains in effect until 15 years following the first commercial sale of a licensed product have elapsed or, if later, the date that the last patent or patent application in the licensed patent rights has expired or been revoked, invalidated or abandoned. As of December 31, 2023, the last-to-expire issued patent relating to Qbrexza that we license under the license agreement with Rose U expires in 2029.Accutane AgreementOn July 29, 2020, we entered into a license and supply agreement for Accutane\u00ae (the \u201cAccutane Agreement\u201d) with DRL. Pursuant to the Accutane Agreement, we agreed to pay $5.0 million, comprised of an upfront payment of $1.0 million paid upon execution, with additional milestone payments totaling $4.0 million. To date, we have paid all of the additional milestone payments. Three additional milestone payments totaling $17.0 million are contingent upon the achievement of certain net sales milestones. Royalties in the low-double digits based on net sales, subject to specified reductions, are also due. The term of the Accutane Agreement is ten years and renewable upon mutual agreement. The agreement contains customary representations, warranties, and indemnities. Each party may also terminate the Accutane Agreement for material breach by the other party or for certain bankruptcy or insolvency related events and we may terminate for upon 180 days written notice to the other party. We commenced sales of this product in April 2021.Anti-Itch Product AgreementOn December 18, 2020, we entered into an asset purchase agreement for our Anti-itch Product (the \u201cAnti-itch APA\u201d) with Sun Pharmaceutical Industries, Inc. (\u201cSun\u201d). Pursuant to the Anti-itch APA, total consideration is $4.0 million, comprised of an upfront payment of $2.0 million, payable upon execution. Through December 31, 2023, we have paid $4.0 million and have no additional payment obligations. The Anti-itch APA contains customary representations, warranties, and indemnities. There are no subsequent milestone payments or royalties beyond the aforementioned payments. We intend to launch this product during the second half of 2024 or first half of 2025.Ximino AgreementOn July 22, 2019, we entered into an asset purchase agreement for Ximino\u00ae (the \u201cXimino APA\u201d) with Sun. Pursuant to the Ximino APA, total consideration is $9.4 million, with an upfront payment of $2.4 million, which was payable within 60 days after execution on September 22, 2019.Pursuant to the terms of the Ximino APA, the remaining $7.0 million is due on the second anniversary and for the next four anniversaries of the Ximino APA thereafter. In addition, we are obligated to pay royalties in the mid-single digits based on net sales of Ximino, subject to specified reductions until the end of 2022. The Ximino APA contains customary representations, warranties, and indemnities. Each party may also terminate the Ximino APA for material breach by the other party or for certain bankruptcy or insolvency related events. No additional licensing or milestone payments are required. We commenced sales of this product in August 2019. We discontinued selling Ximino in September 2023.Exelderm AgreementOn August 31, 2018, we entered into an asset purchase agreement for Exelderm\u00ae (the \u201cExelderm APA\u201d) with Sun. Pursuant to the Exelderm APA, total consideration is $1.6 million, comprised of an upfront payment of $1.2 million, which was payable within 60 days after execution on October 31, 2018. The remaining milestone payment was contingent upon net sales reaching a certain threshold, at which point a $0.4 million payment became due. This threshold was achieved in 2020 and paid in early 2021. We were obligated to pay royalties in the low-double digits based on net sales of Exelderm until the end of 2023, and no additional licensing or milestone payments are required. We commenced sales of this product in August 2018.16",
            "type": "paragraph"
        },
        {
            "id": 15,
            "context": "Targadox AgreementOn March 10, 2015, we entered into a license and supply agreement (as amended) for Targadox\u00ae (the \u201cTargadox Agreement\u201d) with PuraCap International LLC n/k/a Caribe Holdings, Inc. (\u201cCaribe\u201d). We made an upfront payment of $1.3 million. Further payments will be made based on a revenue sharing arrangement and no additional licensing or milestone payments are required. The term of the Targadox Agreement is ten years and automatically renews for three-year periods unless either party provides notice of its intent not to renew at least 180 days prior to the expiration of the applicable term. Under our revenue sharing arrangement, we are entitled to retain a majority of the net profits and pay Caribe a portion of the net profits after deducting certain commercial, marketing and sales expenses during the term of the Targadox Agreement. The Targadox Agreement contains customary representations, warranties, and indemnities. Each party may also terminate the Targadox Agreement for material breach by the other party or for certain bankruptcy or insolvency related events. We commenced sales of this product in October 2016.Research and DevelopmentAs discussed above, on June 29, 2021, we obtained the global rights from DRL for the development and commercialization of DFD-29, a late-stage development modified release oral minocycline that is being developed for the treatment of inflammatory lesions of rosacea. Through this collaboration, the parties were required to work together to complete the development of DFD-29, which included conducting two Phase III studies to assess the efficacy, safety and tolerability of oral DFD-29 for the treatment of rosacea and the January 4, 2024 regulatory submission of an NDA under Section 505(b)(2) of the FDCA. DRL provided development support, including responding to any requests for information or clarification from FDA regarding the NDA.On March 17, 2022, we dosed the first patient in our Phase III clinical trials evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Rosacea. We filed the NDA with the FDA on January 4, 2024. The two Phase III studies conducted in the US and Germany demonstrated that DFD-29 was statistically superior to Oracea\u00ae and Placebo on multiple efficacy endpoints relevant to the treatment of rosacea. DFD-29 also demonstrated statistical superiority to Placebo in reducing erythema of rosacea. The safety profile of DFD-29 in the two Phase III studies was similar to Placebo. Based on the Phase III data, we are seeking an indication to treat inflammatory lesions and erythema of rosacea in patients 18 years of age and older for DFD-29.Intellectual PropertyGeneralWe rely on a combination of contractual provisions, confidentiality policies and procedures and patent, trademark, copyright and trade secrecy laws to protect the proprietary aspects of our technology and business. Three of our marketed products, Accutane, Targadox, and Exelderm, do not have patent protection and/or are not otherwise eligible for patent protection. As part of our development and acquisition strategy, we place a strong emphasis on the patent protection for potential products. Three of our marketed products, Qbrexza, Amzeeq, and Zilxi, as well as DFD-29, currently have patent protection.17",
            "type": "paragraph"
        },
        {
            "id": 16,
            "context": "| \u25cf | There are twenty one issued U.S. patents, fifteen issued foreign patents (Australia, Canada, Europe, Israel, Mexico, United Kingdom, South Africa), six pending U.S. patent applications and one pending foreign application (Canada), all relating to Amzeeq. The issued Amzeeq patents contain claims directed to compositions and use of the compositions (method claims). The issued U.S. and foreign patents relating to Amzeeq will expire between 2030 and 2037 and the pending U.S. and foreign patent applications relating to Amzeeq will expire between 2030 and 2037. |\n| \u25cf | There are fourteen issued U.S. patents, fifteen issued foreign patents (Australia, Canada, Europe, Israel, Mexico, United Kingdom, South Africa), four pending U.S. patent applications and one pending foreign application (Canada), all relating to Zilxi. The issued Zilxi patents contain claims directed to compositions and use of the compositions (method claims). The issued U.S. and foreign patents relating to Zilxi will expire between 2030 and 2037 and the pending U.S. and foreign patent applications relating to Zilxi will expire between 2030 and 2037. |\n| \u25cf | The other patents related to molecular stabilizing platform but not products directly are sixteen issued U.S. patents, three pending U.S. patent applications, and five issued foreign patents (Canada, Israel, and Mexico). |",
            "type": "table"
        },
        {
            "id": 17,
            "context": "Additional Intellectual Property and Proprietary Right ProtectionWe also use other forms of protection, such as trademark, copyright, and trade secret protection, to protect our intellectual property, particularly where we do not believe patent protection is appropriate or obtainable. We aim to take advantage of all of the intellectual property rights that are available to us and believe that this comprehensive approach will provide us with proprietary positions for our product candidates, where available. Patents extend for varying periods according to the date of patent filing or grant and the legal term of patents in various countries where patent protection is obtained. The actual protection afforded by a patent, which can vary from country to country, depends on the type of patent, the scope of its coverage and the availability of legal remedies in the country.Our goal is to obtain, maintain and enforce patent protection for our products, formulations, processes, methods and other proprietary technologies, to preserve our trade secrets, and to operate without infringing on the proprietary rights of other parties, both in the United States and in other countries. Our policy is to actively seek to obtain, where appropriate, the broadest intellectual property protection possible for any product candidates, proprietary information and proprietary technology through a combination of contractual arrangements and patents, both in the U.S. and elsewhere in the world.Patents and other proprietary rights are crucial to the development of our business. We will be able to protect our proprietary technologies from unauthorized use by third parties only to the extent that our proprietary rights are covered by valid and enforceable patents, supported by regulatory exclusivity, or are effectively maintained as trade secrets.Generally, patent applications in the U.S. are maintained in secrecy for a period of 18 months or more. The patent positions of biotechnology and pharmaceutical companies are highly uncertain and involve complex legal and factual questions. Therefore, we cannot predict the breadth of claims allowed in biotechnology and pharmaceutical patents, or their enforceability. To date, there has been no consistent policy regarding the breadth of claims allowed in biotechnology patents. Third parties or competitors may challenge or circumvent our patents or patent applications, if issued. If our competitors prepare and file patent applications in the U.S. that claim technology also claimed by us, we may have to participate in derivation proceedings declared by the USPTO to determine proper inventorship of a claimed of invention, which could result in substantial cost, even if the eventual outcome is favorable to us. Because of the extensive time required for development, testing and regulatory review of a potential product, it is possible that before we commercialize any of our products, any related patent may expire or remain in existence for only a short period following commercialization, thus reducing any advantage of the patent. However, the life of a patent covering a product that has been subject to regulatory approval may be extended through the patent term restoration program, although any such extension could still be minimal.If a patent is issued to a third party containing one or more preclusive or conflicting claims, and those claims are ultimately determined to be valid and enforceable, we may be required to obtain a license under such patent or to develop or obtain alternative technology, neither of which may be possible. In the event of litigation involving a third-party claim, an adverse outcome in the litigation could subject us to significant liabilities to such third party, require us to seek a license under the disputed rights of such third party, and/or require us to cease use of the technology. Moreover, our breach of an existing license or failure to obtain a license to technology required to commercialize our products may seriously harm our business. We also may need to commence litigation to enforce any patents issued to us or to determine the scope and validity of third-party proprietary rights. Litigation could involve substantial costs.Other Intellectual Property RightsWe depend upon trademarks, trade secrets, and continuing technological advances to develop and maintain our competitive position. We also depend upon the skills, knowledge and experience of our scientific and technical personnel, as well as that of our advisors, consultants and other contractors. This knowledge and experience we call \u201cknow-how.\u201d To help protect our proprietary know-how that is not patentable, and for inventions for which patents may be difficult to enforce, we rely on trade secret protection and confidentiality agreements to protect our interests. To this end, we require all employees, scientific advisors, consultants, collaborators and other contractors, upon commencement of a relationship with us, to enter into confidentiality agreements, which prohibit the disclosure of confidential information and, in the case of parties other than our research and development collaborators, require disclosure and assignment to us of the ideas, developments, discoveries and inventions important to our business. These agreements are designed to protect our proprietary information and to grant us ownership of technologies that are developed in connection with their relationship with us. These agreements may not, however, provide protection for our trade secrets in the event of unauthorized disclosure of such information.19",
            "type": "paragraph"
        },
        {
            "id": 18,
            "context": "There can be no assurance that any of our patents, licenses or other intellectual property rights will afford us any protection from competition, that our confidentiality agreements will not be breached, that we will have adequate remedies for any breach, that others will not independently develop equivalent proprietary information or that other third parties will not otherwise gain access to our trade secrets and other intellectual property.We may find it necessary to initiate litigation to enforce our patent rights, to protect our intellectual property or trade secrets or to determine the scope and validity of the proprietary rights of others. Litigation is costly and time-consuming and there can be no assurance that our litigation expenses will not be significant in the future or that we will prevail in any such litigation.CompetitionPharmaceutical IndustryOur competitors include pharmaceutical companies and biotechnology companies, as well as universities and public and private research institutions. In addition, companies that are active in different but related fields represent substantial competition for us. Many of our competitors have significantly greater capital resources, larger research and development staffs and facilities and greater experience in drug development, regulation, manufacturing and marketing than we do. These organizations also compete with us to recruit qualified personnel, attract partners for joint ventures or other collaborations, and license technologies that are competitive with ours. To compete successfully in this industry, we must identify novel and unique drugs or methods of treatment and then complete the development of those drugs as treatments in advance of our competitors.Dermatology SectorThe dermatology competitive landscape is highly fragmented, with a large number of midsize and smaller companies competing in both the prescription sector and the OTC sector. Our competitors are pursuing the development and/or acquisition of pharmaceuticals, medical devices and OTC products that target the same diseases and conditions that we are targeting in dermatology. Competitive factors vary by product line and geographic area in which our products are sold. The principal methods of competition for our products include quality, efficacy, market acceptance, price, and marketing and promotional efforts.Branded products often must compete with therapeutically similar branded or generic products or with generic equivalents. Such competition frequently increases over time. For example, if competitors introduce new products, delivery systems or processes with therapeutic or cost advantages, our products could be subject to progressive price reductions and/or decreased volume of sales. To successfully compete for business, we must often demonstrate that our products offer not only medical benefits, but also cost advantages as compared with other forms of care. Accordingly, we face pressure to continually seek out technological innovations and to market our products effectively.Our major competitors, including Galderma Laboratories, Almirall, Novan Therapeutics, Leo Pharma, Mayne Pharma, Botanix Pharmaceuticals, and Ortho Dermatologics, among others, vary depending on therapeutic and product category, dosage strength and drug-delivery systems, among other factors.Generic CompetitionWe face increased competition from manufacturers of generic pharmaceutical products, who may submit applications to the FDA seeking to market generic versions of our products. In connection with these applications, the generic drug companies may seek to challenge the validity and enforceability of our patents through litigation. When patents covering certain of our products (if applicable) expire or are successfully challenged through litigation or in USPTO proceedings, if a generic company launches a competing product \u201cat risk,\u201d or when the regulatory or licensed exclusivity for our products (if applicable) expires or is otherwise lost, we may face generic competition as a result. Generic versions are generally significantly less expensive than branded versions, and, where available, may be required to be utilized before or in preference to the branded version under third-party reimbursement programs, or substituted by pharmacies. Accordingly, when a branded product loses its market exclusivity, it normally faces intense price competition from generic forms of the product. To successfully compete for business with managed care and pharmacy benefits management organizations, we must often demonstrate that our products offer not only medical benefits, but also cost advantages as compared with other forms of care. Generic products generally face intense competition from other generic equivalents (including authorized generics) and therapeutically similar branded or generic products.20",
            "type": "paragraph"
        },
        {
            "id": 19,
            "context": "Supply and ManufacturingWe have limited experience in manufacturing products for clinical or commercial purposes, and we currently do not have any internal manufacturing capabilities. We currently rely upon multiple contract manufacturers to produce our products and clinical supply of product candidates and will continue to rely upon contract manufacturers for any current or future product candidates under current Good Manufacturing Practice (\u201ccGMP\u201d) regulations for use in pre-clinical and clinical activities. Due to the risks associated with reliance on third-party manufacturing, as part of our current and future strategy of licensing, acquiring, or the future development of assets, we currently, and will continue to, secure manufacturing agreements with either a counterparty to a transaction, with one or more of our contract manufacturers or additional contract manufacturers. As with any supply program, obtaining raw materials of the correct quality cannot be guaranteed, and we cannot ensure that we will be successful. Our third-party manufacturers have a limited number of facilities in which our product candidates can be produced and may have limited experience in manufacturing our product candidates in quantities sufficient for commercialization. Our third-party manufacturers will have other clients and may have other priorities that could affect their ability to perform the work satisfactorily and/or on a timely basis. Both of these occurrences would be beyond our control. We expect to similarly rely on contract manufacturing relationships for any products that we may in-license or acquire in the future. However, there can be no assurance that we will be able to successfully contract with such manufacturers on terms acceptable to us, or at all.Contract manufacturers are subject to ongoing periodic and unannounced inspections by the FDA, the Drug Enforcement Administration and corresponding state and European agencies to ensure strict compliance with cGMPs and other state and federal regulations. We do not have control over third-party manufacturers\u2019 compliance with these regulations and standards, other than through contractual obligations. If they are deemed out of compliance with cGMPs, product recalls could result, inventory could be destroyed, production could be stopped, and supplies could be delayed or otherwise disrupted.If we need to change manufacturers during the clinical or development stage for product candidates or after commercialization for our approved products, the FDA and corresponding foreign regulatory agencies must approve these new manufacturers in advance, which will involve testing and additional inspections to ensure compliance with FDA regulations and standards and may require significant lead times and delay. Furthermore, switching manufacturers may be difficult because the number of potential manufacturers is limited. It may be difficult or impossible for us to find a replacement manufacturer quickly or on terms acceptable to us, or at all.Government and Industry Regulations\u2009-\u2009Overview FDA RegulationsNumerous governmental authorities, principally the FDA and corresponding state and foreign regulatory agencies, impose substantial regulations upon any potential clinical development and the manufacture and marketing of our products. Before marketing in the U.S., any drug that we may develop must undergo rigorous pre-clinical testing and clinical trials and an extensive regulatory approval process implemented by the FDA under the FDCA. The FDA regulates, among other things, the pre-clinical and clinical testing, safety, efficacy, approval, manufacturing, record keeping, lot traceability, individual serialization, adverse event reporting, packaging, labeling, storage, advertising, promotion, export, sale and distribution of biopharmaceutical products.The regulatory review and approval process is lengthy, expensive and uncertain. In the event that we acquire or develop a clinical stage asset, we will be required to submit extensive pre-clinical and clinical data and supporting information to the FDA for each indication or use to establish a product candidate\u2019s safety and efficacy before we can secure FDA approval to market or sell a product in the U.S. The approval process may take many years, depending on the stage of development of a target asset, and requires the expenditure of substantial resources and may involve ongoing requirements for post-marketing studies or surveillance.Clinical testing must meet requirements for institutional review board oversight, informed consent and good clinical practices, and must be conducted pursuant to an Investigational New Drug (\u201cIND\u201d) Application unless exempted.21",
            "type": "paragraph"
        },
        {
            "id": 20,
            "context": "| \u25cf | slow patient enrollment due to the nature of the clinical trial plan, the proximity of patients to clinical sites, the eligibility criteria for participation in the study or other factors; |\n| \u25cf | inadequately trained or insufficient personnel at the study site to assist in overseeing and monitoring clinical trials or delays in approvals from a study site\u2019s review board; |\n| \u25cf | longer treatment time required to demonstrate efficacy or determine the appropriate product dose; |\n| \u25cf | insufficient supply of the drug candidates; |\n| \u25cf | adverse medical events or side effects in treated patients; and |\n| \u25cf | ineffectiveness of the drug candidates. |",
            "type": "table"
        },
        {
            "id": 21,
            "context": "Before receiving FDA approval to market a product, we must demonstrate that the product is safe and effective for its intended use by submitting to the FDA an NDA, Abbreviated NDA (\u201cANDA\u201d), 510(K) or Biologics License Application (\u201cBLA\u201d) containing the pre-clinical and clinical data that have been accumulated, together with chemistry and manufacturing and controls specifications and information, and proposed labeling, among other things. The FDA may refuse to accept an NDA, ANDA, 510(K) or BLA for filing if certain content criteria are not met and, even after accepting an NDA, ANDA, 510(K) or BLA, the FDA may often require additional information, including clinical data, before approval of marketing a product.Section 505(b)(2) NDAs may provide an alternate path to FDA approval for new or improved formulations or new uses of previously approved products. Section 505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from clinical trials not conducted by, or for, the applicant and for which the applicant has not obtained a right of reference. The FDA may then approve the new product candidate for all, or some, of the label indications for which the referenced product has been approved, as well as for any new indication sought by the Section 505(b)(2) applicant.To the extent that the Section 505(b)(2) applicant is relying on the FDA\u2019s findings of safety and effectiveness for an already approved product, the applicant is required to certify to the FDA concerning any patents listed for the approved product in the Orange Book to the same extent that an ANDA applicant would. Thus approval of a Section 505(b)(2) NDA can be stalled until all the listed patents claiming the referenced product have expired; until any non-patent exclusivity, such as exclusivity for obtaining approval of a New Chemical Entity (\u201cNCE\u201d), listed in its publication \u201cApproved Drug Products with Therapeutic Equivalence Evaluations,\u201d also referred to as the \u201cOrange Book,\u201d for the referenced product has expired; and, in the case of a Paragraph IV certification and subsequent patent infringement suit, until the earlier of 30 months, settlement of the lawsuit or a decision in the infringement case that is favorable to the Section 505(b)(2) applicant. In the interim period, the FDA may grant tentative approval. Tentative approval indicates that the FDA has determined that the applicant meets the standards for approval as of the date that the tentative approval is granted. Final regulatory approval can only be granted if the FDA is assured that there is no new information that would affect final regulatory/ approval.The FDA may request a Risk Evaluation and Mitigation Strategy (\u201cREMS\u201d), as part of an NDA, ANDA, 510(K) or BLA. The REMS typically contains some combination of post-marketing obligations of the sponsor to train prescribing physicians, monitor drug use, including off-label use, and conduct sufficient Phase 4 follow-up studies and registries to ensure the continued safe use of the drug.As part of the approval process, the FDA must inspect and approve each manufacturing facility. Among the conditions of approval is the requirement that a manufacturer\u2019s quality control and manufacturing procedures conform to cGMP. Manufacturers must expend significant time, money and effort to ensure continued compliance, and the FDA conducts periodic inspections to certify compliance. It may be difficult for our manufacturers or us to comply with the applicable cGMPs, as interpreted by the FDA, and other FDA regulatory requirements. If we, or our contract manufacturers, fail to comply, then the FDA may not allow us to market products that have been affected by the failure.If the FDA grants approval, the approval will be limited to those conditions and patient populations for which the product is safe and effective, as demonstrated through clinical studies. Further, a product may be marketed only in those dosage forms and for those indications approved in the NDA, ANDA, 510(K), or BLA. Certain changes to an approved BLA, including, with certain exceptions, any significant changes to labeling, require approval of a supplemental application before the drug may be marketed as changed. Any products that we manufacture or distribute pursuant to FDA approvals are subject to continuing monitoring and regulation by the FDA, including compliance with cGMP and the reporting of adverse experiences with the drugs. The nature of marketing claims that the FDA will permit us to make in the labeling and advertising of our products will generally be limited to those specified in FDA approved labeling, and the advertising of our products will be subject to comprehensive monitoring and regulation by the FDA. Drugs whose review was accelerated may carry additional restrictions on marketing activities, including the requirement that all promotional materials are pre-submitted to the FDA. Claims exceeding those contained in approved labeling will constitute a violation of the FDCA. Violations of the FDCA or regulatory requirements at any time during the product development process, approval process, or marketing and sale following approval may result in agency enforcement actions, including withdrawal of approval, recall, seizure of products, warning letters, untitled letters, Form 483s, injunctions, fines and/or civil or criminal penalties. Any agency enforcement action could have a material adverse effect on our business.23",
            "type": "paragraph"
        },
        {
            "id": 22,
            "context": "Pharmaceutical Coverage, Pricing and ReimbursementSales of any pharmaceutical product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurance, and managed healthcare organizations, and the level of reimbursement for such product by third-party payors. Significant uncertainty exists as to the coverage and reimbursement status of any newly approved product. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. One third-party payor\u2019s decision to cover a particular product does not ensure that other payors will also provide coverage for the product. As a result, the coverage determination process can require manufacturers to provide scientific details, information on cost-effectiveness, and clinical support for the use of a product to each payor separately. This can be a time-consuming process, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.In addition, third-party payors are increasingly reducing reimbursements for pharmaceutical products and related services. The U.S. government and state legislatures have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Third-party payors are increasingly challenging the prices charged, examining the medical necessity and reviewing the cost effectiveness of pharmaceutical products, in addition to questioning their safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product. Decreases in third-party reimbursement for any product or a decision by a third-party payor not to cover a product could reduce physician usage and patient demand for the product.At the state level, there are also new laws and ongoing ballot initiatives that create additional pressure on drug pricing and may affect how pharmaceutical products are covered and reimbursed. A number of states have adopted or are considering various pricing actions, such as those requiring pharmaceutical manufacturers to publicly report proprietary pricing information, limit price increases or to place a maximum price ceiling or cap on certain products. Existing and proposed state pricing laws have added complexity to the pricing of pharmaceutical drug products.In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product, or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. Pharmaceutical products may face competition from lower-priced products in foreign countries that have placed price controls on pharmaceutical products and may also compete with imported foreign products. Furthermore, there is no assurance that a product will be considered medically reasonable and necessary for a specific indication, that it will be considered cost-effective by third-party payors, that an adequate level of reimbursement will be established even if coverage is available, or that the third-party payors\u2019 reimbursement policies will not adversely affect the ability for manufacturers to sell products profitably.International RegulationsIn addition to regulations in the United States, there are a variety of foreign regulations governing clinical trials and commercial sales and distribution of any product candidates. The approval process varies from country to country, and the time may be longer or shorter than that required for FDA approval.Failure to comply with applicable federal, state and foreign laws and regulations would likely have a material adverse effect on our business. In addition, federal, state and foreign laws and regulations regarding the manufacture and sale of new drugs are subject to future changes.PHRMA Code and April 3, 2003 Department of Health and Human Services Office of Inspector General, OIG Compliance Program for Pharmaceutical ManufacturersWe have established and implemented a corporate compliance program designed to prevent, detect and correct violations of state and federal healthcare laws, including laws related to advertising and promotion of our products that are in compliance with the PHRMA Code and the Health and Human Services Office of Inspector General (\u201cOIG\u201d) Compliance Program requirements for Pharmaceutical Manufacturers.24",
            "type": "paragraph"
        },
        {
            "id": 23,
            "context": "Healthcare Fraud, Waste and AbuseWe are subject to various federal, state and local laws targeting fraud and abuse in the healthcare industry, violations of which can lead to civil and criminal penalties, including fines, imprisonment and exclusion from participation in federal healthcare programs.These laws are applicable to us as both a manufacturer and a supplier of products reimbursed by federal healthcare programs, and they also apply to physicians and other potential purchasers of our products.The federal Anti-Kickback Statute (42 U.S.C. \u00a7 1320a-7b) prohibits persons from knowingly and willfully soliciting, receiving, offering or providing remuneration, directly or indirectly, to induce either the referral of an individual, or the furnishing, recommending or arranging for a good or service, for which payment may be made under a federal healthcare program such as the Medicare and Medicaid programs. Remuneration is not defined in the federal Anti-Kickback Statute and has been broadly interpreted to include anything of value, including for example, gifts, discounts, coupons, the furnishing of supplies or equipment, credit arrangements, payments of cash, waivers of payments, ownership interests and providing anything at less than its fair market value. Under the federal Anti-Kickback Statute and the applicable criminal healthcare fraud statutes contained within 42 U.S.C. \u00a7 1320a-7b, a person or entity need not have actual knowledge of this statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim, including items or services resulting from a violation of 42 U.S.C. \u00a7 1320a-7b, constitutes a false or fraudulent claim for purposes of the civil False Claims Act (discussed below) or the civil monetary penalties statute, which imposes fines against any person who is determined to have presented or caused to be presented claims to a federal healthcare program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent. The federal Anti-Kickback Statute and implementing regulations provide for certain exceptions for \u201csafe harbors\u201d for certain discounting, rebating or personal services arrangements, among other things. However, the lack of uniform court interpretation of the Anti-Kickback Statute, coupled with novel enforcement theories by government authorities, make compliance with the law difficult. Violations of the federal Anti-Kickback Statute can result in significant criminal fines, exclusion from participation in Medicare and Medicaid and follow-on civil litigation, among other things, for both entities and individuals.In October 2019, the OIG issued a proposed rule to, among other things, add new safe harbors for certain value-based arrangements. Although the value-based proposals would not include pharmaceutical manufacturers among the entities that could permissibly enter into such contracting arrangements, the general trend toward outcomes and value-based contracts in the healthcare industry may continue. It is possible that payors, among other customers, could push manufacturers for novel contracting approaches, including those that would incorporate value-based principles, and these efforts could affect our business.The civil False Claims Act and similar state laws impose liability on any person or entity who, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment by a federal healthcare program. The qui tam provisions of the False Claims Act and similar state laws allow a private individual to bring civil actions on behalf of the federal or state government and to share in any monetary recovery. The Federal Physician Payments Sunshine Act and similar state laws impose reporting requirements for various types of payments to physicians and teaching hospitals. Failure to comply with reporting requirements under these laws could subject manufacturers and others to substantial civil money penalties.The Health Insurance Portability and Accountability Act of 1996 (\u201cHIPAA\u201d) imposes criminal liability and amends provisions on the reporting, investigation, enforcement, and penalizing of civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of, or payment for healthcare benefits, items or services by a healthcare benefit program, which includes both government and privately funded benefits programs; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.Other Healthcare Laws and Compliance RequirementsIn the United States, our activities are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including the Centers for Medicare and Medicaid Services (formerly the Health Care Financing Administration), other divisions of the United States Department of Health and Human Services, the United States Department of Justice and individual United States Attorney offices within the Department of Justice, and state and local governments.25",
            "type": "paragraph"
        },
        {
            "id": 24,
            "context": "Drug Quality and Security Act (\u201cDQSA\u201d)DQSA was enacted by Congress on November 27, 2013. Title II of DQSA, the Drug Supply Chain Security Act (\u201cDSCSA\u201d), outlines steps to build an electronic, interoperable system to identify and trace certain prescription drugs as they are distributed in the United States. This is intended to enhance the FDA\u2019s ability to help protect consumers from exposure to drugs that may be counterfeit, stolen, contaminated, or otherwise harmful. The system is also intended to improve detection and removal of potentially dangerous drugs from the drug supply chain to protect U.S. consumers.Additionally, the DSCSA directs FDA to establish national licensure standards for wholesale distributors and third-party logistics providers, and requires these entities report licensure and other information to FDA annually. The implementation and enforcement of complete unit level traceability of verifiable return serialization, including aggregation throughout the whole supply chain, is not required as of November 27, 2023. Although the rule regarding wholesale distributor verification of saleable returned products does not directly apply to our Company, we are required to assist our wholesale distributor customers by setting in place mechanics that would allow for traceability of returns in the supply chain. If we are not able to come into compliance of this rule, our wholesale distributor customers may not accept our returns on our behalf.We are subject to, and required to be in compliance with, the DQSA. Our Company remains in compliance with the requirements promogulated by the DSCSA and intends on remaining vigilant with regards to any potential modifications to the act. For purposes of our business, we are considered both manufacturers and re-packagers under the act. Currently, we are in compliance with the DSCSA as it relates to our business and operations.",
            "type": "paragraph"
        },
        {
            "id": 25,
            "context": "Item 1A. Risk Factors The following information sets forth risk factors that could cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. You should carefully consider the risks described below, in addition to the other information contained in this report and our other public filings, before making an investment decision. Our business, financial condition or results of operations could be harmed by any of these risks. The risks and uncertainties described below are not the only ones we face. Additional risks not presently known to us or other factors not perceived by us to present significant risks to our business at this time also may impair our business operations.",
            "type": "paragraph"
        },
        {
            "id": 26,
            "context": "Risks Related to Our Business, Industry and Existing Operating Revenue Stream\nFuture revenue from sales of our dermatology products may be lower than expected or lower than in previous periods. The vast majority of our operating income for the foreseeable future is expected to come from the sale of our dermatology products. Any setback that may occur with respect to such products could significantly impair our operating results and/or reduce our revenue and the value of our securities. Setbacks for such products could include, but are not limited to, issues related to: supply chain, shipping; distribution; demand; manufacturing; product safety; product quality; marketing; government regulation; pricing; reimbursement; licensing and approval; intellectual property rights; competition with existing or new products; product acceptance by physicians, other licensed medical professionals and patients; and higher than expected total rebates, returns or recalls.",
            "type": "paragraph"
        },
        {
            "id": 27,
            "context": "Also, the majority of our sales derive from products that are without patent protection and/or are or may become subject to third-party generic competition, the introduction of new competitor products, or increased market share of existing competitor products, any of which could have a significant adverse effect on our operating income.",
            "type": "paragraph"
        },
        {
            "id": 28,
            "context": "We face challenges as our products face generic competition and/or losses of exclusivity. Our products do and may compete with well-established products, both branded and generic, with similar or the same indications. We face increased competition from manufacturers of generic pharmaceutical products, who may submit applications to the FDA seeking to market generic versions of our products. In connection with these applications, the generic drug companies may seek to challenge the validity and enforceability of our patents through litigation. When patents covering certain of our products expire or are successfully challenged through litigation or in USPTO proceedings, if a generic company launches a competing product \u201cat risk,\u201d or when the regulatory or licensed exclusivity for our products expires or is otherwise lost, we may face generic competition as a result.",
            "type": "paragraph"
        },
        {
            "id": 29,
            "context": "26 The majority of our sales derive from products that are without patent protection and/or are or may become subject to third-party generic competition, the introduction of new competitor products, or an increase in market share of existing competitor products, any of which could have a significant adverse impact on our operating income. Three of our marketed products, Qbrexza, Amzeeq, and Zilxi as well as DFD-29, currently have patent protection. Three of our marketed products, Accutane, Targadox, and Exelderm, do not have patent protection or otherwise are not eligible for patent protection. Accutane currently competes in the Isotretinoin market with five other therapeutic equivalent (\u201cAB rated\u201d) products. Targadox faces AB rated generic competition. Exelderm may face AB rated generic competition in the future.Generic versions are generally significantly less expensive than branded versions, and, where available, may be required to be utilized before or in preference to the branded version under third-party reimbursement programs, or substituted by pharmacies. Accordingly, when a branded product loses its market exclusivity, it normally faces intense price competition from generic forms of the product. To successfully compete for business with managed care and pharmacy benefits management organizations, we must often demonstrate that our products offer not only medical benefits, but also cost advantages as compared with other forms of care. If we fail to do so, our results of operations, financial condition or cash flows may be materially adversely affected.Any disruptions to the capabilities, composition, size or existence of our field sales force may have a significant adverse impact on our existing revenue stream. Further, our ability to effectively market and sell any future products that we may develop will depend on our ability to establish and maintain sales and marketing capabilities or to enter into agreements with third parties to market, distribute and sell any such products.Our field sales force has been and is expected to continue to be an important contributor to our commercial success. Any disruptions to our relationship with our field sales force could materially adversely affect our product sales. We may rely on professional employer organizations and staffing organizations for the employment of our field sales force in the future.The establishment, development, and/or expansion of a field sales force, either by us or certain of our partners or vendors, or the establishment of a field sales force to market any products for which we may have or receive marketing approval, is expensive and time-consuming and could delay any such product launch or compromise the successful commercialization of such products. If we are unable to establish and maintain sales and marketing capabilities or any other non-technical capabilities necessary to commercialize any products that may be successfully developed, we will need to contract with third parties to market and sell such products. We may not be able to establish or maintain arrangements with third parties on commercially reasonable terms, or at all, which would have a material adverse effect on our business, prospects, results of operations, financial condition or cash flows.Our current and potential future product candidates may not receive regulatory approval, or such approval may be delayed, which would have a material adverse effect on our business and financial condition. Further, even if a product receives regulatory approval, such product will remain subject to substantial regulatory scrutiny.Our current and potential future product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and abroad. Our failure to obtain marketing approval for any current or future product candidates will prevent us from commercializing the product candidates. Further, any products or future products candidates we license or acquire will be subject to ongoing requirements and review by such regulatory authorities.We have limited experience in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third parties to assist us in this process. To secure marketing approval, we will be required to establish a product candidate\u2019s safety and efficacy by submitting extensive preclinical and clinical data and supporting information for each therapeutic indication. We will further be required to submit information about the product manufacturing and to undergo regulatory inspection of our third-party manufacturing facilities to ensure ongoing compliance with cGMP requirements.Any of our current or future product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude us from obtaining marketing approval or prevent or limit commercial use. If our current or future product candidates receive(s) marketing approval, the accompanying label may limit the approved use of our drug in this way, which could limit sales of the product.27",
            "type": "paragraph"
        },
        {
            "id": 30,
            "context": "The marketing approval process, both in the United States and abroad, is time consuming and expensive. Approval may take many years, and if it is granted can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Our product candidates could be delayed in receiving, or fail to receive, regulatory approval for many reasons, including: the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; the FDA or comparable foreign regulatory authorities may disagree with our development strategy; we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a drug candidate is safe and effective for its proposed indication or is suitable to identify appropriate patient populations; the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval; we may be unable to demonstrate that a product candidate\u2019s clinical and other benefits outweigh its safety risks.Changes to marketing approval policies or the regulatory landscape during the development period may cause rejection of or delays in the approval of an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or decide that our data is insufficient for approval and require costly additional preclinical studies or clinical trials. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable. If we experience delays in obtaining or fail to obtain or maintain any necessary approvals of any current or future product candidates, receive approval for fewer or more limited indications than we request or without including the labeling claims we desire, our future commercial prospects may be harmed and our ability to generate revenue may be materially impaired. Even if we do receive approval, it may be contingent on the performance of costly post-marketing clinical trials to verify whether or not the drug provides the anticipated clinical benefit, in order to maintain the approval.Regulatory approval for any approved product is limited by the FDA to those specific indications and conditions for which clinical safety and efficacy have been demonstrated.Any regulatory approval is limited to those specific diseases and indications for which a product is deemed to be safe and effective. If the FDA or any regulatory authority limits the scope of our indication, or if we are unable to obtain FDA approval for any desired future indications for our products, our ability to effectively market and sell our products may be reduced and our business may be adversely affected. Further, we are only permitted to promote our products for those indications specifically approved by the FDA and there are restrictions around making communications regarding uses not approved and described in the product\u2019s labeling. If our promotional activities fail to comply with these regulations or guidelines, we may be subject to advisory or enforcement action by these authorities. In addition, our failure to follow FDA requirements or guidelines relating to promotion and advertising may cause the FDA to suspend or withdraw an approved product from the market, require a recall or institute fines, or could result in disgorgement of money, operating restrictions, injunctions or criminal prosecution, any of which could harm our business.If the FDA does not conclude that a product candidate satisfies the requirements for the Section 505(b)(2) regulatory approval pathway, or if the requirements for such product candidate under Section 505(b)(2) are not as we expect, the approval pathway for the product candidate will likely take significantly longer, cost significantly more and entail significantly greater complications and risks than anticipated, and in either case may not be successful.The Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Act, added Section 505(b)(2) to the FDCA. Section 505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from studies that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference. Section 505(b)(2), if applicable to us under the FDCA, would allow an NDA we submit to FDA to rely in part on data in the public domain or the FDA\u2019s prior conclusions regarding the safety and effectiveness of approved compounds, which could expedite the development program for our product candidates by potentially decreasing the amount of clinical data that we would need to generate in order to obtain FDA approval. If the FDA does not allow us to pursue the Section 505(b)(2) regulatory pathway as anticipated, we may need to conduct additional clinical trials, provide additional data and information, and meet additional standards for regulatory approval. If this were to occur, the time and financial resources required to obtain FDA approval for these product candidates, and complications and risks associated with these product candidates, would likely substantially increase. We could need to obtain more additional funding, which could result in significant dilution to the ownership interests of our then existing stockholders to the extent we issue equity securities or convertible debt. We cannot assure you that we would be able to obtain such additional financing on terms acceptable to us, if at all. Moreover, inability to pursue the Section 505(b)(2) regulatory pathway would likely result in new competitive products reaching the market more quickly than our product candidates, which would likely materially adversely impact our competitive position and prospects. Even if we are allowed to pursue the Section 505(b)(2) regulatory pathway, we cannot assure you that our product candidates will receive the requisite approvals for commercialization.28",
            "type": "paragraph"
        },
        {
            "id": 31,
            "context": "In addition, notwithstanding the approval of a number of products by the FDA under Section 505(b)(2) over the last few years, certain brand-name pharmaceutical companies and others have objected to the FDA\u2019s interpretation of Section 505(b)(2). If the FDA\u2019s interpretation of Section 505(b)(2) is successfully challenged, the FDA may change its Section 505(b)(2) policies and practices, which could delay or even prevent the FDA from approving any NDA that we submit under Section 505(b)(2). In addition, the pharmaceutical industry is highly competitive, and Section 505(b)(2) NDAs are subject to special requirements designed to protect the patent rights of sponsors of previously approved drugs that are referenced in a Section 505(b)(2) NDA. These requirements may give rise to patent litigation and mandatory delays in approval of our NDAs for up to 30 months or longer depending on the outcome of any litigation. It is not uncommon for a manufacturer of an approved product to file a citizen petition with the FDA seeking to delay approval of, or impose additional approval requirements for, pending competing products. If successful, such petitions can significantly delay, or even prevent, the approval of the new product. However, even if the FDA ultimately denies such a petition, the FDA may substantially delay approval while it considers and responds to the petition. In addition, even if we are able to utilize the Section 505(b)(2) regulatory pathway, there is no guarantee this would ultimately lead to faster product development or earlier approval.Moreover, even if our product candidates are approved under Section 505(b)(2), the approval may be subject to limitations on the indicated uses for which the products may be marketed or to other conditions of approval, or may contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the products.If any of our contract manufacturers fails to produce our products in the volumes that we require on a timely basis, or to comply with stringent regulations applicable to pharmaceutical drug manufacturers, we may face delays in the commercialization of this product candidate or be unable to meet market demand, and may lose potential revenues.The manufacture of pharmaceutical products requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls, and the use of specialized processing equipment. Any termination or disruption of any current or future relationships relating to product development may materially harm our business and financial condition and frustrate any commercialization efforts for affected current or future product candidates.Any current or future contract manufacturers we engage must comply with strictly enforced federal, state and foreign regulations, including cGMP requirements enforced by the FDA through its establishment inspection program. Despite the existence of contract manufacturing agreements and shared cGMP responsibilities, our contract manufacturers\u2019 may ignore these contractual provisions, or otherwise fail to meet the minimum standards set forth in the cGMP regulations, resulting in manufacturing non-compliance. This may go unnoticed or uncorrected despite our best efforts to regulatory audit or confirm the CMOs regulatory responsibilities. Any failure to comply with applicable regulations may result in fines and civil penalties, suspension of production, suspension or delay in product approval, product seizure or recall, or withdrawal of product approval, and would limit the availability of our product. Any manufacturing defect or error discovered after products have been produced and distributed could result in even more significant consequences, including costly recalls, re-stocking costs, damage to our reputation and potential for product liability claims.If the CMOs upon which we rely to manufacture any current products, and any potential product candidates we may in-license or acquire, fail to deliver the required commercial quantities on a timely basis at commercially reasonable prices, we would likely be unable to meet demand for our products and we would lose potential revenues.If serious adverse or unacceptable side effects are identified during the development of any current or future product candidates, we may need to abandon or limit our development of some of the other potential product candidates.If any current or future product candidates are associated with undesirable side effects, toxicities, or other negative characteristics, we may need to abandon such products\u2019 commercialization, development or limit development to more narrow uses or subpopulations. Such side effects may affect patient recruitment or the ability of enrolled patients to complete the trial and could result in potential product liability claims. Many compounds that show initial promise in early-stage testing are later found to cause side effects that prevent further development. If our clinical trials reveal severe or prevalent side effects, our trials could be suspended or terminated, we may be unable to recruit patients and enrolled patients may be unable to complete the trials, and the FDA or comparable foreign regulatory authorities could order issue a clinical hold, or order us to cease further development or deny approval of the product candidate. The FDA may also request additional data, which it has done with increased prevalence in recent years, which has resulted in substantial delays in new drug approvals. Undesirable side effects caused by any current or future product candidates could also result in the inclusion of unfavorable information in our product labeling, denial of regulatory approval by the FDA or other regulatory authorities for any or all targeted indications, and in turn prevent us from commercializing and generating revenues from the sale of such product candidate.29",
            "type": "paragraph"
        },
        {
            "id": 32,
            "context": "| \u25cf | regulatory authorities may require the addition of unfavorable labeling statements, specific warnings or a contraindication; |\n| \u25cf | regulatory authorities may suspend or withdraw their approval of the product, or require it to be removed from the market; |\n| \u25cf | we may be required to change the way the product is administered, conduct additional clinical trials or change the labeling of the product; or |\n| \u25cf | our reputation may suffer. |\n| \u25cf | restrictions on such products or their manufacturers or manufacturing processes; |\n| \u25cf | restrictions on the labeling or marketing of a product; |\n| \u25cf | restrictions on product distribution or use; |\n| \u25cf | requirements to conduct post-marketing studies or clinical trials; |\n| \u25cf | warning letters, untitled letters, or Form 483s; |",
            "type": "table"
        },
        {
            "id": 33,
            "context": "| \u25cf | withdrawal of the products from the market; |\n| \u25cf | refusal to approve pending applications or supplements to approved applications that we submit; |\n| \u25cf | recall of products; |\n| \u25cf | fines, restitution or disgorgement of profits; |\n| \u25cf | suspension or withdrawal of marketing or regulatory approvals; |\n| \u25cf | suspension of any ongoing clinical trials; |\n| \u25cf | denial of permits to import or export our products; |\n| \u25cf | product seizure; or |\n| \u25cf | injunctions or the imposition of civil or criminal penalties. |\n| \u25cf | AKS, which prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under federal and state healthcare programs, such as Medicare and Medicaid. The OIG continues to make modifications to existing AKS safe harbors which may increase liability and risk as well as adversely impact sales relationships. The majority of states also have statutes or regulations similar to these federal laws, which apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor; |\n| \u25cf | federal civil and criminal false claims laws and civil monetary penalty laws, including the federal False Claims Act, which impose criminal and civil penalties, including civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, including the Medicare and Medicaid programs, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government; |\n| \u25cf | the federal Health Insurance Portability and Accountability Act of 1996 (\u201cHIPAA\u201d), which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters; |",
            "type": "table"
        },
        {
            "id": 34,
            "context": "| \u25cf | HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and their respective implementing regulations, which impose obligations on covered healthcare providers, health plans, and healthcare clearinghouses, as well as their business associates that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity, with respect to safeguarding the privacy, security and transmission of individually identifiable health information; |\n| \u25cf | the federal Open Payments program, which requires manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children\u2019s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare & Medicaid Services (\u201cCMS\u201d), information related to \u201cpayments or other transfers of value\u201d made to physicians, which is defined to include doctors, dentists, optometrists, podiatrists, chiropractors, physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, certified nurse-midwives and teaching hospitals and applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by the physicians and their immediate family members; |\n| \u25cf | Increased OIG scrutiny on the sale of our products through specialty pharmacies by means of direct investigation or by issuance of unfavorable Opinion Letters which may curtail or hinder the sales of our products based on risk of enforcement upon our-selves or our buyers; |\n| \u25cf | analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; state and foreign laws that require pharmaceutical companies to comply with the pharmaceutical industry\u2019s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers; |\n| \u25cf | state and foreign laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and |\n| \u25cf | state and foreign laws governing the privacy and security of health information in certain circum-stances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. |",
            "type": "table"
        },
        {
            "id": 35,
            "context": "We are subject to new legislation, regulatory proposals and managed care initiatives that may increase our costs of compliance and adversely affect our ability to market our products, obtain collaborators and raise capital.In the United States and certain foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system that could impact our ability to sell our licensed products profitably. In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (the \u201cPPACA\u201d or collectively, the \u201cACA\u201d), was signed into law, which substantially changed the way healthcare is financed by both governmental and private insurers in the United States. By way of example, the ACA: increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to 23.1%; required collection of rebates for drugs paid by Medicaid managed care organizations; imposed a non-deductible annual fee on pharmaceutical manufacturers or importers who sell certain \u201cbranded prescription drugs\u201d to specified federal government programs; implemented a new methodology under which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected; expanded the eligibility criteria for Medicaid programs; created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and established a Center for Medicare and Medicaid Innovation (\u201cCMMI\u201d) at the CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.Since its enactment, there have been executive, judicial and Congressional challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. On January 20, 2017, President Trump signed an executive order stating that his administration intended to seek prompt repeal of the Affordable Care Act, and, pending repeal, directed the U.S. Department of Health and Human Services and other executive departments and agencies to take all steps necessary to limit any fiscal or regulatory burdens of the Affordable Care Act. On January 28, 2021, President Biden signed an Executive Order on Strengthening Medicaid and the Affordable Care Act and stated his administration\u2019s intentions to reverse the actions of his predecessor and strengthen the ACA. As part of this Executive Order, the Department of Health and Human Services, United States Treasury, and the Department of Labor are directed to review all existing regulations, orders, guidance documents, policies, and agency actions to consider if they are consistent with ensuring both coverage under the ACA and making high-quality healthcare affordable and accessible to Americans. On March 11, 2021, President Biden signed into law the American Rescue Plan Act of 2021 to further strengthen Medicaid and the ACA and on April 5, 2022, President Biden signed the Executive Order on Continuing to Strengthen Americans\u2019 Access to Affordable, Quality Health Coverage in which he celebrated the significant progress his administration believes has been made across the U.S. in making healthcare more affordable and accessible. In this Executive Order, President Biden directed agencies \u201cwith responsibilities related to Americans\u2019 access to health coverage\u201d to \u201creview agency actions to identify ways to continue to expand the availability of affordable health coverage.\u201d The continued expansion of the government\u2019s role in the U.S. healthcare industry may further lower rates of reimbursement for pharmaceutical products. While we are unable to predict the likelihood of changes to the ACA or other healthcare laws which may negatively impact our profitability, we continue to closely monitor all changes.President Biden intends, as his predecessor did, to take action against drug prices which are considered \u201chigh.\u201d Drug pricing continues to be a subject of debate at the executive and legislative levels of U.S. government. The American Rescue Plan Act of 2021 signed into law by President Biden on March 14, 2021 includes a provision that will eliminate the statutory cap on rebates drug manufacturers pay to Medicaid beginning in January 2024. With the elimination of the rebate cap, manufacturers may be required to compensate states in an amount greater than what the state Medicaid programs pay for the drug. Additionally, the Inflation Reduction Act of 2022 contains substantial drug pricing reforms, including the establishment of a drug price negotiation program within the U.S. Department of Health and Human Services that would require manufacturers to charge a negotiated \u201cmaximum fair price\u201d for certain selected drugs or pay an excise tax for noncompliance, the establishment of rebate payment requirements on manufacturers of certain drugs payable under Medicare Parts B and D to penalize price increases that outpace inflation, and requires manufacturers to provide discounts on Part D drugs. Substantial penalties can be assessed for noncompliance with the drug pricing provisions in the Inflation Reduction Act of 2022. The Inflation Reduction Act of 2022 could have the effect of reducing the prices we can charge and reimbursement we receive for our products, if approved, thereby reducing our profitability, and could have a material adverse effect on our financial condition, results of operations and growth prospects. The effect of Inflation Reduction Act of 2022 on our business and the pharmaceutical industry in general is not yet known. 33",
            "type": "paragraph"
        },
        {
            "id": 36,
            "context": "| \u25cf | the severity of the disease under investigation; |\n| \u25cf | the eligibility criteria for a study; |\n| \u25cf | the perceived risks and benefits of the product candidate under study; |\n| \u25cf | the efforts to facilitate timely enrollment in clinical trials; |\n| \u25cf | the patient referral practices of physicians; |\n| \u25cf | the ability to monitor patients adequately during and after treatment; and |",
            "type": "table"
        },
        {
            "id": 37,
            "context": "| \u25cf | the proximity and availability of clinical trial sites for prospective patients. |\n| \u25cf | the success of any potential clinical studies during the drug development process; |\n| \u25cf | limitations of use, contraindications, or warnings contained in the product\u2019s FDA-approved labeling; |\n| \u25cf | changes in the standard of care for the targeted indications for any current or future product candidates, which could reduce the marketing impact of any superiority claims that we could make following FDA approval; |",
            "type": "table"
        },
        {
            "id": 38,
            "context": "| \u25cf | ability to be listed on formularies (lists of recommended or approved medicines and other products) and reimbursement lists by demonstrating the qualities and treatment benefits of our products within their approved indications; and |\n| \u25cf | potential advantages over, and availability of, alternative treatments. |\n| \u25cf | our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel; |\n| \u25cf | the inability of sales personnel to obtain access to physicians and other healthcare providers or persuade adequate numbers of physicians and other healthcare providers to prescribe any future products; |\n| \u25cf | the lack of complementary or other products to be offered by sales personnel, which may put us at a competitive disadvantage from the perspective of sales efficiency relative to companies with more extensive product lines; and |\n| \u25cf | unforeseen costs and expenses associated with creating an independent sales and marketing organization. |",
            "type": "table"
        },
        {
            "id": 39,
            "context": "We are dependent on third parties to supply raw materials used in our products, to manufacture our products, and to provide services for certain core aspects of our business. Any interruption or failure by these suppliers, distributors, and collaboration partners to meet their contractual obligations to us or obligations pursuant to applicable laws and regulations may materially adversely affect our business, financial condition, results of operations and cash flows.We rely on third parties to supply raw materials, to manufacture, warehouse, and distribute our products, as well as to provide customer service support, medical affairs services, clinical studies, sales, and other technical and financial services. All third-party suppliers and contractors are subject to FDA requirements, as well as those of comparable regulatory authorities. Our business and financial viability are dependent on the continued supply of goods and services by these third parties, the regulatory compliance of these third parties and on the strength, validity and terms of our various contracts with these third parties. Any interruption or failure by our suppliers, distributors and collaboration partners to meet their obligations pursuant to various agreements with us on schedule or in accordance with our expectations, misappropriation of our proprietary information, including trade secrets and know-how, or any termination by these third parties of their arrangements with us, which, in each case, could be the result of one or many factors outside of our control, could delay or prevent the future development, future approval, manufacture or commercialization of our products, result in non-compliance with applicable laws and regulations, cause us to incur failure-to-supply penalties with our wholesale customers, disrupt our operations or cause reputational harm to our company, any or all of which could have a material adverse effect on our business, financial condition, results of operations and cash flows. We may also be unsuccessful in resolving any underlying issues with such suppliers, distributors and partners or replacing them within a reasonable time and on commercially reasonable terms.We do not expect to have the resources or capacity to commercially manufacture any future approved product candidates ourselves. We will likely continue to be heavily dependent upon third-party manufacturers, over whose manufacturing practices and processes we will have oversight, but not direct control, which may adversely affect our ability to develop and commercialize products in a timely or cost-effective manner, if at all. If any of our third-party manufacturers should become unavailable to us for any reason, including as a result of capacity constraints, differing priorities, financial difficulties or insolvency, we would likely incur added costs and delays in identifying or qualifying replacements. We may be unable to establish agreements with such replacement manufacturers or to do so on terms acceptable to us, and our reputation, business, financial condition and results of operations could be negatively impacted.The pharmaceutical manufacturing process requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls, and the use of specialized processing equipment. Further, the CMOs with which we contract must comply with strictly enforced federal, state, and foreign regulations, including the cGMP requirements enforced by the FDA. We will rely on our CMOs to comply with all such regulatory requirements, including cGMP requirements, and failure to do so may result in fines and civil penalties, suspension of production, suspension, delay, or withdrawal of product approval, product seizure or recall, and may limit the availability of our product. Any manufacturing defect or error discovered after products have been produced and distributed could result in costly recall procedures, re-stocking costs, damage to our reputation and potential for product liability claims. The FDA would likely hold us ultimately responsible for any product our CMO manufactures and regulatory enforcement for failure to meet FDA requirements would impact both the CMO and ourselves. The FDA considers the owners of drug products to be ultimately responsible for their products, even where a CMO or other third-party manufacturer fails to meet FDA requirements specific to manufacturing activities. Despite the fact that we have limited oversight, and no direct control over these manufacturing activities, any failure by a CMO to meet the requirements of the regulations would have an adverse impact on both the CMO and ourselves.We also may rely on third-party manufacturers to purchase from third-party suppliers the materials necessary to produce our current or future product candidates for anticipated clinical trials. There are a small number of suppliers for certain capital equipment and raw materials that are used to manufacture those products. We do not have any control over the process or timing of the acquisition of these raw materials by our third-party manufacturers. Moreover, we currently do not have any agreements for the commercial production of these raw materials. Any significant delay in the supply of raw material components related to an ongoing clinical trial could considerably delay completion of our clinical trials, product testing and potential regulatory approval.We rely, and expect to continue to rely, on third parties to conduct any future preclinical studies and clinical trials, and those third parties may not perform satisfactorily, including by failing to meet deadlines for the completion of such trials or to comply with applicable regulatory requirements.We expect to rely on third-party contract and clinical research organizations, clinical data management organizations, and medical institutions and clinical investigators to conduct future preclinical studies and clinical trials. Any future agreements with these third parties might terminate for a variety of reasons, including a failure to perform by the third parties. If we need to enter into alternative arrangements, that could delay any future product development activities.37",
            "type": "paragraph"
        },
        {
            "id": 40,
            "context": "| \u25cf | termination of clinical trial sites or entire trial programs or withdrawal of clinical trial participants; |\n| \u25cf | regulatory investigations by governmental authorities related to regulatory issues or alleged non-compliances; |\n| \u25cf | litigation costs and potential monetary awards to patients or other claimants; |",
            "type": "table"
        },
        {
            "id": 41,
            "context": "| \u25cf | harm to our reputation and/or decreased demand for our products and corresponding revenue loss; |\n| \u25cf | reduced resources of our management to pursue our business strategy; and |\n| \u25cf | the inability to commercialize our current products or any current or future product candidates. |",
            "type": "table"
        },
        {
            "id": 42,
            "context": "| \u25cf | exposure to unknown liabilities; |\n| \u25cf | disruption of our business and diversion of our management\u2019s time and attention to develop acquired products or technologies; |\n| \u25cf | difficulty or inability to secure financing to fund development activities for such acquired or in-licensed technologies in the current economic environment; |\n| \u25cf | incurrence of substantial debt or dilutive issuances of securities to pay for acquisitions; |\n| \u25cf | higher than expected acquisition and integration costs; |\n| \u25cf | increased amortization expenses; |\n| \u25cf | difficulty and cost in combining the operations and personnel of any acquired businesses with our operations and personnel; |\n| \u25cf | impairment of relationships with key suppliers or customers of any acquired businesses due to changes in management and ownership; and |\n| \u25cf | inability to retain key employees of any acquired businesses. |",
            "type": "table"
        },
        {
            "id": 43,
            "context": "Our growth is subject to economic and political conditions.Our business is affected by global and local economic and political conditions as well as the state of the financial markets, inflation, recession, financial liquidity, currency volatility, growth, and policy initiatives. There can be no assurance that global economic conditions and financial markets will not worsen and that we will not experience any adverse effects that may be material to our consolidated cash flows, results of operations, financial position or our ability to access capital, such as the adverse effects resulting from a prolonged shutdown in government operations both in the United States and internationally. Political changes, including war or other conflicts, some of which may be disruptive, could interfere with our supply chain, our customers and all of our activities in a particular location.\u200bOur operating history may make it difficult to evaluate our business and prospects as it relates to clinical trials or regulatory approvals.We were incorporated in October 2014 and have only been conducting commercial operations with respect to our products since 2015. We have not yet demonstrated an ability to successfully complete clinical trials or obtain regulatory approvals. Consequently, any predictions about our future performance may not be as accurate as they could be if we had a history of successfully developing and commercializing future pharmaceutical products.In addition, we may encounter unforeseen expenses, difficulties, complications, delays, and other known and unknown factors. We will need to expand our capabilities to support any future commercial activities. We may not be successful in adding such capabilities.We expect our financial condition and operating results to continue to fluctuate from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any past quarterly period as an indication of future operating performance.We may not be able to manage our business effectively if we are unable to attract and retain key personnel.We may not be able to attract or retain qualified management and commercial, sales, scientific and clinical personnel in the future due to the intense competition for qualified personnel among biotechnology, pharmaceutical and other businesses. If we are not able to attract and retain necessary personnel to accomplish our business objectives, we may experience constraints that will significantly impede sales growth of our branded and generic products, the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy.We may decide to sell assets, which could adversely affect our prospects and opportunities for growth.We may from time to time consider selling certain assets if we determine that such assets are not critical to our strategy or we believe the opportunity to monetize the asset is attractive or for various other reasons, including for the reduction of indebtedness. Although our expectation is to engage in asset sales only if they advance or otherwise support our overall strategy, we may be forced to sell assets in response to liquidation or other claims described herein, and any such sale could reduce the size or scope of our business, our market share in particular markets or our opportunities with respect to certain markets, products or therapeutic categories. As a result, any such sale could have a material adverse effect on our business, financial condition, results of operations and cash flows.There is substantial doubt regarding our ability to continue as a going concern. We may need to raise additional funding (which may not be available on acceptable terms to the Company, or at all) and/or to delay, limit or terminate certain of our product development and commercialization efforts or other operations.Our current assumptions, projected commercial sales of our products, clinical development plans and regulatory submission timelines are uncertain and may not emerge as expected. Additionally, as a result of recurring losses from operations, we have concluded that there is substantial doubt regarding our ability to continue as a going concern for a period of at least 12 months from the date of the issuance of the financial statements included in this Annual Report on Form 10-K for the year ended December 31, 2023. In addition to reductions in sales force and marketing expenses, we may also seek to raise capital through additional debt or equity financing, which may include sales of securities under our existing shelf registration statement on Form S-3, including under the Sales Agreement with B. Riley, or under a new registration statement.41",
            "type": "paragraph"
        },
        {
            "id": 44,
            "context": "| \u25cf | our ability to raise additional capital on acceptable terms, or at all; |\n| \u25cf | timely completion of our clinical trials, which may be significantly slower or cost more than we currently anticipate and will depend substantially upon the performance of third-party contractors as well as our ability to timely recruit and enroll patients in our clinical trials, which may be delayed due to numerous factors, including the prevalence of other companies\u2019 clinical trials for their product candidates for the same or similar indications; |\n| \u25cf | whether we are required by the FDA or similar foreign regulatory agencies to conduct additional clinical trials or other studies beyond those planned to support the approval and commercialization of our current or any future product candidates; |\n| \u25cf | acceptance of our proposed indications and primary endpoint assessments relating to the proposed indications of our current or any future product candidates by the FDA and similar foreign regulatory authorities; |\n| \u25cf | our ability to demonstrate to the satisfaction of the FDA and similar foreign regulatory authorities the safety, efficacy and acceptable risk to benefit profile of our current or any future product candidates; |\n| \u25cf | the prevalence, duration and severity of potential side effects experienced with our current or any future product candidates; |\n| \u25cf | the timely receipt of necessary marketing approvals from the FDA and similar foreign regulatory authorities; |",
            "type": "table"
        },
        {
            "id": 45,
            "context": "| \u25cf | achieving and maintaining, and, where applicable, ensuring that our third-party contractors achieve and maintain, compliance with our contractual obligations and with all regulatory requirements applicable to our current or any future product candidates; |\n| \u25cf | our ability to successfully obtain the substances and materials used in our current or any future product candidates from third parties and to have finished products manufactured by third parties in accordance with regulatory requirements and in sufficient quantities for preclinical and clinical testing; |\n| \u25cf | the ability of third parties with whom we contract to manufacture clinical trial supplies of our current or any future product candidates, remain in good standing with regulatory agencies and develop, validate and maintain commercially viable manufacturing processes that are compliant with cGMP; and |\n| \u25cf | a continued acceptable safety profile during clinical development of our current or any future product candidates. |\n| \u25cf | discovery of serious or unexpected adverse events, toxicities, or side effects experienced by study participants or other safety issues; |\n| \u25cf | lack of effectiveness of any product candidate during clinical trials or the failure of a product candidate to meet specified endpoints; |\n| \u25cf | slower than expected rates of subject recruitment and patient enrollment in clinical trials resulting from numerous factors, including the prevalence of other companies\u2019 clinical trials for their product candidates for the same indication, such as atopic dermatitis; |\n| \u25cf | difficulty in retaining subjects who have initiated participation in a clinical trial but may withdraw at any time due to adverse side effects from the therapy, insufficient efficacy, fatigue with the clinical trial process or for any other reason; |\n| \u25cf | difficulty in obtaining IRB approval for studies to be conducted at each site; |\n| \u25cf | delays in manufacturing or obtaining, or inability to manufacture or obtain, sufficient quantities of materials for use in clinical trials; |\n| \u25cf | inadequacy of or changes in our manufacturing process or the product formulation or method of delivery; |\n| \u25cf | changes in applicable laws, regulations and regulatory policies; |\n| \u25cf | delays or failure in reaching agreement on acceptable terms in clinical trial contracts or protocols with prospective CROs, clinical trial sites and other third-party contractors; |",
            "type": "table"
        },
        {
            "id": 46,
            "context": "| \u25cf | inability to add a sufficient number of clinical trial sites; |\n| \u25cf | uncertainty regarding proper dosing; |\n| \u25cf | failure of our contract research organizations (\u201cCROs\u201d) or other third-party contractors to comply with contractual and regulatory requirements or to perform their services in a timely or acceptable manner; |\n| \u25cf | failure by us, our employees, our CROs or their employees or any partner with which we may collaborate or their employees to comply with applicable FDA or other regulatory requirements relating to the con-duct of clinical trials or the handling, storage, security and recordkeeping for drug and biologic products; |\n| \u25cf | scheduling conflicts with participating clinicians and clinical institutions; |\n| \u25cf | failure to design appropriate clinical trial protocols; |\n| \u25cf | inability or unwillingness of medical investigators to follow our clinical protocols; |\n| \u25cf | difficulty in maintaining contact with subjects during or after treatment, which may result in incomplete data; or |\n| \u25cf | insufficient data to support regulatory approval. |",
            "type": "table"
        },
        {
            "id": 47,
            "context": "regulations. Our failure to comply with these regulations and policies may require us to repeat clinical trials, which would delay the regulatory approval process.If any of our CROs or clinical trial sites terminate their involvement in our clinical trials for any reason, we may not be able to enter into arrangements with alternative CROs or clinical trial sites in a timely manner, or do so on commercially reasonable terms or at all. In addition, if our relationship with clinical trial sites is terminated, we may experience the loss of follow-up information on patients enrolled in our ongoing clinical trial unless we are able to transfer the care of those patients to another qualified clinical trial site. In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and could receive cash compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, the integrity of the data generated at the applicable clinical trial site may be questioned by the FDA and comparable foreign regulatory authorities.Additionally, the regulatory submission process for a product candidate is complex. We expect to rely on a third-party service provider for the preparation and submission of filings with the FDA and comparable foreign regulatory authorities for approval of our current and any future product candidates. Our reliance on third-party CROs may adversely affect our development timelines if the third-party CROs do not meet the requirements or satisfy the obligations required to obtain regulatory approval. Any significant delays caused by our collaboration partner or third-party CROs may have an adverse effect on our development timelines or otherwise may delay approval and commercialization of DFD-29. If our relationship with such service provider is terminated prior to completion of our regulatory submission process, we may not be able to enter into an arrangement with an alternative service provider in a timely manner, or do so on commercially reasonable terms, and our submission may be substantially delayed.We are currently dependent on DRL for the manufacture and clinical supply of DFD-29 drug product. Any interruption in our supply may cause serious delays in the timing of our clinical trials, increase our costs and adversely impact our financial results.Pursuant to the terms of our agreement with DRL for the exclusive, worldwide rights to develop and commercialize DFD-29 for the evaluation of treatment, among other potential indications, inflammatory lesions of rosacea (the \u201cDFD-29 Agreement\u201d), DRL is responsible for the manufacture and supply to us of DFD-29 drug product and we are completely reliant upon DRL to provide us with adequate supply for our use. We may experience an interruption in supply if, among other reasons, we incorrectly forecast our supply requirements, DRL allocates supply to its own development programs, DRL incorrectly plans its manufacturing production or DRL is unable to manufacture DFD-29 drug product in a timely manner to match our development or commercial needs. Transferring technology to a new manufacturer will require additional processes, technologies and validation studies, which are costly, may take considerable amounts of time, may not be successful and require review and approval by the FDA and applicable foreign regulatory bodies. Such manufacturer must comply with cGMP requirements enforced by the FDA and applicable foreign regulatory bodies through facilities inspection programs and review of submitted technical information.We may be unable to obtain regulatory approval for our current or any of our future product candidates under applicable regulatory requirements. The FDA and foreign regulatory bodies have substantial discretion in the approval process, including the ability to delay, limit or deny approval of product candidates. The delay, limitation or denial of any regulatory approval would adversely impact our business and our operating results.We may never obtain regulatory approval to commercialize our current or any future product candidates. The research, testing, manufacturing, safety surveillance, efficacy, quality control, recordkeeping, labeling, packaging, storage, approval, sale, marketing, distribution, import, export and reporting of safety and other post-market information related to our current and any future product candidates are subject to extensive regulation by the FDA and other regulatory authorities in the United States and in foreign countries, and such regulations differ from country to country. We are not permitted to market any of our current or any future product candidates in the United States until we receive approval of an NDA, BLA or other applicable regulatory filing from the FDA. We are also not permitted to market our product or our current or any future product candidates in any foreign countries until we receive the requisite approval from the applicable regulatory authorities of such countries.To gain approval to market a new drug, the FDA and foreign regulatory authorities must receive preclinical, clinical and chemistry, manufacturing and controls data that adequately demonstrate the safety, purity, potency, efficacy and compliant manufacturing of the product for the intended indication applied for in an NDA, BLA or other applicable regulatory filing. The development and approval of new drug products and biologic products involves a long, expensive and uncertain process. A delay or failure can occur at any stage in the process. A number of companies in the pharmaceutical and biopharmaceutical industry have suffered significant setbacks in clinical trials, including in Phase 3 clinical development, even after promising results in earlier preclinical studies or clinical trials. These 45",
            "type": "paragraph"
        },
        {
            "id": 48,
            "context": "| \u25cf | the FDA or the applicable foreign regulatory body may disagree with the design, implementation, choice of dose, analysis plans or interpretation of the outcome of one or more clinical trials; |\n| \u25cf | the FDA or the applicable foreign regulatory body may not deem a product candidate safe and effective for its proposed indication, or may deem a product candidate\u2019s safety or other perceived risks to out-weigh its clinical or other benefits; |\n| \u25cf | the FDA or the applicable foreign regulatory body may not find the data from preclinical studies and clinical trials, including the number of subjects in the safety database, sufficient to support approval, or the results of clinical trials may not meet the level of statistical or clinical significance required by the FDA or the applicable foreign regulatory body for approval; |\n| \u25cf | the FDA or the applicable foreign regulatory body may disagree with our interpretation of data from pre-clinical studies or clinical trials performed by us or third parties, or with the interpretation of any partner with which we may collaborate; |\n| \u25cf | the data collected from clinical trials may not be sufficient to support the submission and approval of an NDA, BLA or other applicable regulatory filing; |\n| \u25cf | the FDA or the applicable foreign regulatory body may require additional preclinical studies or clinical trials; |\n| \u25cf | the FDA or the applicable foreign regulatory agency may identify deficiencies in the formulation, manufacturing, quality control, labeling or specifications of our current or any future product candidates; |\n| \u25cf | the FDA or the applicable foreign regulatory agency may require clinical trials in pediatric patients in order to establish pharmacokinetics or safety for this more drug-sensitive population; |\n| \u25cf | the FDA or the applicable foreign regulatory agency may grant approval contingent on the performance of costly additional post-approval clinical trials; |\n| \u25cf | the FDA or the applicable foreign regulatory agency may grant approval but impose substantial and costly post-approval requirements; |\n| \u25cf | the FDA or the applicable foreign regulatory agency may approve our current or any future product candidates for a more limited indication or a narrower patient population than we originally requested; |\n| \u25cf | the FDA or applicable foreign regulatory agency may not approve the labeling that we believe is necessary or desirable for the successful commercialization of our current or any future product candidates; |\n| \u25cf | the FDA or the applicable foreign regulatory body may not approve of the manufacturing processes, controls or facilities of third-party manufacturers or testing labs with which we contract; or |\n| \u25cf | the FDA or the applicable foreign regulatory body may change its approval policies or adopt new regulations in a manner rendering our clinical data or regulatory filings insufficient for approval. |",
            "type": "table"
        },
        {
            "id": 49,
            "context": "approval to enter into an advanced phase of development, or may change the requirements for approval even after such agency has reviewed and commented on the design for the clinical trials. Any delay in obtaining, or inability to obtain, applicable regulatory approval for any of our product candidates would delay or prevent commercialization of our current and any future product candidates and would harm our business, financial condition, operating results and prospects.We may conduct clinical trials for our current and any future product candidates, in whole or in part, outside of the United States and the FDA and applicable foreign regulatory authorities may not accept data from such trials, which would likely result in additional costs to us and delay our business plan.We may in the future choose to conduct, one or more of our clinical trials outside the United States. Although the FDA or applicable foreign regulatory authority may accept data from clinical trials conducted outside the United States or the applicable jurisdiction, acceptance of such study data by the FDA or applicable foreign regulatory authority may be subject to certain conditions. Where data from foreign clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will not approve the application on the basis of foreign data alone unless those data are applicable to the U.S. population and U.S. medical practice; the studies were performed by clinical investigators of recognized competence; and the data are considered valid without the need for an on-site inspection by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. Many foreign regulatory bodies have similar requirements. In addition, such foreign studies would be subject to the applicable local laws of the foreign jurisdictions where the studies are conducted. There can be no assurance the FDA or applicable foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA or applicable foreign regulatory authority does not accept such data, it would likely result in the need for additional clinical trials, which would be costly and time-consuming and delay aspects of our business plan.Risks Related to Intellectual Property, Generic Competition and Paragraph IV LitigationIf we are unable to obtain and maintain patent protection for our technology and products or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products may be impaired.Our commercial success will depend in part on obtaining and maintaining patent protection and trade secret protection in the United States and other countries with respect to our products or any current or future product candidates that we may license or acquire and our manufacturing methods, as well as successfully defending these patents and trade secrets against third-party challenges, which is expensive and time-consuming. A patent is the grant of a property right which allows its holder to exclude others from, among other things, selling the subject invention in, or importing such invention into, the jurisdiction that granted the patent. We have obtained, acquired or in-licensed a number of patents and patent applications covering key aspects of certain of our principal products. In the aggregate, our patents are of material importance to our business taken as a whole. We seek to protect our proprietary position by filing or obtaining licenses under patent applications in the United States and abroad related to our products and any other current or future product candidates. We will only be able to protect our technologies from unauthorized use by third parties to the extent that valid and enforceable patents cover them. Our success is predicated, in part, by our ability to maintain the integrity of our trade secrets.It is possible that we or our licensors will fail to timely identify patentable aspects of our research and development output before it is too late to obtain patent protection, which may result in third parties using our proprietary information, impairing our abilities to compete in the market, to generate revenues, and to achieve profitability. Moreover, should we enter into other collaborations, we may be required to consult with or cede control to collaborators regarding the prosecution, maintenance and enforcement of our patents. Therefore, such patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner.The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. In addition, no consistent policy regarding the breadth of claims allowed in pharmaceutical or biotechnology patents has emerged to date in the U.S. The patent situation outside the U.S. is even more uncertain. The laws of foreign countries may not protect our rights to the same extent as the laws of the United States. For example, European patent law restricts the patentability of methods of treatment of the human body more than United States law does. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until eighteen (18) months after a first filing, if at all. Therefore, we cannot know with certainty whether we or our licensors were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, 47",
            "type": "paragraph"
        },
        {
            "id": 50,
            "context": "or that we were the first to file for patent protection of such inventions. In the event that a third party has also filed a U.S. patent application relating to any current or future product candidates or a similar invention, we may have to participate in derivation proceedings declared by the USPTO to determine proper inventorship of a claimed invention. The costs of these proceedings could be substantial, and it is possible that our efforts would be unsuccessful, resulting in a material adverse effect on our U.S. patent position. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents.Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. On September 16, 2011, the Leahy-Smith America Invents Act (the \u201cLeahy-Smith Act\u201d), was signed into law. The Leahy-Smith Act includes a number of significant changes to United States patent law. These include provisions that affect the way patent applications are prosecuted and may also affect patent litigation. The United States Patent Office recently developed new regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first-inventor-to-file provisions, which became effective on March 16, 2013. Courts continue to consider the constitutionality of certain provisions of the Leahy-Smith Act, including the Supreme Court in a recent decision affecting inter partes review procedures. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition.Moreover, we may be subject to a third-party pre-issuance submission of prior art to the USPTO, or become involved in opposition, derivation, reexamination, inter partes review, post-grant review or other administrative proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, render unenforceable, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us. We may also be unable to manufacture or commercialize products without infringing third-party patent rights, under which a license might not be available. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop, or commercialize our current or future product candidates.Even if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us, or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner.The issuance of a patent does not foreclose challenges to its inventorship, scope, validity or enforceability. Therefore, our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.Generic drug approvals and successful challenges against the validity of our patents may cause us to lose exclusivity of some of our products.In the U.S., the Hatch-Waxman Act provides non-patent regulatory exclusivity for five years from the date of the first FDA approval of a new drug compound in an NDA. The FDA, with one exception, is prohibited during those five years from accepting for filing a generic, or ANDA that references the NDA. In reference to the foregoing exception, if a patent is indexed in the FDA Orange Book for the new drug compound, a generic may file an ANDA four years from the NDA approval date if it also files a Paragraph IV Certification with the FDA challenging the patent. Protection under the Hatch-Waxman Act will not prevent the filing or approval of another full NDA. However, the NDA applicant would be required to conduct its own pre-clinical and adequate and well-controlled clinical trials to independently demonstrate safety and effectiveness.48",
            "type": "paragraph"
        },
        {
            "id": 51,
            "context": "| \u25cf | our licensors might not have been the first to make the inventions covered by each of our pending patent applications and issued patents; |\n| \u25cf | our licensors might not have been the first to file patent applications for these inventions; |\n| \u25cf | others may independently develop similar or alternative technologies or duplicate our products or our current or future product candidates\u2019 technologies; |\n| \u25cf | it is possible that none of the pending patent applications licensed to us will result in issued patents; |\n| \u25cf | the issued patents covering our products or any current or future product candidates may not provide a basis for commercially viable active products, may not provide us with any competitive advantages, or may be challenged and defeated by third parties; |\n| \u25cf | we may not develop additional proprietary technologies that are patentable; or |\n| \u25cf | patent rights of others may have an adverse effect on our business. |",
            "type": "table"
        },
        {
            "id": 52,
            "context": "| \u25cf | diversion of management\u2019s attention from our core business; |\n| \u25cf | substantial damages for past infringement; |\n| \u25cf | injunctions prohibiting us from selling or licensing our product unless the patent holder licenses the patent to us, which it would not be required to do; |\n| \u25cf | requirements that we pay substantial royalties or grant cross licenses under our patents; |\n| \u25cf | redesigning our processes so they do not infringe, which may not be possible or could require substantial funds and time; and |\n| \u25cf | harm to our reputation and subsequent adverse effect on the valuation of our securities and revenue. |",
            "type": "table"
        },
        {
            "id": 53,
            "context": "If we fail to comply with our obligations in our intellectual property licenses and funding arrangements with third parties, or if we breach an agreement under which we license rights to any product or future product candidate, we could lose rights that are important to our business.If we fail to comply with our obligations under current or future license and funding agreements, our counterparties may have the right to terminate these agreements, in which event we might not be able to develop, manufacture, or market any product or utilize any technology that is covered by these agreements or may face other penalties under the agreements. Such an occurrence could materially and adversely affect the value of a product candidate being developed under any such agreement or could restrict our drug discovery activities. Termination of these agreements or reduction or elimination of our rights under these agreements may result in our having to negotiate new or reinstated agreements with less favorable terms or cause us to lose our rights under these agreements, including our rights to important intellectual property or technology. Further, any uncured, material breach under our license agreement with any current or future licensor could result in our loss of rights to our products or current or future product candidates and may lead to a complete termination of any future product development efforts.Risks Related to our Platform and DataOur business and operations would suffer in the event of computer system failures, cyber-attacks, or deficiencies in our or third parties\u2019 cybersecurity.We are increasingly dependent upon information technology systems, infrastructure, and data to operate our business. In the ordinary course of business, we collect, store, and transmit confidential information, including, but not limited to, information related to our intellectual property and proprietary business information, personal information, and other confidential information. It is critical that we maintain such confidential information in a manner that preserves its confidentiality and integrity. Furthermore, we have outsourced elements of our operations to third party vendors, who each have access to our confidential information, which increases our disclosure risk.While we recently implemented internal security and business continuity measures, our internal computer systems and those of current and future third parties on which we rely may fail and are vulnerable to damage from computer viruses and unauthorized access. Our information technology and other internal infrastructure systems, including corporate firewalls, servers, data center facilities, lab equipment, and connection to the internet, face the risk of breakdown or other damage or interruption from service interruptions, system malfunctions, natural disasters, terrorism, war, and telecommunication and electrical failures, as well as security breaches from inadvertent or intentional actions by our employees, contractors, consultants, business partners, and/or other third parties, or from cyber-attacks by malicious third parties (including the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information), each of which could compromise our system infrastructure or lead to the loss, destruction, alteration, disclosure, or dissemination of, or damage or unauthorized access to, our data or data that is processed or maintained on our behalf, or other assets.If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations, and could result in financial, legal, business, and reputational harm to us. For example, in 2021, we were the victim of a cybersecurity incident that affected our accounts payable function and led to approximately $9.5 million in wire transfers being misdirected to fraudulent accounts. The matter was reported to the FBI and remains under their investigation. The cybersecurity incident does not appear to have compromised any personally identifiable information or protected health information. Fortress, as our controlling stockholder and supporting partner in our back-office functions, provided us with $9.5 million to ensure our accounts payable operations continued to function smoothly. The $9.5 million of support was in the form of a related party note which the boards of both companies have agreed and converted into 1,476,044 shares of our common stock upon the consummation of our IPO in November 2021 at the IPO price. The federal government has been able to trace and seize the fraudulently transferred cryptocurrency associated with the breach. Once the cryptocurrency has been converted back into U.S. dollars, we expect to receive a notification letter to initiate the return of the cash to the Company. This process could take as long as six months or more to complete. Given the recent market declines, volatility, and liquidity issues with cryptocurrency, there is no certainty as to the amount we will ultimately recover. We may incur additional expenses and losses as a result of this cybersecurity incident, including related to investigation fees and remediation costs.In addition, the loss or corruption of, or other damage to, clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on third parties for the manufacture of our drug candidates or any future drug candidates and to conduct clinical trials, and similar events relating to 51",
            "type": "paragraph"
        },
        {
            "id": 54,
            "context": "| \u25cf | our current or any future product candidates are approved for commercial sale, due to our ability to establish the necessary commercial infrastructure to launch this product candidate without substantial delays, including hiring sales and marketing personnel and contracting with third parties for warehousing, distribution, cash collection and related commercial activities; |\n| \u25cf | we acquire or in-license new products for development and/or sale; |\n| \u25cf | we are required by the FDA, or foreign regulatory authorities, to perform studies in addition to those currently expected; |",
            "type": "table"
        },
        {
            "id": 55,
            "context": "| \u25cf | there are any delays in completing our clinical trials or the development of our current or any future product candidates; |\n| \u25cf | we execute other collaborative, licensing or similar arrangements that require us to make payments and/ or expend funds; |\n| \u25cf | there are variations in the level of expenses related to our future development programs; |\n| \u25cf | there are any product liability or intellectual property infringement lawsuits in which we may become involved; |\n| \u25cf | there are any regulatory developments affecting our products, current or future product candidates, or the product candidates of our competitors; or |\n| \u25cf | the level of underlying demand for our products and wholesalers\u2019 buying patterns. |\n| \u25cf | obtain and maintain regulatory approval for our products, or any other current or future product candidates that we may license or acquire; |\n| \u25cf | manufacture commercial quantities of our current products or current or future product candidates, if approved, at acceptable cost levels; and |\n| \u25cf | maintain and/or expand our commercial organization and the supporting infrastructure required to successfully market and sell our products or current or future product candidates, if approved. |\n| \u25cf | fund our operations and continue our efforts to hire additional personnel; |\n| \u25cf | qualify and outsource the commercial-scale manufacturing of our products under cGMP; and |\n| \u25cf | acquire, in-license and/ or develop additional product candidates. |\n| \u25cf | the potential for delays in our efforts to seek regulatory approval for any current or future product candidates, and any costs associated with such delays; |\n| \u25cf | the costs of maintaining and/or establishing a commercial organization to sell, market and distribute our products and/or current or future product candidates; |\n| \u25cf | the rate of progress and costs of our efforts to prepare for the submission of NDA or BLA for any product candidates that we may in-license or acquire in the future, and the potential that we may need to conduct additional clinical trials to support applications for regulatory approval; |",
            "type": "table"
        },
        {
            "id": 56,
            "context": "| \u25cf | the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights associated with any current or future product candidates, including any such costs we may be required to expend if licensors are unwilling or unable to do so; |\n| \u25cf | the cost and timing of securing sufficient supplies of our products and current or future product candidates from our contract manufacturers in preparation for commercialization, manufacture, and/or sale; |\n| \u25cf | the effect of competing technological and market developments; |\n| \u25cf | the terms and timing of any collaborative, licensing, co-promotion or other arrangements that we may establish; |\n| \u25cf | the potential that we may be required to file a lawsuit to defend our patent rights or regulatory exclusivities from challenges by companies seeking to market generic versions of our branded products; and |\n| \u25cf | the success of sales efforts of our current products and/or the commercialization of any current or future product candidates. |",
            "type": "table"
        },
        {
            "id": 57,
            "context": "| \u25cf | permit the board of directors to establish the number of directors and fill any vacancies and newly created directorships; |\n| \u25cf | provide that, after a removal for cause, vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum; |\n| \u25cf | prohibit cumulative voting in the election of directors; |\n| \u25cf | require majority voting to amend our certificate of incorporation and bylaws; |\n| \u25cf | authorize the issuance of \u201cblank check\u201d preferred stock that our board of directors could use to implement a stockholder rights plan; |\n| \u25cf | restrict the forum for certain litigation against us to Delaware or federal courts; |\n| \u25cf | establish advance notice requirements for nominations for election to our board of directors or for proposing matters that can be acted upon by stockholders at annual stockholder meetings; and |\n| \u25cf | bestow majority control of the stockholder vote to Fortress by virtue of their exclusive ownership of our Class A Common Stock. |",
            "type": "table"
        },
        {
            "id": 58,
            "context": "Our Third Amended and Restated Certificate of Incorporation provides, subject to limited exceptions, that the Court of Chancery of the State of Delaware is the sole and exclusive forum for certain stockholder litigation matters, which could limit our stockholders\u2019 ability to obtain a chosen judicial forum for disputes with us or our directors, officers, employees or stockholders.Our Third Amended and Restated Certificate of Incorporation requires to the fullest extent permitted by law, that derivative actions brought in our name, actions against directors, officers and employees for breach of fiduciary duty and other similar actions must be brought in the Court of Chancery in the State of Delaware or, if that court lacks subject matter jurisdiction, another federal or state court situated in the State of Delaware. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and consented to the forum provisions in our certificate of incorporation. In addition, our Third Amended and Restated Certificate of Incorporation provides that the federal district courts of the United States are the exclusive forum for the resolution of any complaint asserting a cause of action under the Securities Act and the Exchange Act.This choice of forum provision may limit a stockholder\u2019s ability to bring a claim in a judicial forum of its choosing for disputes with us or any of our directors, officers, other employees or stockholders, which may discourage lawsuits with respect to such claims. Alternatively, if a court were to find the choice of forum provision contained in our Third Amended and Restated Certificate of Incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, operating results and financial condition.The requirements of being a public company may strain our resources, divert our management\u2019s attention and affect our ability to attract and retain qualified board members.As a public company, we are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, and are required to comply with the applicable requirements of the Sarbanes-Oxley Act and the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of Nasdaq, and other applicable securities rules and regulations. Compliance with these rules and regulations increases our legal and financial compliance costs, makes some activities more difficult, time-consuming or costly and increases demand on our systems and resources. Among other things, the Exchange Act requires that we file annual, quarterly and current reports with respect to our business and operating results and maintain effective disclosure controls and procedures and internal controls over financial reporting. Significant resources and management oversight is required to maintain and, if required, improve our disclosure controls and procedures and internal controls over financial reporting to meet this standard. As a result, management\u2019s attention may be diverted from other business concerns, which could harm our business and operating results. Although we hired additional employees to comply with these requirements, we may need to hire even more employees in the future, which will increase our costs and expenses.Reduced reporting and disclosure requirements applicable to us as an EGC could make our common stock less attractive to investors.We are an EGC and, as long as we continue to be an EGC, we may continue to avail ourselves of exemptions from various reporting requirements applicable to other public companies. Consequently, we are not required to have our independent registered public accounting firm audit our internal control over financial reporting under Section 404 of the Sarbanes-Oxley Act, and we are subject to reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. In addition, the JOBS Act provides that an EGC can take advantage of an extended transition period for complying with new or revised accounting standards. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of the dates such pronouncements are effective for public companies. We could be an EGC for up to five years following the completion of our November 2021 public offering. We will cease to be an EGC upon the earliest of: (i) the end of the fiscal year following the fifth anniversary of the aforementioned offering, (ii) the first fiscal year after our annual gross revenue is $1.235 billion or more, (iii) the date on which we have, during the previous three-year period, issued more than $1.0 billion in nonconvertible debt securities or (iv) the end of any fiscal year in which the market value of our common stock held by non-affiliates exceeded $700 million as of the end of the second quarter of that fiscal year. We cannot predict whether investors will find our common stock less attractive if we choose to rely on these exemptions. If some investors find our common stock less attractive as a result of any choices to reduce future disclosure, there may be a less active trading market for our common stock, and the price of our common stock may be more volatile.56",
            "type": "paragraph"
        },
        {
            "id": 59,
            "context": "| \u25cf | significant volatility in the market price and trading volume of companies in our industry; |\n| \u25cf | announcements of new solutions or technologies, commercial relationships, acquisitions, or other events by us or our competitors; |\n| \u25cf | price and volume fluctuations in the overall stock market from time to time; |\n| \u25cf | changes in how customers perceive the benefits of our products and future offerings; |\n| \u25cf | the public\u2019s reaction to our press releases, other public announcements, and filings with the SEC; |\n| \u25cf | fluctuations in the trading volume of our shares or the size of our public float; |\n| \u25cf | actual or anticipated changes or fluctuations in our results of operations or financial projections; |\n| \u25cf | changes in actual or future expectations of investors or securities analysts; |\n| \u25cf | litigation involving us, our industry, or both; |\n| \u25cf | governmental or regulatory actions or audits; |\n| \u25cf | regulatory developments applicable to our business, including those related to privacy in the United States or globally; |\n| \u25cf | general economic conditions and trends; |\n| \u25cf | major catastrophic events in our domestic and foreign markets; and |\n| \u25cf | departures of key employees. |",
            "type": "table"
        },
        {
            "id": 60,
            "context": "Risks Related to our Relationship with Fortress Biotech, Inc.Fortress controls a voting majority of our common stock, which could be detrimental to our other shareholders.Pursuant to the terms of the Class A Common Stock held by Fortress, Fortress will be entitled to cast, for each share of Class A Common Stock held by Fortress, the number of votes that is equal to 1.1 times a fraction, the numerator of which is the number of shares of our outstanding common stock and the denominator of which is the number of shares of outstanding Class A Common Stock (the \u201cClass A Common Stock Ratio\u201d). Thus, Fortress will at all times have voting control of Journey. Further, for a period of ten (10) years from the date of the first issuance of shares of Class A Common Stock, the holders of record of the shares of Class A Common Stock (or other capital stock or securities issued upon conversion of or in exchange for the Class A Common Stock), exclusively and as a separate class, shall be entitled to appoint or elect the majority of the directors of Journey. This concentration of voting power may delay, prevent or deter a change in control of us even when such a change may be in the best interests of all stockholders, could deprive our stockholders of an opportunity to receive a premium for their shares of common stock as part of a sale of Journey or our assets, and might affect the prevailing market price of our common stock.We are a \u201ccontrolled company\u201d within the meaning of Nasdaq listing standards and, as a result, qualify for exemptions from certain corporate governance requirements. Although we do not presently intend to take advantage of these exemptions, we may do so in the future.We are a \u201ccontrolled company\u201d within the meaning of Nasdaq listing standards. Under these rules, a company of which more than 50% of the voting power is held by an individual, a group or another company is a \u201ccontrolled company\u201d and may elect not to comply with certain corporate governance requirements of Nasdaq, including (i) the requirement that a majority of the Board of Directors consist of independent directors, (ii) the requirement that we have a nominating and corporate governance committee that is composed entirely of independent directors with a written charter addressing the committee\u2019s purpose and responsibilities and (iii) the requirement that we have a compensation committee that is composed entirely of independent directors with a written charter addressing the committee\u2019s purpose and responsibilities. Although we presently are not taking advantage of these exemptions, we may do so in the future. Accordingly, our stockholders may not have the same protections afforded to stockholders of companies that are subject to all of the corporate governance requirements of Nasdaq. Investors may find our common stock less attractive as a result of our reliance on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.We may have received better terms from unaffiliated third parties than the terms we receive in our arrangements with Fortress.We have arrangements with Fortress in connection with management and administration services for the Company. While we believe the terms of these arrangements are reasonable, they might not reflect terms that would have resulted from arm\u2019s-length negotiations between unaffiliated third parties. The terms of the arrangement relate to, among other things, systems, insurance, accounting, legal, finance, tax and human resources. We might have received better terms from third parties because, among other things, third parties might have competed with each other to win our business.The ownership by our executive officers and some of our directors of shares of equity securities of Fortress and/or rights to acquire equity securities of Fortress might create, or appear to create, conflicts of interest.Because of their current or former positions with Fortress, some of our executive officers and directors own shares of Fortress common stock and/or options to purchase shares of Fortress common stock. Their individual holdings of common stock and/or options to purchase common stock of Fortress may be significant compared to their total assets. Ownership by our directors and officers, after our separation, of common stock and/or options to purchase common stock of Fortress might appear to create conflicts of interest when these directors and officers are faced with decisions that could have different implications for Fortress than for us.58",
            "type": "paragraph"
        },
        {
            "id": 61,
            "context": "Fortress\u2019 current or future financial obligations and arrangements, or an event of default thereon, may change the ownership dynamic of us by Fortress.Any default or breach by Fortress under any current or future credit agreement or arrangements may have an adverse effect on our business. Fortress has pledged as collateral to certain of its creditors equity in the Company. If Fortress were to default on its obligations to any such creditor, that creditor, whose interests may not align with those of our other stakeholders, could acquire a controlling interest in the Company. In addition, Fortress\u2019 current credit agreement with Oaktree Capital (the \u201cOaktree Credit Agreement\u201d) contains certain affirmative and negative covenants and events of default that apply in different instances to Fortress itself, its private subsidiaries, its public subsidiaries, or combinations of the foregoing. Although we are not a party to the Oaktree Credit Agreement, because Fortress controls our stockholder vote, Fortress may not permit us to effect certain actions which we feel would be in the Company\u2019s best interests, but which Fortress cannot allow so as to remain in compliance with the Oaktree Credit Agreement.General RisksFailure to manage our growth effectively could cause our business to suffer and have an adverse effect on our business, operating results and financial condition.We have experienced significant growth in a short period of time. To manage our growth effectively, we must continually evaluate and evolve our organization. We must also manage our employees, operations, finances and capital investments efficiently. Our efficiency, productivity and the quality of our products may be adversely impacted if we do not train our new personnel, particularly our sales and support personnel, quickly and effectively, or if we fail to appropriately coordinate across our organization. Additionally, our rapid growth may place a strain on our resources, infrastructure and ability to maintain the quality of our products. You should not consider our revenue growth and levels of profitability in recent periods as indicative of future performance. In future periods, our revenue or profitability could decline or grow more slowly than we expect. Failure to manage our growth effectively could cause our business to suffer and have an adverse effect on our operating results and financial condition.If securities or industry analysts do not publish research or reports about our business, or publish inaccurate or unfavorable research reports about our business, our share price and trading volume could decline.The trading market for our common stock partially depends on the research and reports that securities or industry analysts publish about us or our business. We do not have any control over these analysts. If one or more of the analysts who cover us should downgrade our shares or change their opinion of our business prospects, our share price would likely decline. If one or more of these analysts ceases coverage of our company or fails to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our share price or trading volume to decline.Our reported financial results may be adversely affected by changes in accounting principles generally accepted in the United States. If our estimates or judgments relating to our critical accounting policies prove to be incorrect, our results of operations could be adversely affected.U.S. generally accepted accounting principles (\u201cGAAP\u201d) are subject to interpretation by the Financial Accounting Standards Board (\u201cFASB\u201d), the SEC and various bodies formed to promulgate and interpret appropriate accounting principles. A change in these principles or interpretations could have a significant effect on our reported results of operations and could affect the reporting of transactions already completed before the announcement of a change.59",
            "type": "paragraph"
        },
        {
            "id": 62,
            "context": "The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes appearing elsewhere in this report on Form 10-K. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, as discussed in the section titled \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations \u2014 Critical Accounting Policies and Estimates.\u201d The results of these estimates form the basis for making judgments about the carrying values of assets, liabilities and equity, and the amount of revenue and expenses that are not readily apparent from other sources. Significant estimates, judgments, and assumptions used in our financial statements include, but are not limited to, those related to revenue recognition, accounts receivable and related reserves, useful lives and realizability of long-lived assets, research and development costs, assumptions used in the valuation of warrants, accounting for share-based compensation, and valuation allowances against deferred tax assets. These estimates are periodically reviewed for any changes in circumstances, facts, and experience. Our results of operations may be adversely affected if our assumptions change or if actual circumstances differ from those in our assumptions, which could cause our results of operations to fall below the expectations of securities analysts and investors, resulting in a decline in the market price of our common stock.Global and national financial events may have an impact on our business and financial condition in ways that we currently cannot predict.A credit crisis, turmoil in the global or U.S. financial system, recession or similar possible events in the future could negatively impact us. A financial crisis or recession may limit our ability to raise capital through credit and equity markets. The prices for the products and services that we intend to provide may be affected by a number of factors, and it is unknown how these factors may be impacted by a global or national financial event.If our estimates or judgments relating to our critical accounting policies are erroneous or based on assumptions that change or prove to be incorrect, our operating results could fall below the expectations of securities analysts and investors, resulting in a decline in our stock price.The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. We base our estimates on our best judgment, historical experience, information derived from third parties and on various other assumptions that we believe to be reasonable under the circumstances, as discussed in the section titled \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations,\u201d the results of which form the basis for making judgments about the carrying values of assets, liabilities, equity, revenue and expenses that are not readily apparent from other sources. Our operating results may be adversely affected if our judgments prove to be wrong, assumptions change or actual circumstances differ from those in our assumptions, which could cause our operating results to fall below the expectations of securities analysts and investors, resulting in a decline in our stock price. Significant assumptions and estimates used in preparing our consolidated financial statements include those related to revenue recognition, share-based compensation and income taxes.Changes in tax laws or regulations that are applied adversely to us may have a material adverse effect on our business, cash flow, financial condition or results of operations.New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our business operations and financial performance. For example, the United States recently passed the Inflation Reduction Act, which provides for a minimum tax equal to 15% of the adjusted financial statement income of certain large corporations, as well as a 1% excise tax on certain share buybacks by public corporations that would be imposed on such corporations. In addition, it is uncertain if and to what extent various states will conform to newly enacted federal tax legislation. Changes in corporate tax rates, the realization of net deferred tax assets relating to our operations, the taxation of foreign earnings, and the deductibility of expenses could have a material impact on the value of our deferred tax assets, could result in significant one-time charges, and could increase our future U.S. tax expense.\u200b60",
            "type": "paragraph"
        },
        {
            "id": 63,
            "context": "Item 1B. Unresolved Staff Comments\n\u200b\nNone.\n\u200b\nItem 2. Properties\nOur executive offices are located at 9237 E Via de Ventura Blvd. Suite 105, Scottsdale, AZ 85258. We believe that our existing facilities are adequate to meet our current requirements. We do not own any real property. In September 2022, we amended our lease and entered into a new 25-month extension of the office space in Scottsdale, AZ at an average annual rent of $0.1 million. The term of this amended lease commenced on January 1, 2023 and will expire on January 31, 2025.",
            "type": "paragraph"
        },
        {
            "id": 64,
            "context": "61\nItem 3. Legal Proceedings To our knowledge, there are no legal proceedings pending against us, other than routine actions, administrative proceedings, and other actions not deemed material, that are expected to have a material adverse effect on our financial condition, results of operations, or cash flows. In the ordinary course of business, however, the Company may be subject to both insured and uninsured litigation. Suits and claims may be brought against the Company by customers, suppliers, partners and/or third parties (including tort claims for personal injury arising from clinical trials of the Company\u2019s product candidates and property damage) alleging deficiencies in performance, breach of contract, etc., and seeking resulting alleged damages.",
            "type": "paragraph"
        },
        {
            "id": 65,
            "context": "\u200b\nItem 4. Mine Safety Disclosures\nNot applicable.\n\u200b\n62\nPART II\u200b\nItem 5. Market for Registrant\u2019s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities\n\u200b\nMarket information\n\u200b Our common stock is listed on the Nasdaq Capital Market and trades under the symbol \u201cDERM.\u201d We commenced trading on the Nasdaq Capital Market on November 12, 2021. Prior to November 12, 2021 there was no public market for our common stock.",
            "type": "paragraph"
        },
        {
            "id": 66,
            "context": "\u200b\nEquity Compensation Plans\n\u200b\nWe do not maintain any deferred compensation, retirement, pension or profit-sharing plans. Our board of directors has adopted an incentive plan, allowing for the grant of equity and cash-based awards to our employees and directors.\n\u200b\nSales of Unregistered Securities\n\u200b\nNone.\n\u200b\nUse of Proceeds from Sales of Registered Securities\n\u200b On December 30, 2022, we filed a shelf registration statement on Form S-3 (File No. 333 - 269079), which was declared effective by the SEC on January 26, 2023. This shelf registration statement covers the offering, issuance and sale by us of up to an aggregate of $150.0 million of the Company\u2019s common stock, preferred stock, debt securities, warrants, and units (the \u201c2022 Shelf\u201d). In connection with the 2022 Shelf, we entered into an At Market Issuance Sales Agreement (the \u201cSales Agreement\u201d) with B. Riley Securities, Inc. (\u201cB. Riley\u201d), relating to shares of our common stock. In accordance with the terms of the Sales Agreement, we may offer and sell up to 4,900,000 shares of our common stock, par value $0.0001 per share, from time to time through or to B. Riley acting as our agent or principal. During 2023, we issued 748,703 shares of common stock under the 2022 Shelf, generating net proceeds of $4.5 million. At December 31, 2023, 4,151,297 shares remain available for issuance under the Sales Agreement.",
            "type": "paragraph"
        },
        {
            "id": 67,
            "context": "We currently intend to use the net proceeds from this offering for general corporate purposes, including working capital, research and development, payments for research and development\u2009\u2014\u2009licenses acquired, sales and marketing activities, general administrative matters, operating expenses and capital expenditures.",
            "type": "paragraph"
        },
        {
            "id": 68,
            "context": "\u200b\nHolders\n\u200b As of March 28, 2024, there were approximately 44 holders of record for our common stock and 1 holder of record for our Class A common stock. The actual number of stockholders is greater than this number of record holders and includes stockholders who are beneficial owners and whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.",
            "type": "paragraph"
        },
        {
            "id": 69,
            "context": "\u200b\nDividends\n\u200b\nWe have never paid cash dividends on any of our capital stock and currently intend to retain our future earnings, if any, to fund the development and growth of our business.\n\u200b\nItem 6.\n[RESERVED.]\n\u200b\n63\nItem 7. Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations\nForward-Looking Statements You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our consolidated financial statements and the related notes included elsewhere in this Form 10-K. Our consolidated financial statements have been prepared in accordance with U.S. GAAP. The following discussion and analysis contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the \u201cExchange Act\u201d). Please see the section titled \u201cSpecial Cautionary Notice Regarding Forward-Looking Statements\u201d elsewhere in this Annual Report on Form 10-K for more information. In evaluating our business, you should carefully consider the information set forth under the heading \u201cRisk Factors\u201d herein. As used below, the words \u201cwe,\u201d \u201cus\u201d and \u201cour\u201d refer to Journey Medical Corporation and its consolidated subsidiaries.",
            "type": "paragraph"
        },
        {
            "id": 70,
            "context": "Overview We are a commercial-stage pharmaceutical company founded in October 2014 that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Our current portfolio includes seven branded and two authorized generic prescription drugs for dermatological conditions that are marketed in the U.S. We are managed by experienced life science executives with a track record of creating value for their stakeholders and bringing novel medicines to the market, enabling patients to experience increased quality of life, and enabling physicians and other licensed medical professionals to provide better care for their patients. We aim to acquire rights to future products by licensing or otherwise acquiring an ownership interest in, funding the research and development of, and eventually commercializing, the products through our field sales organization. Since inception, we have made significant investments to build out our commercial product portfolios, which we believe, coupled with our experienced dermatology sales leadership team and field sales force, will position our business for growth. We are a majority-owned subsidiary of Fortress.",
            "type": "paragraph"
        },
        {
            "id": 71,
            "context": "Critical Accounting Policies and Uses of Estimates Our consolidated financial statements have been prepared in accordance with U.S. GAAP. The preparation of these consolidated financial statements requires us to make difficult, subjective or complex judgments, often as a result of the need to make estimates and assumptions about the effect of matters that are inherently uncertain in the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.",
            "type": "paragraph"
        },
        {
            "id": 72,
            "context": "While our significant accounting policies are described in greater detail in Note 2, \u201cBasis of Presentation and Summary of Significant Accounting Policies\u201d in our consolidated financial statements, appearing under Part II, Item 8 and beginning at page F-1 of this Annual Report on Form 10-K, we believe that the following accounting policies and estimates are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements in understanding our historical and future performance. These policies relate to the more significant areas involving management\u2019s judgments and estimates.",
            "type": "paragraph"
        },
        {
            "id": 73,
            "context": "Revenue Recognition Our gross product revenues are subject to a variety of deductions, which generally are estimated and recorded in the same period that the revenues are recognized. Such variable consideration represents chargebacks, coupons, discounts, other sales allowances and sales returns. These deductions represent estimates of the related obligations and, as such, knowledge and judgment are required when estimating the impact of these revenue deductions on gross sales for a reporting period. Historically, adjustments to these estimates to reflect actual results or updated expectations have not been material to our overall business. Coupons, however, can have a significant impact on year-over-year individual product revenue growth trends. If any of our ratios, factors, assessments, experiences, or judgments are not indicative or accurate estimates of our future experience, our results could be materially affected. The potential of our estimates to vary differs by program, product, type of customer and geographic location.",
            "type": "paragraph"
        },
        {
            "id": 74,
            "context": "64 Recent Accounting PronouncementsSee Note 2, \u201cBasis of Presentation and Summary of Significant Accounting Policies\u201d in our consolidated financial statements, appearing under Part II, Item 8 and beginning at page F-1 of this Annual Report on Form 10-K for information about recent accounting pronouncements, the timing of their adoption, if applicable, and our assessment, if any, of their potential impact on our financial condition and results of operations.Emerging Growth Company and Smaller Reporting Company StatusWe are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (\u201cJOBS Act\u201d). Under the JOBS Act, emerging growth companies can delay the adoption of new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. Other exemptions and reduced reporting requirements under the JOBS Act for emerging growth companies include presentation of only two years of audited financial statements in our annual reports on Form 10-K, an exemption from the requirement to provide an auditor\u2019s report on internal controls over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, as amended, an exemption from any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation and less extensive disclosure about our executive compensation arrangements. We have elected to use the extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that (i) we are no longer an emerging growth company or (ii) we affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act.We are also a \u201csmaller reporting company,\u201d meaning that either (i) the market value of our shares held by non-affiliates is less than $250 million or (ii) the market value of our shares held by non-affiliates is less than $700 million and our annual revenue was less than $100 million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the market value of our shares held by non-affiliates is less than $250 million or (ii) our annual revenue was less than $100 million during the most recently completed fiscal year and the market value of our shares held by non-affiliates is less than $700 million. As a smaller reporting company, we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K, have reduced disclosure obligations regarding executive compensation, and smaller reporting companies are permitted to delay adoption of certain recent accounting pronouncements discussed in Note 2 See Note 2, \u201cBasis of Presentation and Summary of Significant Accounting Policies\u201d in our consolidated financial statements, appearing under Part II, Item 8 and beginning at page F-1 of this Annual Report on Form 10-K.\u200b65",
            "type": "paragraph"
        },
        {
            "id": 75,
            "context": "| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | For the Years Ended December 31, | Change |\n| ($ in thousands, except per share data) | 2023 | 2022 | $ | % | \u200b |\n| Revenue: | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Product revenue, net | \u200b | $ | 59,662 | \u200b | $ | 70,995 | \u200b | $ | (11,333) | \u200b | (16) | % |\n| Other revenue | \u200b | \u200b | 19,519 | \u200b | \u200b | 2,674 | \u200b | \u200b | 16,845 | \u200b | 630 | % |\n| Total revenue | \u200b | \u200b | 79,181 | \u200b | \u200b | 73,669 | \u200b | \u200b | 5,512 | \u200b | 7 | % |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Operating expenses | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Cost of goods sold - product revenue | \u200b | \u200b | 26,660 | \u200b | \u200b | 30,775 | \u200b | \u200b | (4,115) | \u200b | (13) | % |\n| Research and development | \u200b | \u200b | 7,541 | \u200b | \u200b | 10,943 | \u200b | \u200b | (3,402) | \u200b | (31) | % |\n| Selling, general and administrative | \u200b | \u200b | 43,910 | \u200b | \u200b | 59,468 | \u200b | \u200b | (15,558) | \u200b | (26) | % |\n| Loss on impairment of intangible assets | \u200b | \u200b | 3,143 | \u200b | \u200b | \u2014 | \u200b | \u200b | 3,143 | \u200b | 100 | % |\n| Total operating expenses | \u200b | \u200b | 81,254 | \u200b | \u200b | 101,186 | \u200b | \u200b | (19,932) | \u200b | (20) | % |\n| Loss from operations | \u200b | \u200b | (2,073) | \u200b | \u200b | (27,517) | \u200b | \u200b | 25,444 | \u200b | (92) | % |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Other expense | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Interest income | \u200b | \u200b | (322) | \u200b | \u200b | (60) | \u200b | \u200b | (262) | \u200b | 437 | % |\n| Interest expense | \u200b | \u200b | 1,698 | \u200b | \u200b | 2,019 | \u200b | \u200b | (321) | \u200b | (16) | % |\n| Foreign exchange transaction losses | \u200b | \u200b | 183 | \u200b | \u200b | 89 | \u200b | \u200b | 94 | \u200b | 106 | % |\n| Total other expense | \u200b | \u200b | 1,559 | \u200b | \u200b | 2,048 | \u200b | \u200b | (489) | \u200b | (24) | % |\n| Loss before income taxes | \u200b | \u200b | (3,632) | \u200b | \u200b | (29,565) | \u200b | \u200b | 25,933 | \u200b | (88) | % |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Income tax expense | \u200b | \u200b | 221 | \u200b | \u200b | 63 | \u200b | \u200b | 158 | \u200b | 251 | % |\n| Net Loss | \u200b | \u200b | (3,853) | \u200b | \u200b | (29,628) | \u200b | \u200b | 25,775 | \u200b | (87) | % |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | For the Years Ended December 31, | \u200b | Change |\n| ($in thousands) | 2023 | 2022 | $ | % | \u200b |\n| Qbrexza\u00ae | \u200b | $ | 25,410 | \u200b | $ | 26,715 | \u200b | $ | (1,305) | \u200b | (5) | % |\n| Accutane\u00ae | \u200b | 20,168 | \u200b | 18,373 | \u200b | 1,795 | \u200b | 10 | % |\n| Amzeeq | \u200b | 6,201 | \u200b | 7,242 | \u200b | (1,041) | \u200b | (14) | % |\n| Targadox\u00ae | \u200b | 3,204 | \u200b | 7,972 | \u200b | (4,768) | \u200b | (60) | % |\n| Exelderm\u00ae | \u200b | \u200b | 2,395 | \u200b | \u200b | 3,463 | \u200b | \u200b | (1,068) | \u200b | (31) | % |\n| Zilxi | \u200b | \u200b | 1,962 | \u200b | \u200b | 2,273 | \u200b | \u200b | (311) | \u200b | (14) | % |\n| Ximino\u00ae | \u200b | \u200b | 287 | \u200b | \u200b | 4,957 | \u200b | \u200b | (4,670) | \u200b | (94) | % |\n| Luxamend\u00ae | \u200b | \u200b | 35 | \u200b | \u200b | \u2014 | \u200b | \u200b | 35 | \u200b | 100 | % |\n| Total net product revenue | \u200b | $ | 59,662 | \u200b | $ | 70,995 | \u200b | $ | (11,333) | \u200b | (16) | % |",
            "type": "table"
        },
        {
            "id": 76,
            "context": "| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | For the Years Ended | \u200b |\n| \u200b | \u200b | December 31, | \u200b | Change |\n| ($in thousands) | \u200b | 2023 | 2022 | \u200b | $ | \u200b | % |\n| Non-refundable upfront payment from Maruho | \u200b | $ | 19,000 | \u200b | $ | \u2014 | \u200b | $ | 19,000 | \u200b | 100 | % |\n| Net milestone payment from Maruho | \u200b | \u2014 | \u200b | 2,500 | \u200b | (2,500) | \u200b | (100) | % |\n| Royalties on sales of Rapifort\u00ae Wipes 2.5% | \u200b | 519 | \u200b | 174 | \u200b | 345 | \u200b | 198 | % |\n| Total other revenue | \u200b | $ | 19,519 | \u200b | $ | 2,674 | \u200b | $ | 16,845 | \u200b | 630 | % |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | Chargebacks | \u200b | Distributor | \u200b | Prompt | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | Managed | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | and other | \u200b | Service | Pay | \u200b | \u200b | \u200b | \u200b | Care | \u200b | Gov\u2019t | \u200b | \u200b | \u200b |\n| ($\u2019s in thousands) | allowances | Fees | Discounts | Returns | Coupons | Rebates | Rebates | Total |\n| Balance as of December 31, 2021 | \u200b | $ | 622 | \u200b | $ | 791 | \u200b | $ | 197 | \u200b | $ | 3,240 | \u200b | $ | 4,992 | \u200b | $ | 3,492 | \u200b | $ | 690 | \u200b | $ | 14,024 |\n| Current provision related to sales in the current period | \u200b | 2,663 | \u200b | 5,868 | \u200b | 1,104 | \u200b | 5,387 | \u200b | 117,883 | \u200b | 22,654 | \u200b | 3,651 | \u200b | 159,210 |\n| Checks/credits issued to third parties | \u200b | (3,032) | \u200b | (5,730) | \u200b | (1,094) | \u200b | (4,938) | \u200b | (121,179) | \u200b | (22,552) | \u200b | (3,331) | \u200b | (161,856) |\n| Balance as of December 31, 2022 | \u200b | $ | 253 | \u200b | $ | 929 | \u200b | $ | 207 | \u200b | $ | 3,689 | \u200b | $ | 1,696 | \u200b | $ | 3,594 | \u200b | $ | 1,010 | \u200b | $ | 11,378 |\n| Current provision related to sales in the current period | \u200b | 1,856 | \u200b | 5,439 | \u200b | 976 | \u200b | 5,483 | \u200b | 94,822 | \u200b | 22,934 | \u200b | 5,191 | \u200b | 136,701 |\n| Checks/credits issued to third parties | \u200b | (2,016) | \u200b | (5,470) | \u200b | (1,041) | \u200b | (5,095) | \u200b | (93,074) | \u200b | (21,318) | \u200b | (5,948) | \u200b | (133,962) |\n| Balance as of December 31, 2023 | \u200b | $ | 93 | \u200b | $ | 898 | \u200b | $ | 142 | \u200b | $ | 4,077 | \u200b | $ | 3,444 | \u200b | $ | 5,210 | \u200b | $ | 253 | \u200b | $ | 14,117 |",
            "type": "table"
        },
        {
            "id": 77,
            "context": "The increase in our reserves for gross-to-net sales accruals from period-to-period is driven by increases in our reserves for coupons and managed care rebates of $1.7 million and $1.6 million, respectively. Our provision for coupons was $3.4 million at December 31, 2023 compared to $1.7 million at December 31, 2022. The increase in the coupon reserve is primarily due to an increase in our channel reserve at December 31, 2023 for rebates not credited at the end of the year as a result of the timing of receipt. Our provision for managed care rebates was $5.2 million at December 31, 2023 compared to $3.6 million at December 31, 2022. The increase in the managed care rebate reserve is primarily due to the timing of invoices received.Cost of Goods SoldCost of goods sold decreased by $4.1 million, or 13%, to $26.7 million for the year ended December 31, 2023, from $30.8 million for the year ended December 31, 2022. The decrease is mainly due to lower-than-prior-year product royalties driven by lower sales of products from period-to-period, and a permanent contractual decrease in the Qbrexza royalty percentage from the prior-year period.Research and Development Research and development expense decreased by $3.4 million, or 31%, to $7.5 million for the year ended December 31, 2023 from $10.9 million for the year ended December 31, 2022. The decrease is related to lower clinical trial expenses to develop our DFD-29 product as the project winds down and eventually concludes.Selling, General and Administrative Expenses (\u201cSG&A\u201d)Selling, general and administrative expenses decreased by $15.6 million, or 26%, to $43.9 million for the year ended December 31, 2023, from $59.5 million for the year ended December 31, 2022. The decrease is mainly due to our expense reduction efforts primarily in sales and marketing and other SG&A areas. During the last quarter of 2022, we began implementing a cost reduction initiative designed to improve operational efficiencies, optimize expenses, and reduce overall costs. The initiative is intended to reduce selling, general, and administrative expenses to better align costs with their revenue-generating capabilities. In connection with the cost reduction initiative, during the last quarter of 2022 and the first two quarters of 2023, we executed a headcount reduction to our sales force and implemented marketing and other cost cuts.Loss on impairment of intangible assetsWe recorded a loss on the impairment of intangible assets of $3.1 million during 2023 related to the impairment of the Ximino intangible asset as a result of lower net product revenues and gross profit levels for the Ximino products. We discontinued selling Ximino on September 29, 2023.Interest ExpenseInterest expense decreased $0.3 million to $1.7 million for the year ended December 31, 2023, from $2.0 million for the year ended December 31, 2022. This decrease was driven in part by the total repayment of our prior credit facility with East West Bank during the third quarter of 2023 and no additional borrowing of funds until entering into the Credit Facility with SWK in December 2023. As we utilize this Credit Facility during 2024 to help us fund our operations, we expect interest expenses may increase year-over-year from the fiscal year ended December 31, 2023.Income tax expenseIncome tax expense increased by $0.2 million during 2023 due to an increase in certain state taxes driven by the Maruho New License Agreement.68",
            "type": "paragraph"
        },
        {
            "id": 78,
            "context": "| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | For the Years ended December 31, | \u200b | Increase |\n| ($\u2019s in thousands) | 2023 | 2022 | (Decrease) |\n| Net cash provided by (used in) operating activities | \u200b | $ | 5,240 | \u200b | $ | (13,534) | \u200b | $ | 18,774 |\n| Net cash used in investing activities | \u200b | (5,000) | \u200b | (20,000) | \u200b | 15,000 |\n| Net cash provided by (used in) financing activities | \u200b | (4,804) | \u200b | 16,456 | \u200b | (21,260) |\n| Net change in cash and cash equivalents | \u200b | \u200b | (4,564) | \u200b | \u200b | (17,078) | \u200b | \u200b | (12,514) |",
            "type": "table"
        },
        {
            "id": 79,
            "context": "| \u25cf | We are required to make regular payments under the SWK Credit Facility. Based on the amount currently outstanding under the SWK facility and current interest rates, and assuming we do not make further draws under the SWK facility, we expect to make the following payments: |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | Payments by Period |\n| \u200b | Total | 2024 | 2025 | 2026 | 2027 |\n| \u200b | \u200b | ($\u2019s in thousands) |\n| Interest | \u200b | $ | 6,770 | \u200b | $ | 1,998 | \u200b | $ | 1,993 | \u200b | $ | 1,693 | \u200b | $ | 1,086 |\n| Principal | \u200b | \u200b | 15,000 | \u200b | \u200b | \u2014 | \u200b | \u200b | \u2014 | \u200b | \u200b | 4,500 | \u200b | \u200b | 10,500 |\n| Exit fee | \u200b | 750 | \u200b | \u2014 | \u200b | \u2014 | \u200b | \u2014 | \u200b | 750 |\n| Total | \u200b | $ | 22,520 | \u200b | $ | 1,998 | \u200b | $ | 1,993 | \u200b | $ | 6,193 | \u200b | $ | 12,336 |\n| \u25cf | Pursuant to the Vyne Product Acquisition Agreement, upon the achievement of net sales milestones with respect to the products purchased in the Vyne Product Acquisition, we are also required to pay contingent consideration consisting of a one-time payment, per product, of $10.0 million and $20.0 million upon each product reaching annual net sales of $100 million and $200 million, respectively. Each required payment must only be paid one time following the first achievement of the applicable annual net sales milestone amount. |\n| \u25cf | On June 29, 2021, we entered into the DFD-29 Agreement to obtain the global rights for the development and commercialization of DFD-29 with DRL. Based on the development and commercialization of DFD-29, additional contingent regulatory and commercial milestone payments totaling up to $158.0 million may also become payable. Royalties ranging from ten percent to twenty percent are payable on net sales of the product. Additionally, the Company was required to fund and |",
            "type": "table"
        },
        {
            "id": 80,
            "context": "| oversee the Phase 3 clinical trials beginning upon the license of DFD-29 in 2021. The two Phase 3 clinical trials substantially concluded in July 2023 upon the receipt of positive topline results from the trials. In January 2024, the Company paid a $4.0 million filing fee to the FDA upon filing of an NDA for DFD-29. The Company is obligated to make a $3.0 million milestone payment to DRL in April 2024 based on the FDA\u2019s acceptance of the NDA filed in January 2024. |\n| \u25cf | We are contractually obligated to make installment milestone payments of $3.0 million on Ximino, all of which is classified as current as it is due within a year of December 31, 2023. |\n| \u25cf | We are contractually obligated to make sales-based royalty payments to Dermira (for Qbrexza), Sun Pharmaceutical Industries (for Exelderm) and PuraCap Caribe (for Targadox). Due to the contingent nature of these obligations, the amounts of these payments cannot be reasonably predicted as of the date of this Annual Report on Form 10-K. |",
            "type": "table"
        },
        {
            "id": 81,
            "context": "Item 7A. Quantitative and Qualitative Disclosures About Market Risks\nWe are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this item.\n\u200b\nItem 8. Financial Statements and Supplementary Data.\nThe information required by this Item is set forth in the financial statements and notes thereto beginning at page F-1 of this Annual Report on Form 10-K.\n\u200b\nItem 9.\nChanges in and Disagreements with Accountants on Accounting and Financial Disclosure.\n\u200b\nNone.\n\u200b\n71\nItem 9A. Controls and Procedures.\nDisclosure Controls and Procedures We maintain \u201cdisclosure controls and procedures,\u201d as such term is defined under Rule 13a-15(e) promulgated under the Exchange Act, designed to ensure that information required to be disclosed in our reports filed pursuant to the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC\u2019s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and our principal financial officer, as appropriate to allow timely decisions regarding required disclosures.",
            "type": "paragraph"
        },
        {
            "id": 82,
            "context": "In designing and evaluating the disclosure controls and procedures, we recognize that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and we are required to apply our judgment in evaluating the cost-benefit relationship of possible controls and procedures. We have carried out an evaluation as of the end of the period covered by this Annual Report on Form 10-K under the supervision, and with the participation, of our management, including our Chief Executive Officer (who serves as our principal executive officer) and our Interim Chief Financial Officer (who serves as our principal financial officer), of the effectiveness of the design and operation of our disclosure controls and procedures.",
            "type": "paragraph"
        },
        {
            "id": 83,
            "context": "Based on that evaluation, our Chief Executive Officer and Interim Chief Financial Officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Annual Report on Form 10-K in providing reasonable assurance of achieving the desired control objectives.",
            "type": "paragraph"
        },
        {
            "id": 84,
            "context": "Management\u2019s Report on Internal Control over Financial Reporting Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f). Internal control over financial reporting refers to the process designed by, or under the supervision of, our principal executive officer and principal financial officer, and effected by our Board of Directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles, and includes those policies and procedures that:",
            "type": "paragraph"
        },
        {
            "id": 85,
            "context": "Internal control over financial reporting has inherent limitations. Internal control over financial reporting is a process that involves human diligence and compliance and is subject to lapses in judgment and breakdowns resulting from human failures. Internal control over financial reporting also can be circumvented by collusion or improper management override. Because of such limitations, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.",
            "type": "paragraph"
        },
        {
            "id": 86,
            "context": "Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2023. In making the assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated Framework (2013). Based on the results of this assessment, management (including our Chief Executive Officer and our Interim Chief Financial Officer) has concluded that, as of December 31, 2023, our internal control over financial reporting was effective.",
            "type": "paragraph"
        },
        {
            "id": 87,
            "context": "This Annual Report does not include an attestation report on internal control over financial reporting from our independent registered public accounting firm due to our status as an emerging growth company under the JOBS Act.\n72 Changes in Internal Control over Financial ReportingThere have not been any changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during our most recent fiscal quarter ended December 31, 2023 to which this report relates that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.\u200b",
            "type": "paragraph"
        },
        {
            "id": 88,
            "context": "Item 9B. Other Information\nN o n e .\n\u200b\nItem 10. Directors, Executive Officers and Corporate Governance\nThe information required by this Item is incorporated herein by reference from our Proxy Statement for our 2024 Annual Meeting of Stockholders.\n\u200b\nItem 11. Executive Compensation\nThe information required by this Item is incorporated herein by reference from our Proxy Statement for our 2024 Annual Meeting of Stockholders.\n\u200b\nItem 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters\n\u200b\nThe information required by this Item is incorporated herein by reference from our Proxy Statement for our 2024 Annual Meeting of Stockholders.\n\u200b\nItem 13. Certain Relationships and Related Transactions, and Director Independence\n.\nThe information required by this Item is incorporated herein by reference from our Proxy Statement for our 2024 Annual Meeting of Stockholders.\n\u200b\nItem 14. Principal Accounting Fees and Services\n\u200b\nThe information required by this Item is incorporated by reference from our Proxy Statement for our 2024 Annual Meeting of Stockholders.\n\u200b\n\u200b\n74\nPART IV\nItem 15. Exhibits and Financial Statement Schedules\nThe following financial statements are filed as part of this report:\n\u200b\n\n| Report of Independent Registered Public Accounting Firm (KPMG LLP, Short Hills, New Jersey; PCAOB# 185) | F-2 |\n| Consolidated Balance Sheets as of December 31, 2023 and 2022 | F-3 |\n| Consolidated Statements of Operations for the years ended December 31, 2023 and 2022 | F-4 |\n| Consolidated Statement of Changes in Stockholders\u2019 Equity for the years ended December 31, 2023 and 2022 | F-5 |\n| Consolidated Statements of Cash Flows for the years ended December 31, 2023 and 2022 | F-6 |\n| Notes to Consolidated Financial Statements | F-7 |",
            "type": "table"
        },
        {
            "id": 89,
            "context": "\u200b\n\u200b\n75\n\n| (b) | Exhibits. |\n| Exhibit Number | Description |\n| 3.1 | \u200b | Third Amended and Restated Certificate of Incorporation of Journey Medical Corporation, filed on March 28, 2022 and incorporated herein by reference. |\n| 3.2 | \u200b | Amended and Restated Bylaws of Journey Medical Corporation, filed as Exhibit 3.2 to Form 10-K, filed on March 28, 2022 and incorporated herein by reference. |\n| 4.1 | \u200b | Form of Common Stock Certificate, filed as Exhibit 4.1 to Form S-1, filed on October 22, 2021 and incorporated herein by reference. |\n| 4.2 | \u200b | Description of Securities of Journey Medical Corporation, filed as Exhibit 4.2 to Form 10-K, filed on March 28, 2022 and incorporated herein by reference. |\n| 10.1 | \u200b | Journey Medical Corporation 2015 Stock Plan, filed as Exhibit 10.1 to Form S-1, filed on October 22, 2021 and incorporated herein by reference.# |\n| 10.2 | \u200b | Amendment to Journey Medical Corporation 2015 Stock Plan, filed as Exhibit 10.1 to Form 8-K filed on June 21, 2022 and incorporated herein by reference.# |\n| 10.3 | \u200b | Executive Employment Agreement with Claude Maraoui, dated September 22, 2014, filed as Exhibit 10.2 to Form S-1, filed on October 22, 2021 and incorporated herein by reference.# |\n| 10.4 | \u200b | Non-Employee Director Compensation Plan, filed as Exhibit 10.4 to Form S-1, filed on October 22, 2021 and incorporated herein by reference.# |\n| 10.5 | \u200b | Journey Medical Corporation 2023 Employee Stock Purchase Plan, filed as Exhibit 10.1 to Form 8-K filed on June 23, 2023 and incorporated herein by reference.# |\n| 10.6 | \u200b | Asset Purchase Agreement for Qbrexza, entered into by and between Journey Medical Corporation and Dermira, Inc., a subsidiary of Eli Lilly and Company, dated as of March 31, 2021, filed as Exhibit 10.6 to Form S-1, filed on October 22, 2021 and incorporated herein by reference.** |\n| 10.7 | \u200b | Asset Purchase Agreement between VYNE Therapeutics Inc. and Journey Medical Corporation, dated as of January 12, 2022, filed as Exhibit 10.1 to Form 8-K filed on January 13, 2022 and incorporated herein by reference.** |\n| 10.8 | \u200b | License and Supply Agreement for Accutane, entered into by and between Journey Medical Corporation and Dr. Reddy\u2019s Laboratories Ltd., dated as of July 29, 2020, filed as Exhibit 10.7 to Form S-1, filed on October 22, 2021 and incorporated herein by reference.** |\n| 10.9 | \u200b | License and Supply Agreement for Targadox, entered into by and between Journey Medical Corporation and Blu Caribe Inc., dated as of March 10, 2015, filed as Exhibit 10.8 to Form S-1, filed on October 22, 2021 and incorporated herein by reference.** |\n| 10.10 | \u200b | First Amendment to the License and Supply Agreement for Targadox, entered into by and between Journey Medical Corporation and Blu Caribe Inc., dated as of August 26, 2015, filed as Exhibit 10.9 to Form S-1, filed on October 22, 2021 and incorporated herein by reference.** |\n| 10.11 | \u200b | Asset Purchase Agreement for Exelderm, entered into by and between Journey Medical Corporation and Sun Pharmaceutical Industries, Inc., dated as of August 31, 2018, filed as Exhibit 10.10 to Form S-1, filed on October 22, 2021 and incorporated herein by reference.** |\n| 10.12 | \u200b | Amendment 1 to the Asset Purchase Agreement for Exelderm, entered into by and between Journey Medical Corporation and Sun Pharmaceutical Industries, Inc., dated as of September 5, 2018, filed as Exhibit 10.11 to Form S-1, filed on October 22, 2021 and incorporated herein by reference. ** |\n| 10.13 | \u200b | Asset Purchase Agreement for Ximino, entered into by and between Journey Medical Corporation and Sun Pharmaceutical Industries, Inc., dated as of July 22, 2019, filed as Exhibit 10.12 to Form S-1, filed on October 22, 2021 and incorporated herein by reference.** |\n| 10.14 | \u200b | Asset Purchase Agreement for the Anti-itch Product, entered into by and between Journey Medical Corporation and Sun Pharmaceutical Industries, Inc., dated as of December 18, 2020, filed as Exhibit 10.13 to Form S-1, filed on October 22, 2021 and incorporated herein by reference.** |\n| 10.15 | \u200b | License, Collaboration, and Assignment Agreement for DFD-29, entered into by and between Journey Medical Corporation and Dr. Reddy\u2019s Laboratories Ltd., dated as of June 29, 2021, filed as Exhibit 10.14 to Form S-1, filed on October 22, 2021 and incorporated herein by reference.** |\n| 10.16 | \u200b | Asset Purchase Agreement between Journey Medical Corporation and VYNE Therapeutics Inc., dated as of January 12, 2022, filed as Exhibit 10.1 to the Form 8-K filed on January 13, 2022 and incorporated herein by reference. ** |",
            "type": "table"
        },
        {
            "id": 90,
            "context": "| 10.17 | \u200b | Fortress Promissory Note, dated as of June 6, 2015, filed as Exhibit 10.16 to Form S-1, filed on October 22, 2021 and incorporated herein by reference. |\n| 10.18 | \u200b | At Market Issuance Sales Agreement, dated as of December 30, 2022, by and between Journey Medical Corporation and B. Riley Securities, Inc., filed as Exhibit 1.2 to Form S-3, filed on December 30, 2022 and incorporated herein by reference. |\n| 10.19 | \u200b | License Agreement, dated as of August 31, 2023, between Journey Medical Corporation and Maruho Co., Ltd. filed as Exhibit 10.1 to Form 10 - Q filed on November 13, 2023.** |\n| 10.20 | \u200b | Second Amended and Restated License Agreement, dated as of August 31, 2023, between Journey Medical Corporation and Maruho Co., Ltd. filed as Exhibit 10.2 to Form 10 - Q filed on November 13, 2023.** |\n| 10.21 | \u200b | Credit Agreement, dated as of December 27, 2023, between Journey Medical Corporation with SWK Funding LLC. *** |\n| 21.1 | \u200b | List of Subsidiaries of Journey Medical Corporation.* |\n| 23.1 | \u200b | Consent of KPMG LLP.* |\n| 31.1 | \u200b | Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. * |\n| 31.2 | \u200b | Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. * |\n| 32.1 | \u200b | Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. *** |\n| 32.2 | \u200b | Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. *** |\n| 97.1 | \u200b | Clawback Policy of Journey Medical Corporation* |\n| 101 | \u200b | The following financial information from the Company\u2019s Quarterly Report on Form 10-K for the period ended December 31, 2023, formatted in Extensible Business Reporting Language (XBRL): (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements of Operations, (iii) the Consolidated Statement of Stockholders\u2019 Equity, (iv) the Consolidated Statements of Cash Flows, and (v) Notes to the Consolidated Financial Statements. |\n| 104 | \u200b | Cover page from the Company\u2019s Annual Report on Form 10-K for the year ended December 31, 2023, formatted in Inline XBRL. |\n| Item 16. | Form 10-K Summary |",
            "type": "table"
        },
        {
            "id": 91,
            "context": "| Report of Independent Registered Public Accounting Firm ( KPMG LLP , Short Hills, New Jersey ; PCAOB# 185 ) | F-2 |\n| Consolidated Balance Sheets as of December 31, 2023 and 2022 | F-3 |\n| Consolidated Statements of Operations for the years ended December 31, 2023 and 2022 | F-4 |\n| Consolidated Statement of Changes in Stockholders\u2019 Equity for the years ended December 31, 2023 and 2022 | F-5 |\n| Consolidated Statements of Cash Flows for the years ended December 31, 2023 and 2022 | F-6 |\n| Notes to Consolidated Financial Statements | F-7 |",
            "type": "table"
        },
        {
            "id": 92,
            "context": "Report of Independent Registered Public Accounting Firm To the Stockholders and Board of DirectorsJourney Medical Corporation: Opinion on the Consolidated Financial Statements We have audited the accompanying consolidated balance sheets of Journey Medical Corporation and subsidiary (the Company) as of December 31, 2023 and 2022, the related consolidated statements of operations, changes in stockholders\u2019 equity and cash flows for each of the years then ended December 31, 2023, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the years then ended December 31, 2023, in conformity with U.S. generally accepted accounting principles.Going ConcernThe accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has suffered recurring losses from operations, and as a result has concluded that this raises substantial doubt about its ability to continue as a going concern. Management\u2019s plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.Basis for OpinionThese consolidated financial statements are the responsibility of the Company\u2019s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company\u2019s internal control over financial reporting. Accordingly, we express no such opinion.Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion./s/ KPMG LLPWe have served as the Company\u2019s auditor since 2021.Short Hills, New JerseyMarch 28, 2024F-2",
            "type": "paragraph"
        },
        {
            "id": 93,
            "context": "| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | December 31, |\n| \u200b | 2023 | 2022 |\n| ASSETS | \u200b | \u200b |\n| Current assets | \u200b | \u200b |\n| Cash and cash equivalents | $ | 27,439 | $ | 32,003 |\n| Accounts receivable, net of reserves | \u200b | 15,222 | \u200b | 28,208 |\n| Inventory | \u200b | 10,206 | \u200b | 14,159 |\n| Prepaid expenses and other current assets | \u200b | 3,588 | \u200b | 3,309 |\n| Total current assets | \u200b | 56,455 | \u200b | 77,679 |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Intangible assets, net | \u200b | 20,287 | \u200b | 27,197 |\n| Operating lease right-of-use asset, net | \u200b | 101 | \u200b | 189 |\n| Other assets | \u200b | 6 | \u200b | 95 |\n| Total assets | \u200b | $ | 76,849 | \u200b | $ | 105,160 |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| LIABILITIES AND STOCKHOLDERS\u2019 EQUITY | \u200b | \u200b |\n| Current liabilities | \u200b | \u200b |\n| Accounts payable | \u200b | $ | 18,149 | \u200b | $ | 36,570 |\n| Due to related party | \u200b | 195 | \u200b | 413 |\n| Accrued expenses | \u200b | 20,350 | \u200b | 19,388 |\n| Accrued interest | \u200b | 22 | \u200b | 160 |\n| Income taxes payable | \u200b | \u200b | 53 | \u200b | \u200b | 35 |\n| Line of credit | \u200b | \u200b | \u2014 | \u200b | \u200b | 2,948 |\n| Deferred cash payment, net of discount | \u200b | \u200b | \u2014 | \u200b | \u200b | 4,991 |\n| Installment payments \u2013 licenses, short-term | \u200b | 3,000 | \u200b | 2,244 |\n| Operating lease liability, short-term | \u200b | 99 | \u200b | 83 |\n| Total current liabilities | \u200b | 41,868 | \u200b | 66,832 |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Term loan, net of discount | \u200b | 14,622 | \u200b | 19,826 |\n| Installment payments \u2013 licenses, long-term | \u200b | \u2014 | \u200b | 1,412 |\n| Operating lease liability, long-term | \u200b | 9 | \u200b | 108 |\n| Total liabilities | \u200b | 56,499 | \u200b | 88,178 |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Commitments and contingencies (Note 14) | \u200b | \u200b |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Stockholders\u2019 equity | \u200b | \u200b |\n| Common stock, $ .0001 par value, 50,000,000 shares authorized, 13,323,952 and 11,765,700 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively | \u200b | 1 | \u200b | 1 |\n| Common stock - Class A, $ .0001 par value, 50,000,000 shares authorized, 6,000,000 shares issued and outstanding as of December 31, 2023 and December 31, 2022 | \u200b | 1 | \u200b | 1 |\n| Additional paid-in capital | \u200b | 92,703 | \u200b | 85,482 |\n| Accumulated deficit | \u200b | ( 72,355 ) | \u200b | ( 68,502 ) |\n| Total stockholders\u2019 equity | \u200b | 20,350 | \u200b | 16,982 |\n| Total liabilities and stockholders\u2019 equity | \u200b | $ | 76,849 | \u200b | $ | 105,160 |",
            "type": "table"
        },
        {
            "id": 94,
            "context": "| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | Year Ended December 31, |\n| \u200b | 2023 | 2022 |\n| Revenue: | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Product revenue, net | \u200b | $ | 59,662 | \u200b | $ | 70,995 |\n| Other revenue | \u200b | \u200b | 19,519 | \u200b | \u200b | 2,674 |\n| Total revenue | \u200b | \u200b | 79,181 | \u200b | \u200b | 73,669 |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Operating expenses | \u200b | \u200b | \u200b | \u200b |\n| Cost of goods sold\u2009\u2013\u2009product revenue | \u200b | 26,660 | \u200b | 30,775 |\n| Research and development | \u200b | 7,541 | \u200b | 10,943 |\n| Selling, general and administrative | \u200b | 43,910 | \u200b | 59,468 |\n| Loss on impairment of intangible assets | \u200b | 3,143 | \u200b | \u2014 |\n| Total operating expenses | \u200b | 81,254 | \u200b | 101,186 |\n| Loss from operations | \u200b | ( 2,073 ) | \u200b | ( 27,517 ) |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Other expense (income) | \u200b | \u200b |\n| Interest income | \u200b | ( 322 ) | \u200b | ( 60 ) |\n| Interest expense | \u200b | \u200b | 1,698 | \u200b | \u200b | 2,019 |\n| Foreign exchange transaction losses | \u200b | \u200b | 183 | \u200b | \u200b | 89 |\n| Total other expense (income) | \u200b | 1,559 | \u200b | 2,048 |\n| Loss before income taxes | \u200b | ( 3,632 ) | \u200b | ( 29,565 ) |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Income tax expense | \u200b | 221 | \u200b | 63 |\n| Net Loss | \u200b | $ | ( 3,853 ) | \u200b | $ | ( 29,628 ) |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Net loss per common share: | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Basic and diluted | \u200b | $ | ( 0.21 ) | \u200b | $ | ( 1.69 ) |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Weighted average number of common shares: | \u200b | \u200b | \u200b | \u200b |\n| Basic and diluted | \u200b | 18,232,422 | \u200b | 17,531,274 |",
            "type": "table"
        },
        {
            "id": 95,
            "context": "| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | Additional | \u200b | \u200b | \u200b | Total |\n| \u200b | Common Stock | Common Stock A | \u200b | Paid-in | \u200b | (Accumulated | \u200b | Shareholders\u2019 |\n| \u200b | Shares | Amount | Shares | Amount | Capital | Deficit) | Equity |\n| Balance as of December 31, 2021 | \u200b | 11,316,344 | \u200b | $ | 1 | \u200b | 6,000,000 | \u200b | $ | 1 | \u200b | $ | 80,915 | \u200b | $ | ( 38,874 ) | \u200b | $ | 42,043 |\n| Share-based compensation | \u200b | \u2014 | \u200b | \u200b | \u2014 | \u200b | \u2014 | \u200b | \u200b | \u2014 | \u200b | \u200b | 4,425 | \u200b | \u200b | \u2014 | \u200b | \u200b | 4,425 |\n| Exercise of stock options for cash | \u200b | 155,649 | \u200b | \u200b | \u2014 | \u200b | \u2014 | \u200b | \u200b | \u2014 | \u200b | \u200b | 142 | \u200b | \u200b | \u2014 | \u200b | \u200b | 142 |\n| Issuance of common stock for vested restricted stock units | \u200b | 293,707 | \u200b | \u200b | \u2014 | \u200b | \u2014 | \u200b | \u200b | \u2014 | \u200b | \u200b | \u2014 | \u200b | \u200b | \u2014 | \u200b | \u200b | \u2014 |\n| Net loss | \u200b | \u2014 | \u200b | \u200b | \u2014 | \u200b | \u2014 | \u200b | \u200b | \u2014 | \u200b | \u200b | \u2014 | \u200b | \u200b | ( 29,628 ) | \u200b | \u200b | ( 29,628 ) |\n| Balance as of December 31, 2022 | \u200b | 11,765,700 | \u200b | $ | 1 | \u200b | 6,000,000 | \u200b | $ | 1 | \u200b | $ | 85,482 | \u200b | $ | ( 68,502 ) | \u200b | $ | 16,982 |\n| Share-based compensation | \u200b | \u2014 | \u200b | \u200b | \u2014 | \u200b | \u2014 | \u200b | \u200b | \u2014 | \u200b | \u200b | 2,606 | \u200b | \u200b | \u2014 | \u200b | \u200b | 2,606 |\n| Exercise of stock options for cash | \u200b | 82,300 | \u200b | \u200b | \u2014 | \u200b | \u2014 | \u200b | \u200b | \u2014 | \u200b | \u200b | 121 | \u200b | \u200b | \u2014 | \u200b | \u200b | 121 |\n| Issuance of common stock for vested restricted stock units | \u200b | 727,249 | \u200b | \u200b | \u2014 | \u200b | \u2014 | \u200b | \u200b | \u2014 | \u200b | \u200b | \u2014 | \u200b | \u200b | \u2014 | \u200b | \u200b | \u2014 |\n| Issuance of common stock, ATM offering, net of issuance costs of $ 140 | \u200b | 748,703 | \u200b | \u200b | \u2014 | \u200b | \u2014 | \u200b | \u200b | \u2014 | \u200b | \u200b | 4,494 | \u200b | \u200b | \u2014 | \u200b | \u200b | 4,494 |\n| Net loss | \u200b | \u2014 | \u200b | \u200b | \u2014 | \u200b | \u2014 | \u200b | \u200b | \u2014 | \u200b | \u200b | \u2014 | \u200b | \u200b | ( 3,853 ) | \u200b | \u200b | ( 3,853 ) |\n| Balance as of December 31, 2023 | \u200b | 13,323,952 | \u200b | $ | 1 | \u200b | 6,000,000 | \u200b | $ | 1 | \u200b | $ | 92,703 | \u200b | $ | ( 72,355 ) | \u200b | $ | 20,350 |",
            "type": "table"
        },
        {
            "id": 96,
            "context": "| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | Year Ended |\n| \u200b | \u200b | December 31, |\n| \u200b | 2023 | 2022 |\n| Cash flows from operating activities | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Net loss | \u200b | $ | ( 3,853 ) | \u200b | $ | ( 29,628 ) |\n| Adjustments to reconcile net loss to net cash used in operating activities: | \u200b | \u200b | \u200b | \u200b |\n| Bad debt expense | \u200b | 435 | \u200b | 284 |\n| Non-cash interest expense | \u200b | 353 | \u200b | 770 |\n| Amortization of debt discount | \u200b | 356 | \u200b | 63 |\n| Amortization of acquired intangible assets | \u200b | 3,767 | \u200b | 4,277 |\n| Amortization of operating lease right-of-use assets | \u200b | 88 | \u200b | 88 |\n| Share-based compensation | \u200b | 2,606 | \u200b | 4,425 |\n| Loss on impairment of intangible assets | \u200b | 3,143 | \u200b | - |\n| Changes in operating assets and liabilities: | \u200b | \u200b | \u200b | \u200b |\n| Accounts receivable | \u200b | 12,551 | \u200b | ( 5,380 ) |\n| Inventory | \u200b | 3,953 | \u200b | 1,744 |\n| Prepaid expenses and other current assets | \u200b | ( 279 ) | \u200b | ( 871 ) |\n| Other assets | \u200b | \u2014 | \u200b | 55 |\n| Accounts payable | \u200b | \u200b | ( 18,421 ) | \u200b | \u200b | 14,343 |\n| Related party expenses | \u200b | ( 218 ) | \u200b | ( 228 ) |\n| Accrued expenses | \u200b | 962 | \u200b | ( 3,568 ) |\n| Accrued interest | \u200b | ( 138 ) | \u200b | 160 |\n| Income tax payable | \u200b | 18 | \u200b | 27 |\n| Lease liabilities | \u200b | ( 83 ) | \u200b | ( 95 ) |\n| Net cash provided by (used in) operating activities | \u200b | 5,240 | \u200b | ( 13,534 ) |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| Cash flows from investing activities | \u200b | \u200b | \u200b | \u200b |\n| Acquired intangible assets | \u200b | \u200b | ( 5,000 ) | \u200b | \u200b | ( 20,000 ) |\n| Net cash (used in) investing activities | \u200b | ( 5,000 ) | \u200b | ( 20,000 ) |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| Cash flows from financing activities | \u200b | \u200b | \u200b | \u200b |\n| Proceeds from the exercise of stock options | \u200b | 121 | \u200b | 142 |\n| Payment of license installment note payable | \u200b | \u200b | ( 1,000 ) | \u200b | \u200b | ( 5,000 ) |\n| Payment of debt issuance costs associated with convertible preferred shares | \u200b | \u200b | \u2014 | \u200b | \u200b | ( 214 ) |\n| Proceeds from line of credit | \u200b | 28,000 | \u200b | 5,000 |\n| Repayment of line of credit | \u200b | ( 30,948 ) | \u200b | ( 2,864 ) |\n| Proceeds from term-loan | \u200b | 15,000 | \u200b | 19,763 |\n| Repayment of EWB term-loan | \u200b | \u200b | ( 20,000 ) | \u200b | \u200b | \u2014 |\n| Payment of issuance costs associated with EWB term-loan modification | \u200b | ( 91 ) | \u200b | \u2014 |\n| Payment of issuance costs associated with issuance of SWK term-loan | \u200b | ( 380 ) | \u200b | \u2014 |\n| Proceeds from issuance of common stock, ATM offering, net of issuance costs | \u200b | 4,494 | \u200b | \u2014 |\n| Offering costs for the issuance of common stock - initial public offering | \u200b | \u200b | \u2014 | \u200b | \u200b | ( 371 ) |\n| Net cash (used in) provided by financing activities | \u200b | ( 4,804 ) | \u200b | 16,456 |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Net change in cash | \u200b | ( 4,564 ) | \u200b | ( 17,078 ) |\n| Cash at the beginning of the period | \u200b | 32,003 | \u200b | 49,081 |\n| Cash at the end of the period | \u200b | $ | 27,439 | \u200b | $ | 32,003 |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Supplemental disclosure of cash flow information: | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Cash paid for interest | \u200b | $ | 1,127 | \u200b | $ | 993 |\n| Cash paid for income taxes | \u200b | $ | 181 | \u200b | $ | 168 |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Supplemental disclosure of non-cash financing and investing activities: | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Deferred payment for asset acquisition | \u200b | $ | \u2014 | \u200b | $ | 4,740 |\n| ROU assets obtained in exchange for lease liabilities | \u200b | $ | \u2014 | \u200b | $ | 188 |",
            "type": "table"
        },
        {
            "id": 97,
            "context": "JOURNEY MEDICAL CORPORATIONNotes to Financial Statements\u200b NOTE 1. ORGANIZATION AND PLAN OF BUSINESS OPERATIONSJourney Medical Corporation (collectively \u201cJourney\u201d or the \u201cCompany\u201d) is a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The Company\u2019s current product portfolio includes seven branded and two authorized generic prescription drugs for dermatological conditions that are marketed in the U.S. The Company acquires rights to products and product candidates by licensing or otherwise acquiring an ownership interest in, funding the research and development of, and eventually commercializing, the products through its exclusive field sales organization.As of December 31, 2023 and 2022, the Company is a majority-owned subsidiary of Fortress Biotech, Inc. (\u201cFortress\u201d or \u201cParent\u201d).Liquidity and Capital ResourcesAt December 31, 2023, the Company had $ 27.4 million in cash and cash equivalents as compared to $ 32.0 million at December 31, 2022.On December 27, 2023, the Company entered into a Credit Agreement (the \u201cCredit Agreement\u201d) with SWK Funding LLC (\u201cSWK\u201d). The Credit Agreement provides for a term loan facility (the \u201cCredit Facility\u201d) in the original principal amount of up to $ 20.0 million. On the closing date, the Company drew $ 15.0 million. The remaining $ 5.0 million may be drawn upon the Company\u2019s request within 12 months after the closing date. Loans under the Credit Facility (the \u201cTerm Loans\u201d) mature on December 27, 2027, and bear interest at a rate per annum equal to the three-month term Secured Overnight Financing Rate (\u201cSOFR\u201d) (subject to a SOFR floor of 5 %) plus 7.75 %. The interest rate resets quarterly. Interest payments begin in February 2024 and are paid quarterly. Beginning in February 2026, the Company is required to repay a portion of the outstanding principal of the Term Loans quarterly in an amount equal to 7.5 % of the principal amount of funded Term Loans.On August 31, 2023, the Company entered into a license agreement (the \u201cNew License Agreement\u201d) with Maruho Co., Ltd., a Japanese company specializing in dermatology (\u201cMaruho\u201d), whereby the Company granted an exclusive license to Maruho to develop and commercialize Qbrexza\u00ae for the treatment of primary axillary hyperhidrosis in South Korea, Taiwan, Hong Kong, Macau, Thailand, Indonesia, Malaysia, Philippines, Singapore, Vietnam, Brunei, Cambodia, Myanmar and Laos (the \u201cTerritory\u201d). Under the terms of the New License Agreement, in exchange for the exclusive rights to Qbrexza \u00ae in the Territory, Maruho paid $ 19.0 million to the Company as a non-refundable upfront payment.On December 30, 2022, the Company filed a shelf registration statement on Form S-3 (File No. 333-269079), which was declared effective by the Securities and Exchange Commission (\u201cSEC\u201d) on January 26, 2023. This shelf registration statement covers the offering, issuance and sale by the Company of up to an aggregate of $ 150.0 million of the Company\u2019s common stock, preferred stock, debt securities, warrants, and units (the \u201c2022 Shelf\u201d). In connection with the 2022 Shelf, the Company entered into an At Market Issuance Sales Agreement (the \u201cSales Agreement\u201d) relating to shares of the Company\u2019s common stock. The Company may offer and sell up to 4,900,000 shares of its common stock, from time to time. During 2023, the Company issued 748,703 shares of common stock under the 2022 Shelf, generating net proceeds of $ 4.5 million. At December 31, 2023, 4,151,297 shares remain available for issuance under the 2022 Shelf.The Company regularly evaluates market conditions, its liquidity profile, and financing alternatives, including out-licensing arrangements for its products to enhance its capital structure. The Company may seek to raise capital through debt or equity financings to expand its product portfolio and for other strategic initiatives, which may include sales of securities under either the 2022 Shelf or a new registration statement or drawing on the SWK Credit Facility. The Company cannot make any assurances that such additional financing will be available and, if available, the terms may negatively impact the Company\u2019s business and operations. The Company\u2019s current assumptions, projected commercial sales of our products, clinical development plans and regulatory submission timelines are uncertain and may not emerge as expected. Additionally, as a result of recurring losses, substantial doubt exists about the Company\u2019s ability to continue as a going concern for a period of at least twelve months from the date of issuance of these financial statements.The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the F-7",
            "type": "paragraph"
        },
        {
            "id": 98,
            "context": "JOURNEY MEDICAL CORPORATIONNotes to Financial Statements recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that may be necessary if the Company is unable to continue as a going concern. \u200b NOTE 2. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation and Principles of ConsolidationThe Company\u2019s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (\u201cGAAP\u201d). The Company\u2019s consolidated financial statements include the accounts of the Company and the accounts of the Company\u2019s wholly-owned subsidiary, JG Pharma, Inc. (\u201cJG\u201d or \u201cJG Pharma\u201d). All intercompany balances and transactions have been eliminated. Emerging Growth CompanyFrom time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (\u201cFASB\u201d) or other standard-setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company\u2019s audited consolidated financial statements upon adoption. Under the Jumpstart Our Business Startups Act of 2012, as amended, the Company meets the definition of an emerging growth company and elected the extended transition period for complying with new or revised accounting standards, which delays the adoption of these accounting standards until they would apply to private companies. Use of EstimatesThe preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates made by management include provisions for coupons, chargebacks, wholesaler fees, specialty pharmacy discounts, managed care rebates, product returns, and other allowances customary to the pharmaceutical industry. Significant estimates made by management also include inventory realization, valuation of intangible assets, useful lives of amortizable intangible assets and share-based compensation. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company\u2019s future results of operations will be affected. Segment InformationOperating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. Concentrations of Credit RiskFinancial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company\u2019s deposits are held at financial institutions that management believes to be of high credit quality. The Company has not experienced any losses on these deposits. F-8",
            "type": "paragraph"
        },
        {
            "id": 99,
            "context": "JOURNEY MEDICAL CORPORATIONNotes to Financial Statements The Company\u2019s accounts receivable primarily represent amounts due from drug wholesalers and specialty pharmacies in the United States. The Company performs periodic credit evaluations of customers and does not require collateral. An allowance for doubtful accounts is maintained for potential credit losses based on the aging of accounts receivable, historical bad debts experience, and the customer\u2019s current ability to pay its obligations to the Company. Accounts receivables balances are written off against the allowance when it is probable that the receivable will not be collected. See Note 17 for significant customers. Cash and Cash EquivalentsThe Company considers highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at December 31, 2023 and 2022 consisted entirely of cash and cash equivalents in institutions within the United States. Balances at certain institutions have exceeded Federal Deposit Insurance Corporation insured limits. Accounts Receivable, NetThe Company\u2019s accounts receivable consists of amounts due from customers related to product sales and have standard payment terms. For certain customers, the accounts receivable for the customer are net of prompt payment or specialty pharmacy discounts. The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company reserves against accounts receivable for estimated losses that may arise from a customer\u2019s inability to pay, and any amounts determined to be uncollectible are written off against the reserve when it is probable that the receivable will not be collected. The Company has historically not experienced significant credit losses. The allowance for doubtful accounts was $ 0.5 million and $ 0.4 million at December 31, 2023 and 2022, respectively. InventoriesInventories are recorded at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. The Company periodically reviews the composition of inventory in order to identify excess, obsolete, slow-moving or otherwise non-saleable items taking into account anticipated future sales compared with quantities on hand, and the remaining shelf life of goods on hand. If non-saleable items are observed and there are no alternate uses for the inventory, the Company records a write-down to net realizable value in the period that the decline in value is first recognized. The Company\u2019s inventory reserves were $ 0.3 million and $ 0.4 million at December 31, 2023 and 2022, respectively. LeasesArrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company\u2019s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. Variable lease expenses are recorded when incurred.In calculating the right-of-use asset and lease liability, the Company elects to combine lease and non-lease components. Research and Development CostsResearch and development costs are expensed as incurred. Research and development costs primarily consist of personnel related expenses, payments made to third parties for license and milestone costs related to in-licensed products and technology, and payments made to third party contract research organizations. ContingenciesThe Company records accruals for contingencies and legal proceedings expected to be incurred in connection with a loss contingency when it is probable that a liability has been incurred and the amount can be reasonably estimated. F-9",
            "type": "paragraph"
        },
        {
            "id": 100,
            "context": "| Level 1: | Quoted prices in active markets for identical assets or liabilities. |\n| Level 2: | Observable inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace. |\n| Level 3: | Unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. |",
            "type": "table"
        },
        {
            "id": 101,
            "context": "JOURNEY MEDICAL CORPORATIONNotes to Financial Statements loss associated with its intangible asset balance. See Note 5 for further details. The Company did not record any impairment losses on long-lived assets for the year ended December 31, 2022. Share-based CompensationThe Company has a share-based compensation plan in place and records the associated share-based compensation expense over the requisite service period. The share-based compensation plan and related compensation expense are discussed more fully in Note 16 to the Company\u2019s consolidated financial statements. Compensation expense for service-based stock options is charged against operations on a straight-line basis over the vesting period, which is generally four years. Forfeitures are recorded as they occur. Share-based compensation costs are recorded in both research and development and selling, general and administrative expense in the Company\u2019s consolidated statements of operations. Options granted have a term of 10 years from the grant date. The Company estimates the fair value of all service-based stock option awards as of the grant date by applying the Black-Scholes option pricing valuation model. The application of this valuation model involves assumptions, including the fair value of the common stock, expected volatility, risk-free interest rate, expected dividends and the expected term of the option. The assumptions used in calculating the fair value of share-based awards represent management\u2019s best estimates and involve inherent uncertainties and the application of management\u2019s judgment. The following inputs are used in the Black-Scholes calculation. Expected term\u2014The Company has elected to use the \u201csimplified method\u201d for estimating the expected term of options, whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the option (generally 10 years). Expected volatility\u2014 Historical information is the primary basis for the selection of the expected volatility of options granted. However, as the Company has limited trading history for its common shares, the expected volatility was estimated based on the average volatility for comparable guideline publicly traded biotechnology companies over a period equal to the expected term of the stock option grants. The comparable companies were chosen based on their similar size, stage in the life cycle or area of specialty. Risk-free interest rate\u2014 The risk-free interest rate is selected based upon yields of United States Treasury issues with a term equal to the expected life of the option being valued. Expected dividend yield\u2014The Company has not issued any dividends in our history and do not expect to issue dividends over the life of the options; therefore, the Company has estimated the dividend yield to be zero.Restricted stock units (\u201cRSU\u2019s\u201d) that are service based are recorded as deferred compensation and amortized into compensation expense on a straight-line basis over the vesting period, which ranges from three to four years in duration. Compensation cost for service based RSU\u2019s is based on the grant date fair value of the award, which is the closing market price of the Company\u2019s common stock on the grant date multiplied by the number of shares awarded. Net (Loss) Income Per Share Basic net (loss) income per share of common stock is calculated by dividing net (loss) income by the weighted-average number of shares of common stock outstanding during the reporting period. Diluted earnings per share is calculated by dividing net income by the weighted-average number of shares of common stock outstanding during the reporting period after giving effect to dilutive potential common shares for stock options and restricted stock units, determined using the treasury stock method. See Note 19 below. Revenue RecognitionThe Company records and recognizes revenue in a manner that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The Company\u2019s revenues primarily result from contracts with customers, which are generally short-term and have a single performance obligation \u2013 the delivery of product. The Company\u2019s performance obligation to deliver products is satisfied at the point in time that the goods are received by the customer, which is when the customer obtains title to and has the risks and rewards of ownership of the F-11",
            "type": "paragraph"
        },
        {
            "id": 102,
            "context": "JOURNEY MEDICAL CORPORATIONNotes to Financial Statements products. The transaction price is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods to a customer. The consideration promised in a contract with a customer may include fixed amounts, variable amounts, or both.Many of the Company\u2019s products sold are subject to a variety of deductions. Revenues are recorded net of provisions for variable consideration, including coupons, chargebacks, wholesaler fees, specialty pharmacy discounts, managed care rebates, product returns, and other deductions customary to the pharmaceutical industry. Accruals for these provisions are presented in the consolidated financial statements as reductions to gross sales in determining net sales and as a contra asset within accounts receivable, net (if settled via credit) and other current liabilities (if paid in cash). Amounts recorded for revenue deductions can result from a series of judgements about future events and uncertainties and can rely on estimates and assumptions. The following section briefly describes the nature of the Company\u2019s provisions for variable consideration and how such provisions are estimated:Coupons \u2014 The Company offers coupons on products for qualified commercially-insured parties with prescription drug co-payments. Such product sales flow through both traditional wholesaler and specialty pharmacy channels. Coupons are processed and redeemed at the time of prescription fulfilment by the pharmacy. The majority of the coupon reserve accrual at the end of the period reflects expected redemptions for product in the distribution channel. The expected accrual reserve requires us to estimate the distribution channel inventory at period end, the expected redemption rates, and the cost per coupon claim that the Company expects to receive. The estimate of product remaining in the distribution channel is comprised of estimated inventory at the wholesaler as well as an estimate at the specialty pharmacies, which the Company estimates based upon historical ordering patterns. The estimated redemption rate is based on historical redemptions as a percentage of units sold. The cost per coupon is based on the coupon rate.Chargebacks and Government Chargebacks \u2014 The Company sells a portion of its products indirectly through wholesaler distributors to contracted indirect customers and qualified government healthcare providers. The Company enters into specific agreements with or provides discounts to these indirect customers and entities to establish pricing for the Company\u2019s products, and in-turn, the indirect customers and entities independently purchase these products. The Company\u2019s provision for chargebacks is based on expected sell-through levels by the Company\u2019s wholesale customers to the indirect customers and estimated wholesaler inventory levels as well as historical chargeback rates. The Company continually monitors its reserve for chargebacks and adjusts the reserve accordingly when expected chargebacks differ from actual experience.Wholesaler fees \u2014 The Company provides allowances to its wholesale customers for sales order management, data, and distribution services. The Company also pays administrative and other fees to certain wholesale customers consistent with pharmaceutical industry practices. The Company records a provision for these fees based on contracted rates. Assumptions used to establish the provision include contract sales volumes and average contract pricing. The Company regularly reviews the information related to these estimates and adjusts the provision accordingly.Specialty Pharmacy Discounts \u2014 The Company has in place contractual arrangements with specialty pharmacies and provides for contractually agreed upon discounts. These discounts are recorded at the time of sale based on the customer\u2019s contracted rate and recorded as a reduction of revenue. F-12",
            "type": "paragraph"
        },
        {
            "id": 103,
            "context": "JOURNEY MEDICAL CORPORATIONNotes to Financial Statements Managed Care Rebates \u2014 The Company is subject to rebates in connection with its agreements with certain contracted commercial payers. The Company estimates its managed care rebates based on the Company\u2019s estimated payer mix and the applicable contractual rebate rate. The Company\u2019s accrual for managed care rebates is based on an estimate of future claims that the Company expects to receive, which considers an estimate for inventory in the distribution channel. The accrual is recognized at the time of sale, resulting in a reduction of gross product revenue.Product Returns \u2014 Consistent with industry practice, the Company offers customers a right to return any unused product. The customer\u2019s right of return commences six months prior to product expiration date and ends one year after product expiration date. Products returned for expiration are reimbursed at current wholesale acquisition cost or indirect contract price. The Company estimates the amount of its product sales that may be returned by the Company\u2019s customers and accrues this estimate as a reduction of revenue in the period the related product revenue is recognized. The Company estimates products returns as a percentage of sales to its customers. Income TaxesAs of December 31, 2023, the Company was 52.01 % owned by Fortress Biotech, Inc. (\u201cFortress\u201d) and was filing consolidated federal tax returns and consolidated or combined state tax returns in multiple jurisdictions with Fortress for tax years prior to 2021. As the Company completed its initial public offering on November 12, 2021, it deconsolidated from the Fortress consolidated group for federal income tax purpose. The financial statements recognize the current and deferred income tax consequences that result from the activities during the current and preceding periods, as if the Company were a separate taxpayer rather than a member of the Fortress consolidated income tax return group. Fortress has agreed that the Company does not have to make payments to Fortress for the use of net operating losses (\u201cNOLs\u201d) of Fortress (including other Fortress group members). Since Fortress does not require the Company to pay in any form for the utilization of the consolidated group\u2019s NOLs, the tax benefit realized have been recorded as a capital contribution.The Company records income taxes using the asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax effects attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases, and operating loss and tax credit carryforwards. The Company establishes a valuation allowance if it believes it is more likely than not that the deferred tax assets will not be recovered based on an evaluation of objective verifiable evidence. The Company has considered its history of cumulative tax and book income/loss incurred since inception, and the other positive and negative evidence, and has concluded that it is not more likely than not that it will realize the benefits of the net deferred tax assets as of December 31, 2023 and 2022 and therefore a full valuation allowance on all of the deferred tax assets is required.For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the largest amount of the benefit that is greater than 50 % likely of being realized. For tax positions that are not more likely than not of being sustained upon audit, the Company does not recognize any portion of the benefit. For the years ended December 31, 2023 and 2022, the Company had no unrecognized tax benefits and does not anticipate any significant change to the unrecognized tax benefit balance. The Company classifies interest and penalties related to uncertain tax positions as income tax expense, if applicable. There was no interest expense or penalties related to unrecognized tax benefits recorded through December 31, 2023 and 2022. Comprehensive IncomeThe Company has no components of other comprehensive income, and therefore, comprehensive income equals net income. Recently Issued Accounting PronouncementsIn November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires that an entity report segment information in accordance with Topic 280, Segment Reporting. The amendment in the ASU is intended to improve reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. The amendments in this update are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact of the new standard on its consolidated financial statements.In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which expands disclosures in an entity\u2019s income tax rate reconciliation table and disclosures regarding cash taxes paid both in the U.S. and F-13",
            "type": "paragraph"
        },
        {
            "id": 104,
            "context": "| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | December 31, |\n| ($\u2019s in thousands) | 2023 | 2022 |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Raw materials | \u200b | $ | 4,640 | \u200b | $ | 6,454 |\n| Work-in-process | \u200b | 884 | \u200b | 395 |\n| Finished goods | \u200b | 4,987 | \u200b | 7,739 |\n| Inventory at cost | \u200b | \u200b | 10,511 | \u200b | \u200b | 14,588 |\n| Inventory reserves | \u200b | \u200b | ( 305 ) | \u200b | \u200b | ( 429 ) |\n| Total Inventories | \u200b | $ | 10,206 | \u200b | $ | 14,159 |\n| \u200b | \u200b | \u200b | \u200b |\n| \u200b | Aggregate |\n| \u200b | \u200b | Consideration |\n| ($\u2019s in thousands) | \u200b | Transferred |\n| Consideration transferred to Vyne at closing | \u200b | $ | 20,000 |\n| Fair Value of deferred cash payment due January 2023 | \u200b | 4,740 |\n| Transaction costs | \u200b | 223 |\n| Total consideration transferred at closing | \u200b | $ | 24,963 |",
            "type": "table"
        },
        {
            "id": 105,
            "context": "| \u200b | \u200b | \u200b | \u200b |\n| \u200b | Assets |\n| ($\u2019s in thousands) | \u200b | Recognized |\n| Inventory | \u200b | $ | 6,041 |\n| Identifiable intangibles: | \u200b |\n| Amzeeq intangible | \u200b | 15,162 |\n| Zilxi intangible | \u200b | 3,760 |\n| Fair value of net identifiable assets acquired | \u200b | $ | 24,963 |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | Estimated | December 31, |\n| ($\u2019s in thousands) | \u200b | Useful Lives (Years) | \u200b | 2023 | 2022 |\n| Intangible assets - product licenses | 3 - 9 | \u200b | $ | 37,925 | \u200b | $ | 37,925 |\n| Accumulated amortization | \u200b | ( 14,495 ) | \u200b | ( 10,728 ) |\n| Accumulated impairment loss | \u200b | ( 3,143 ) | \u200b | \u2014 |\n| Total intangible assets | \u200b | $ | 20,287 | \u200b | $ | 27,197 |\n| \u200b | \u200b | \u200b | \u200b |\n| \u200b | Total |\n| For the years ended | Amortization |\n| December 31, 2024 | \u200b | $ | 3,257 |\n| December 31, 2025 | \u200b | 3,257 |\n| December 31, 2026 | \u200b | 2,471 |\n| December 31, 2027 | \u200b | 1,775 |\n| Thereafter | \u200b | 5,585 |\n| Subtotal | \u200b | \u200b | 16,345 |\n| Asset not yet placed in service | \u200b | 3,942 |\n| Total | \u200b | $ | 20,287 |",
            "type": "table"
        },
        {
            "id": 106,
            "context": "| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | December 31, 2023 |\n| ($\u2019s in thousands) | Level 1 | Level 2 | Level 3 | Total |\n| Assets | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Cash and cash equivalents | \u200b | $ | 27,439 | \u200b | $ | \u2014 | \u200b | $ | \u2014 | \u200b | $ | 27,439 |\n| Total | \u200b | $ | 27,439 | \u200b | $ | \u2014 | \u200b | $ | \u2014 | \u200b | $ | 27,439 |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | December 31, 2022 |\n| ($\u2019s in thousands) | Level 1 | Level 2 | Level 3 | Total |\n| Assets | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Cash and cash equivalents | \u200b | $ | 32,003 | \u200b | $ | \u2014 | \u200b | $ | \u2014 | \u200b | $ | 32,003 |\n| Total | \u200b | $ | 32,003 | \u200b | $ | \u2014 | \u200b | $ | \u2014 | \u200b | $ | 32,003 |",
            "type": "table"
        },
        {
            "id": 107,
            "context": "| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | December 31, |\n| ($\u2019s in thousands) | 2023 | 2022 |\n| Accrued expenses and other short-term liabilities: | \u200b | \u200b |\n| Accrued coupons and rebates | $ | 9,987 | $ | 7,604 |\n| Accrued compensation | \u200b | \u200b | 3,374 | \u200b | \u200b | 2,586 |\n| Accrued royalties payable | \u200b | \u200b | 2,015 | \u200b | \u200b | 2,627 |\n| Return reserve | \u200b | 4,077 | \u200b | 3,689 |\n| Accrued inventory | \u200b | 352 | \u200b | 112 |\n| Accrued research and development | \u200b | 20 | \u200b | 1,404 |\n| Accrued legal, accounting and tax | \u200b | \u200b | 185 | \u200b | \u200b | 334 |\n| Accrued iPledge program | \u200b | \u200b | 174 | \u200b | \u200b | 447 |\n| Other | \u200b | 166 | \u200b | 585 |\n| Total accrued expenses | \u200b | $ | 20,350 | \u200b | $ | 19,388 |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | December 31, 2023 |\n| ($\u2019s in thousands) | Short-Term | Long-Term | Total |\n| Installment payments - licenses | \u200b | $ | 3,000 | \u200b | $ | \u2014 | \u200b | $ | 3,000 |\n| Less: imputed interest | \u200b | \u2014 | \u200b | \u2014 | \u200b | \u2014 |\n| Sub-total installment payments - licenses | \u200b | $ | 3,000 | \u200b | $ | \u2014 | \u200b | $ | 3,000 |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | December 31, 2022 |\n| ($\u2019s in thousands) | \u200b | Short-Term | \u200b | Long-Term | \u200b | Total |\n| Installment payments - licenses | \u200b | $ | 2,500 | \u200b | $ | 1,500 | \u200b | $ | 4,000 |\n| Less: imputed interest | \u200b | ( 256 ) | \u200b | ( 88 ) | \u200b | ( 344 ) |\n| Sub-total installment payments - licenses | \u200b | $ | 2,244 | \u200b | $ | 1,412 | \u200b | $ | 3,656 |",
            "type": "table"
        },
        {
            "id": 108,
            "context": "| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | For the Years Ended December 31, |\n| \u200b | 2023 | \u200b | 2022 |\n| Operating lease cost | \u200b | $ | 97 | \u200b | $ | 93 |\n| Variable lease cost | \u200b | \u200b | 5 | \u200b | \u200b | 4 |\n| Total lease cost | \u200b | $ | 102 | \u200b | $ | 97 |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | For the Years Ended December 31, |\n| \u200b | 2023 | 2022 |\n| Cash paid for amounts included in the measurement of lease liabilities | \u200b | $ | 92 | \u200b | $ | 100 | \u200b |\n| Right-of-use assets exchanged for new operating lease liabilities | \u200b | $ | \u2014 | \u200b | $ | 188 | \u200b |\n| Weighted-average remaining lease term - operating leases | \u200b | 1.1 | \u200b | 2.1 | \u200b |\n| Weighted-average discount rate - operating leases | \u200b | 6.25 | % | 6.25 | % |\n| \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b |\n| For the year ended December 31, | ($\u2019s in thousands) |\n| 2024 | \u200b | $ | 102 |\n| 2025 | \u200b | 9 |\n| Total lease payments | \u200b | \u200b | 111 |\n| Less: present value discount | \u200b | \u200b | ( 3 ) |\n| Total operating lease liabilities | \u200b | $ | 108 |",
            "type": "table"
        },
        {
            "id": 109,
            "context": "| \u200b | \u200b | \u200b | \u200b |\n| \u200b | December 31, |\n| ($\u2019s in thousands) | \u200b | 2023 |\n| \u200b | \u200b | \u200b | \u200b |\n| Principal balance | \u200b | $ | 15,000 |\n| Plus: Exit fee | \u200b | 750 |\n| Less: Debt discount and fees | \u200b | \u200b | ( 1,128 ) |\n| Net carry amount (Long-term) | \u200b | $ | 14,622 |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| December 31, 2022 |\n| \u200b | \u200b | \u200b | \u200b | Net |\n| \u200b | \u200b | Principal | \u200b | Unamortized | \u200b | Carry |\n| ($\u2019s in thousands) | \u200b | Balance | \u200b | Discount & Fees | \u200b | Amount |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Deferred cash payment | \u200b | $ | 5,000 | \u200b | $ | 9 | $ | 4,991 |\n| EWB Revolving LOC | \u200b | 2,948 | \u200b | \u2014 | 2,948 |\n| Total Short-Term Debt | \u200b | $ | 7,948 | \u200b | $ | 9 | $ | 7,939 |\n| EWB Term Loan (Long-term) | \u200b | $ | 20,000 | \u200b | $ | 174 | $ | 19,826 |\n| Total Debt & Obligations | \u200b | $ | 27,948 | \u200b | $ | 183 | $ | 27,765 |",
            "type": "table"
        },
        {
            "id": 110,
            "context": "| \u200b | \u200b | \u200b | \u200b |\n| Years ending December 31, | Term Loan |\n| 2024 | \u200b | $ | \u2014 |\n| 2025 | \u200b | \u2014 |\n| 2026 | \u200b | 4,500 |\n| 2027 | \u200b | 11,250 |\n| Total | \u200b | 15,750 |\n| Debt discount | \u200b | ( 1,128 ) |\n| Total, net | \u200b | 14,622 |\n| Current portion | \u200b | \u2014 |\n| Term-loan (long-term) | \u200b | $ | 14,622 |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | Year Ended December 31, |\n| \u200b | \u200b | 2023 | \u200b | 2022 |\n| Interest payments on term loans and LOC | \u200b | $ | 989 | \u200b | $ | 1,153 |\n| Amortization/accretion | \u200b | \u200b | 356 | \u200b | \u200b | 347 |\n| Imputed interest on acquired intangible assets | \u200b | \u200b | 353 | \u200b | \u200b | 519 |\n| Total interest expense and financing fees | \u200b | $ | 1,698 | \u200b | $ | 2,019 |",
            "type": "table"
        },
        {
            "id": 111,
            "context": "JOURNEY MEDICAL CORPORATIONNotes to Financial Statements Voting RightsEach holder of Common Stock is entitled to one vote per share of Common Stock held on all matters submitted to a vote of the stockholders, including the election of directors. The Company\u2019s Certificate of Incorporation and bylaws do not provide for cumulative voting rights.Each holder of Class A Common Stock is entitled to a number of votes that is equal to 1.1 times a fraction, the numerator of which is the sum of the shares of outstanding Common Stock, including the Class A Common Stock, and the denominator of which is the number of outstanding shares of Class A Common Stock. Thus, the holders of the Class A Common Stock will at all times constitute a voting majority.DividendsThe holders of the Company\u2019s outstanding shares of Common Stock and Class A Common Stock are entitled to receive dividends, if any, as may be declared from time to time by the Company\u2019s Board of Directors out of legally available funds.LiquidationIn the event of the Company\u2019s liquidation, dissolution or winding up, holders of Common Stock and Class A Common Stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of the Company\u2019s debts and other liabilities, subject to the satisfaction of any liquidation preference granted to the holders of any outstanding shares of Preferred Stock.Rights and PreferenceHolders of the Company\u2019s Common Stock and Class A Common Stock have no preemptive, conversion or subscription rights, and there is no redemption or sinking fund provisions applicable to either the Common Stock or the Class A Common Stock. The rights, preferences and privileges of the holders of Common Stock and Class A Common Stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of the Company\u2019s Preferred Stock that are or may be issued. NOTE 16. SHARE-BASED COMPENSATION In 2015, the Company\u2019s Board of Directors adopted, and stockholders approved, the Journey Medical Corporation 2015 Stock Plan (the \u201cPlan\u201d) authorizing the Company to grant up to 4,642,857 shares of Common Stock to eligible employees, directors, and consultants in the form of restricted stock, restricted stock units (\u201cRSUs\u201d), stock options and other types of grants. The amount, terms, and exercisability provisions of grants are determined by the Board of Directors. At the Company\u2019s 2022 Annual Meeting, held on June 21, 2022, the Company\u2019s stockholders approved, among other matters, an amendment to the Plan to increase the number of shares of Common Stock issuable under the Plan by 3,000,000 to 7,642,857 . At December 31, 2023 there were 1,487,994 shares available for issuance under the Plan.The Company grants stock options to employees, non-employees and Directors with exercise prices equal to the closing price of the underlying shares of the Company\u2019s common stock on the Nasdaq Capital Market on the date that the options are granted. Options granted have a term of ten years from the grant date. Options granted generally vest over four-year period. Compensation cost for stock options is charged against operations on a straight-line basis over the vesting period. The Company estimates the fair value of stock options on the grant date by applying the Black-Scholes option pricing valuation model. F-21",
            "type": "paragraph"
        },
        {
            "id": 112,
            "context": "| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | Year Ended December 31, |\n| ($\u2019s in thousands) | \u200b | 2023 | 2022 |\n| Research and development | \u200b | $ | 110 | \u200b | $ | 73 |\n| Selling, general and administrative | \u200b | 2,496 | \u200b | 4,352 |\n| Total non-cash compensation expense related to share-based compensation included in operating expense | \u200b | $ | 2,606 | \u200b | $ | 4,425 |\n| \u200b | \u200b | \u200b |\n| \u200b | 2023 |\n| Risk-free interest rate | 3.45 % - 4.44 % |\n| Expected volatility | 89.09 % - 101.75 % |\n| Weighted average expected volatility | 91.08 % |\n| Expected term (years) | 5.37 - 6.25 |\n| Expected dividend yield | 0 % |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | Weighted |\n| \u200b | \u200b | Weighted | \u200b | average |\n| \u200b | \u200b | Number | \u200b | average | \u200b | Aggregate | \u200b | remaining |\n| \u200b | \u200b | of | \u200b | exercise | \u200b | intrinsic | \u200b | contractual |\n| \u200b | Shares | price | value | life (years) |\n| Outstanding options at December 31, 2022 | \u200b | 2,960,000 | \u200b | $ | 1.76 | \u200b | $ | 2,217,815 | \u200b | 5.65 |\n| Granted | \u200b | 430,756 | \u200b | \u200b | 1.64 | \u200b | \u200b | \u2014 | \u200b | \u2014 |\n| Exercised | \u200b | ( 82,300 ) | \u200b | \u200b | 1.46 | \u200b | \u200b | \u2014 | \u200b | \u2014 |\n| Forfeited | \u200b | ( 504,687 ) | \u200b | \u200b | 3.06 | \u200b | \u200b | \u2014 | \u200b | \u2014 |\n| Expired | ( 33,900 ) | \u200b | 3.58 | \u200b | \u2014 | \u2014 |\n| Outstanding options at December 31, 2023 | 2,769,869 | \u200b | $ | 1.49 | \u200b | $ | 3,441,146 | 4.53 |\n| Options vested and exercisable at December 31, 2023 | 1,984,475 | \u200b | $ | 0.96 | \u200b | $ | 1,758,134 | 2.83 |",
            "type": "table"
        },
        {
            "id": 113,
            "context": "| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | Weighted |\n| \u200b | \u200b | \u200b | \u200b | average |\n| \u200b | \u200b | Number of | \u200b | grant date |\n| \u200b | units | Fair value |\n| Unvested balance at December 31, 2022 | \u200b | 2,261,048 | \u200b | $ | 4.05 |\n| Granted | \u200b | 119,888 | \u200b | \u200b | 1.82 |\n| Vested | \u200b | ( 727,249 ) | \u200b | \u200b | 3.96 |\n| Forfeited | \u200b | ( 346,764 ) | \u200b | \u200b | 4.10 |\n| Unvested balance at December 31, 2023 | \u200b | 1,306,923 | \u200b | $ | 3.88 |",
            "type": "table"
        },
        {
            "id": 114,
            "context": "| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | Year Ended December 31, |\n| ($ in thousands) | 2023 | 2022 |\n| Qbrexza\u00ae | \u200b | $ | 25,410 | \u200b | $ | 26,715 |\n| Accutane\u00ae | \u200b | \u200b | 20,168 | \u200b | \u200b | 18,373 |\n| Amzeeq | \u200b | \u200b | 6,201 | \u200b | \u200b | 7,242 |\n| Targadox\u00ae | \u200b | \u200b | 3,204 | \u200b | \u200b | 7,972 |\n| Exelderm\u00ae | \u200b | 2,395 | \u200b | 3,463 |\n| Zilxi | \u200b | 1,962 | \u200b | 2,273 |\n| Ximino\u00ae | \u200b | 287 | \u200b | 4,957 |\n| Luxamend\u00ae | \u200b | 35 | \u200b | \u2014 |\n| Total product revenues | \u200b | $ | 59,662 | \u200b | $ | 70,995 |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | Year Ended December 31, |\n| ($in thousands) | \u200b | 2023 | 2022 |\n| Non-refundable upfront payment from Maruho | $ | 19,000 | \u200b | $ | \u2014 |\n| Net milestone payment from Maruho | \u200b | \u200b | \u2014 | \u200b | \u200b | 2,500 |\n| Royalties on sales of Rapifort\u00ae Wipes 2.5 % | \u200b | $ | 519 | \u200b | \u200b | 174 |\n| Total other revenue | \u200b | $ | 19,519 | \u200b | $ | 2,674 |",
            "type": "table"
        },
        {
            "id": 115,
            "context": "| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | Years Ended December 31, |\n| ($\u2019s in thousands) | 2023 | 2022 |\n| Current: | \u200b | \u200b | \u200b | \u200b |\n| Federal | \u200b | $ | 34 | \u200b | $ | \u2014 |\n| State | \u200b | 187 | \u200b | 63 |\n| Total current | \u200b | 221 | \u200b | 63 |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Deferred: | \u200b | \u200b |\n| Federal | \u200b | ( 753 ) | \u200b | ( 6,701 ) |\n| State | \u200b | ( 94 ) | \u200b | ( 1,737 ) |\n| Total deferred | \u200b | ( 847 ) | \u200b | ( 8,438 ) |\n| Valuation allowance | \u200b | \u200b | 847 | \u200b | \u200b | 8,438 |\n| Total income tax expense | \u200b | $ | 221 | \u200b | $ | 63 |",
            "type": "table"
        },
        {
            "id": 116,
            "context": "| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | December 31, |\n| ($\u2019s in thousands) | 2023 | 2022 |\n| Deferred tax assets: | \u200b | \u200b | \u200b | \u200b |\n| Net operating loss carryforwards | \u200b | $ | 4,376 | \u200b | $ | 6,553 |\n| Amortization of license fees | \u200b | 5,603 | \u200b | 4,951 |\n| R&D capitalization | \u200b | 3,312 | \u200b | 2,462 |\n| Stock compensation | \u200b | 1,081 | \u200b | 1,293 |\n| Lease liability | \u200b | \u200b | 27 | \u200b | \u200b | 48 |\n| Reserve on sales return, discount and bad debt | \u200b | 3,566 | \u200b | 2,988 |\n| Accruals and reserves | \u200b | 723 | \u200b | 574 |\n| Tax credits | \u200b | 1,491 | \u200b | 1,152 |\n| Business interest expense deduction limit | \u200b | \u2014 | \u200b | 322 |\n| State taxes | \u200b | \u2014 | \u200b | 13 |\n| Total deferred tax assets | \u200b | 20,179 | \u200b | 20,356 |\n| Less: valuation allowance | \u200b | \u200b | ( 20,154 ) | \u200b | \u200b | ( 19,307 ) |\n| Deferred tax assets, net | \u200b | $ | 25 | \u200b | $ | 1,049 |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Deferred tax liability: | \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| Section 481(a) adjustment on reserve on sales return, discount and bad debt | \u200b | \u200b | \u2014 | \u200b | \u200b | ( 1,001 ) |\n| Right-of-use asset | \u200b | \u200b | ( 25 ) | \u200b | \u200b | ( 48 ) |\n| Deferred tax assets, net | \u200b | $ | \u2014 | \u200b | $ | \u2014 |\n| \u200b | \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | Years Ended December 31, |\n| \u200b | 2023 | 2022 |\n| Percentage of pre-tax income: | \u200b | \u200b | \u200b |\n| U.S. federal statutory income tax rate | 21 | % | 21 | % |\n| State taxes, net of federal benefit | ( 1 ) | % | 4 | % |\n| Non-deductible items | ( 4 ) | % | ( 0 ) | % |\n| Provision to return | ( 1 ) | % | 0 | % |\n| State tax adjustments | ( 1 ) | % | 0 | % |\n| Change in valuation allowance | \u200b | ( 23 ) | % | ( 28 ) | % |\n| Share-based compensation | \u200b | ( 10 ) | % | 0 | % |\n| Tax credits | 13 | % | 3 | % |\n| Effective income tax rate | ( 6 ) | % | ( 0 ) | % |",
            "type": "table"
        },
        {
            "id": 117,
            "context": "| \u200b | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | Year ended December 31, |\n| \u200b | \u200b | 2023 | 2022 |\n| Basic and diluted | \u200b | 18,232,422 | \u200b | 17,531,274 |\n| Potentially dilutive securities: | \u200b | \u200b | \u200b | \u200b |\n| Unvested restricted stock units | \u200b | 1,306,923 | \u200b | 2,261,048 |\n| Stock options | \u200b | 1,345,193 | \u200b | 1,566,131 |\n| Total potentially dilutive securities | \u200b | 20,884,538 | \u200b | 21,358,453 |",
            "type": "table"
        },
        {
            "id": 118,
            "context": "| Journey Medical Corporation |\n| By: | /s/ Claude Maraoui |\n| Name: Claude Maraoui |\n| Title: President, Chief Executive Officer, and Director |\n| March 28, 2024 |\n| Signature | Title | Date |\n| /s/ Claude Maraoui | President, Chief Executive Officer and Director | March 28, 2024 |\n| Claude Maraoui | (Principal Executive Officer) |\n| \u200b | \u200b | \u200b |\n| /s/ Lindsay A. Rosenwald, M.D. | \u200b | Executive Chairman | \u200b | March 28, 2024 |\n| Lindsay A. Rosenwald, M.D. | \u200b | \u200b | \u200b | \u200b |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| /s/ Joseph Benesch | Interim Chief Financial Officer | March 28, 2024 |\n| Joseph Benesch | (Principal Financial Officer) |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| /s/ Neil Herskowitz | Director | March 28, 2024 |\n| Neil Herskowitz |\n| \u200b | \u200b | \u200b | \u200b | \u200b |\n| /s/ Justin Smith | Director | March 28, 2024 |\n| Justin Smith |",
            "type": "table"
        }
    ],
    "html_tables": [
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Qbrexza\u00ae (a medicated cloth towelette for the treatment of primary axillary hyperhidrosis), acquired and launched in May 2021;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Accutane\u00ae (an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne), licensed in July 2020 and launched in March 2021;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Amzeeq\u00ae (minocycline) topical foam, 4% (a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and children nine years and older), acquired and launched in January 2022;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Zilxi\u00ae (minocycline) topical foam, 1.5% (a topical minocycline treatment for inflammatory lesions of rosacea in adults), acquired and launched in January 2022;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Exelderm\u00ae Cream and Solution (a broad-spectrum antifungal intended for topical use), acquired and launched in October 2018; </span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Targadox\u00ae (an oral doxycycline drug for adjunctive therapy for severe acne), licensed in March 2015 and launched in October 2016; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Luxamend\u00ae (a water-based emulsion formulated to provide an optimally moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis), acquired in 2021 and launched in 2023.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">sulconazole nitrate cream and solution, 1% antifungal agents indicated for the treatment of </span><i style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;\">tinea cruris</i><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\"> and </span><i style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;\">tinea corporis</i><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\"> caused by </span><i style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;\">Trichophyton rubrum</i><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">,</span><i style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;\"> Trichophyton mentagrophytes</i><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">,</span><i style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;\"> Epidermophyton floccosum</i><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">,</span><i style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;\"> </i><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">and</span><i style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;\"> Microsporum canis</i><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">,* and for the treatment of </span><i style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;\">tinea versicolor</i><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">. *Efficacy for this organism in the organ system was studied in fewer than 10 infections. EXELDERM</span><sup style=\"font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;\">\u00ae</sup><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\"> Cream is also indicated for the treatment of </span><i style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;\">tinea pedis</i><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\"> (athlete\u2019s foot). Effectiveness of EXELDERM</span><sup style=\"font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;\">\u00ae</sup><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\"> Solution has not been proven in </span><i style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;\">tinea pedis</i><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">. These products were launched in January 2020; and </span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">doxycycline hyclate immediate release 50mg tablets, indicated as adjunctive therapy for severe acne to reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of doxycycline hyclate and other antibacterial drugs, launched in May 2018.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><i style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;\">Commercial leadership of our management team with a track record of commercial execution</i><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">. We have a highly skilled and customer-focused management team in critical leadership positions across our Company. Our senior management team has over 135 years of collective sales and marketing experience in the pharmaceutical industry and a proven track record of developing businesses and creating value. Members of our management team have developed, launched, commercialized, and managed brands generating over $3 billion in aggregate peak sales, collectively, at leading dermatology organizations. This experience includes improving business performance through organic revenue growth, maximizing operational efficiencies and through the identification, consummation and integration of licensing and acquisition opportunities. Our senior management team has extensive roots in the dermatology industry, with many of them having worked at and held senior positions with Medicis Pharmaceutical, Inc. leading up to the company\u2019s acquisition by Valeant Pharmaceuticals, Inc. (now Bausch Health Pharmaceuticals, Inc.) for $2.6 billion in 2012. Our strategic approach leverages our management team\u2019s experience with the capabilities of our field sales force to drive performance based on prescribing habits, brand preferences, promotional strategies and profit optimization while focusing on customer service excellence for our providers and their patients.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><i style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;\">Performance and experience of our accomplished field sales force</i><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">. Our current seasoned field sales force has deep-rooted and longstanding customer relationships in their respective territories. We have strategically optimized our sales outreach to cover over 80% of dermatologists in the top 50 U.S. metropolitan statistical areas and over 70% of the overall dermatology prescribing market. We are able to leverage the experience of our field sales force to create a tailored and entrepreneurial compensation plan that incentivizes our field sales force and aligns their activities with our corporate performance and growth objectives. We intend to continue to build a team of committed, experienced employees and to engage with patients and members of the dermatology community. Additionally, we believe that consolidation in the medical dermatology industry has resulted in an enhanced opportunity for a medical dermatology-focused company to build relationships with these stakeholders and has made available a large and growing talent pool of experienced individuals who can make significant contributions to our Company.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><i style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;\">Specialized and differentiated access and distribution model</i><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">. We have a specialized and differentiated access and distribution network of over 600 specialty pharmacies and wholesalers, where we directly sell our products, with limited distribution through traditional national wholesalers. This decentralized approach allows us to maximize our brand equity across our product portfolio through strategic relationships directly with pharmacies and allows us to provide exceptional customer service and access to patients and physicians.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><i style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;\">Active business development initiative</i><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">. Business development plays a vital role in our growth strategy as we look to build scale. We consistently evaluate both synergistic acquisitions that leverage our existing infrastructure, as well as more transformative assets that would require building out or restructuring our field sales force. We have extensive relationships in the industry that help us stay abreast of developments in our space and continually monitor new opportunities. We believe that we are an ideal partner for development stage companies with limited or no commercial capabilities, as well as established pharmaceutical companies looking to deprioritize their dermatology portfolio. We regularly engage in discussions with an array of companies, including traditional large pharma, mid-size specialty pharma companies and smaller companies that focus on research and development, although we have not entered into any definitive agreements or arrangements. Another important part of our business development strategy is to continue to out-license our branded products and/or proprietary technologies in global markets.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">There are twenty one issued U.S. patents, fifteen issued foreign patents (Australia, Canada, Europe, Israel, Mexico, United Kingdom, South Africa), six pending U.S. patent applications and one pending foreign application (Canada), all relating to Amzeeq. The issued Amzeeq patents contain claims directed to compositions and use of the compositions (method claims). The issued U.S. and foreign patents relating to Amzeeq will expire between 2030 and 2037 and the pending U.S. and foreign patent applications relating to Amzeeq will expire between 2030 and 2037.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">There are fourteen issued U.S. patents, fifteen issued foreign patents (Australia, Canada, Europe, Israel, Mexico, United Kingdom, South Africa), four pending U.S. patent applications and one pending foreign application (Canada), all relating to Zilxi. The issued Zilxi patents contain claims directed to compositions and use of the compositions (method claims). The issued U.S. and foreign patents relating to Zilxi will expire between 2030 and 2037 and the pending U.S. and foreign patent applications relating to Zilxi will expire between 2030 and 2037.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">The other patents related to molecular stabilizing platform but not products directly are sixteen issued U.S. patents, three pending U.S. patent applications, and five issued foreign patents (Canada, Israel, and Mexico).</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">slow patient enrollment due to the nature of the clinical trial plan, the proximity of patients to clinical sites, the eligibility criteria for participation in the study or other factors;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">inadequately trained or insufficient personnel at the study site to assist in overseeing and monitoring clinical trials or delays in approvals from a study site\u2019s review board;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">longer treatment time required to demonstrate efficacy or determine the appropriate product dose;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">insufficient supply of the drug candidates;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">adverse medical events or side effects in treated patients; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">ineffectiveness of the drug candidates.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">regulatory authorities may require the addition of unfavorable labeling statements, specific warnings or a contraindication;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">regulatory authorities may suspend or withdraw their approval of the product, or require it to be removed from the market;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">we may be required to change the way the product is administered, conduct additional clinical trials or change the labeling of the product; or</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">our reputation may suffer.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">restrictions on such products or their manufacturers or manufacturing processes;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">restrictions on the labeling or marketing of a product;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">restrictions on product distribution or use;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">requirements to conduct post-marketing studies or clinical trials;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">warning letters, untitled letters, or Form 483s;</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">withdrawal of the products from the market;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">refusal to approve pending applications or supplements to approved applications that we submit;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">recall of products;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">fines, restitution or disgorgement of profits;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">suspension or withdrawal of marketing or regulatory approvals;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">suspension of any ongoing clinical trials;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">denial of permits to import or export our products;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">product seizure; or</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">AKS, which prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under federal and state healthcare programs, such as Medicare and Medicaid. The OIG continues to make modifications to existing AKS safe harbors which may increase liability and risk as well as adversely impact sales relationships. The majority of states also have statutes or regulations similar to these federal laws, which apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">federal civil and criminal false claims laws and civil monetary penalty laws, including the federal False Claims Act, which impose criminal and civil penalties, including civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, including the Medicare and Medicaid programs, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the federal Health Insurance Portability and Accountability Act of 1996 (\u201cHIPAA\u201d), which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and their respective implementing regulations, which impose obligations on covered healthcare providers, health plans, and healthcare clearinghouses, as well as their business associates that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the federal Open Payments program, which requires manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children\u2019s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare &amp; Medicaid Services (\u201cCMS\u201d), information related to \u201cpayments or other transfers of value\u201d made to physicians, which is defined to include doctors, dentists, optometrists, podiatrists, chiropractors, physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, certified nurse-midwives and teaching hospitals and applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by the physicians and their immediate family members;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Increased OIG scrutiny on the sale of our products through specialty pharmacies by means of direct investigation or by issuance of unfavorable Opinion Letters which may curtail or hinder the sales of our products based on risk of enforcement upon our-selves or our buyers;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; state and foreign laws that require pharmaceutical companies to comply with the pharmaceutical industry\u2019s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">state and foreign laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">state and foreign laws governing the privacy and security of health information in certain circum-stances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the severity of the disease under investigation;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the eligibility criteria for a study;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the perceived risks and benefits of the product candidate under study;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the efforts to facilitate timely enrollment in clinical trials;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the patient referral practices of physicians;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the ability to monitor patients adequately during and after treatment; and</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the proximity and availability of clinical trial sites for prospective patients.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the success of any potential clinical studies during the drug development process;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">limitations of use, contraindications, or warnings contained in the product\u2019s FDA-approved labeling;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">changes in the standard of care for the targeted indications for any current or future product candidates, which could reduce the marketing impact of any superiority claims that we could make following FDA approval;</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">ability to be listed on formularies (lists of recommended or approved medicines and other products) and reimbursement lists by demonstrating the qualities and treatment benefits of our products within their approved indications; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">potential advantages over, and availability of, alternative treatments.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the inability of sales personnel to obtain access to physicians and other healthcare providers or persuade adequate numbers of physicians and other healthcare providers to prescribe any future products;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the lack of complementary or other products to be offered by sales personnel, which may put us at a competitive disadvantage from the perspective of sales efficiency relative to companies with more extensive product lines; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">unforeseen costs and expenses associated with creating an independent sales and marketing organization.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">termination of clinical trial sites or entire trial programs or withdrawal of clinical trial participants;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">regulatory investigations by governmental authorities related to regulatory issues or alleged non-compliances;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">litigation costs and potential monetary awards to patients or other claimants;</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">harm to our reputation and/or decreased demand for our products and corresponding revenue loss;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">reduced resources of our management to pursue our business strategy; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the inability to commercialize our current products or any current or future product candidates.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">exposure to unknown liabilities;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">disruption of our business and diversion of our management\u2019s time and attention to develop acquired products or technologies;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">difficulty or inability to secure financing to fund development activities for such acquired or in-licensed technologies in the current economic environment;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">incurrence of substantial debt or dilutive issuances of securities to pay for acquisitions;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">higher than expected acquisition and integration costs;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">increased amortization expenses;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">difficulty and cost in combining the operations and personnel of any acquired businesses with our operations and personnel;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">impairment of relationships with key suppliers or customers of any acquired businesses due to changes in management and ownership; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">inability to retain key employees of any acquired businesses.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">our ability to raise additional capital on acceptable terms, or at all;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">timely completion of our clinical trials, which may be significantly slower or cost more than we currently anticipate and will depend substantially upon the performance of third-party contractors as well as our ability to timely recruit and enroll patients in our clinical trials, which may be delayed due to numerous factors, including the prevalence of other companies\u2019 clinical trials for their product candidates for the same or similar indications;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">whether we are required by the FDA or similar foreign regulatory agencies to conduct additional clinical trials or other studies beyond those planned to support the approval and commercialization of our current or any future product candidates;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">acceptance of our proposed indications and primary endpoint assessments relating to the proposed indications of our current or any future product candidates by the FDA and similar foreign regulatory authorities;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">our ability to demonstrate to the satisfaction of the FDA and similar foreign regulatory authorities the safety, efficacy and acceptable risk to benefit profile of our current or any future product candidates;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the prevalence, duration and severity of potential side effects experienced with our current or any future product candidates;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the timely receipt of necessary marketing approvals from the FDA and similar foreign regulatory authorities;</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">achieving and maintaining, and, where applicable, ensuring that our third-party contractors achieve and maintain, compliance with our contractual obligations and with all regulatory requirements applicable to our current or any future product candidates;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">our ability to successfully obtain the substances and materials used in our current or any future product candidates from third parties and to have finished products manufactured by third parties in accordance with regulatory requirements and in sufficient quantities for preclinical and clinical testing;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the ability of third parties with whom we contract to manufacture clinical trial supplies of our current or any future product candidates, remain in good standing with regulatory agencies and develop, validate and maintain commercially viable manufacturing processes that are compliant with cGMP; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">a continued acceptable safety profile during clinical development of our current or any future product candidates.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">discovery of serious or unexpected adverse events, toxicities, or side effects experienced by study participants or other safety issues;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">lack of effectiveness of any product candidate during clinical trials or the failure of a product candidate to meet specified endpoints;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">slower than expected rates of subject recruitment and patient enrollment in clinical trials resulting from numerous factors, including the prevalence of other companies\u2019 clinical trials for their product candidates for the same indication, such as atopic dermatitis;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">difficulty in retaining subjects who have initiated participation in a clinical trial but may withdraw at any time due to adverse side effects from the therapy, insufficient efficacy, fatigue with the clinical trial process or for any other reason;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">difficulty in obtaining IRB approval for studies to be conducted at each site;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">delays in manufacturing or obtaining, or inability to manufacture or obtain, sufficient quantities of materials for use in clinical trials;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">inadequacy of or changes in our manufacturing process or the product formulation or method of delivery;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">changes in applicable laws, regulations and regulatory policies;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">delays or failure in reaching agreement on acceptable terms in clinical trial contracts or protocols with prospective CROs, clinical trial sites and other third-party contractors;</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">inability to add a sufficient number of clinical trial sites;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">uncertainty regarding proper dosing;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">failure of our contract research organizations (\u201cCROs\u201d) or other third-party contractors to comply with contractual and regulatory requirements or to perform their services in a timely or acceptable manner;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">failure by us, our employees, our CROs or their employees or any partner with which we may collaborate or their employees to comply with applicable FDA or other regulatory requirements relating to the con-duct of clinical trials or the handling, storage, security and recordkeeping for drug and biologic products;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">scheduling conflicts with participating clinicians and clinical institutions;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">failure to design appropriate clinical trial protocols;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">inability or unwillingness of medical investigators to follow our clinical protocols;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">difficulty in maintaining contact with subjects during or after treatment, which may result in incomplete data; or</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">insufficient data to support regulatory approval.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the FDA or the applicable foreign regulatory body may disagree with the design, implementation, choice of dose, analysis plans or interpretation of the outcome of one or more clinical trials;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the FDA or the applicable foreign regulatory body may not deem a product candidate safe and effective for its proposed indication, or may deem a product candidate\u2019s safety or other perceived risks to out-weigh its clinical or other benefits;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the FDA or the applicable foreign regulatory body may not find the data from preclinical studies and clinical trials, including the number of subjects in the safety database, sufficient to support approval, or the results of clinical trials may not meet the level of statistical or clinical significance required by the FDA or the applicable foreign regulatory body for approval;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the FDA or the applicable foreign regulatory body may disagree with our interpretation of data from pre-clinical studies or clinical trials performed by us or third parties, or with the interpretation of any partner with which we may collaborate;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the data collected from clinical trials may not be sufficient to support the submission and approval of an NDA, BLA or other applicable regulatory filing;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the FDA or the applicable foreign regulatory body may require additional preclinical studies or clinical trials;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the FDA or the applicable foreign regulatory agency may identify deficiencies in the formulation, manufacturing, quality control, labeling or specifications of our current or any future product candidates;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the FDA or the applicable foreign regulatory agency may require clinical trials in pediatric patients in order to establish pharmacokinetics or safety for this more drug-sensitive population;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the FDA or the applicable foreign regulatory agency may grant approval contingent on the performance of costly additional post-approval clinical trials;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the FDA or the applicable foreign regulatory agency may grant approval but impose substantial and costly post-approval requirements;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the FDA or the applicable foreign regulatory agency may approve our current or any future product candidates for a more limited indication or a narrower patient population than we originally requested;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the FDA or applicable foreign regulatory agency may not approve the labeling that we believe is necessary or desirable for the successful commercialization of our current or any future product candidates;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the FDA or the applicable foreign regulatory body may not approve of the manufacturing processes, controls or facilities of third-party manufacturers or testing labs with which we contract; or</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the FDA or the applicable foreign regulatory body may change its approval policies or adopt new regulations in a manner rendering our clinical data or regulatory filings insufficient for approval.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">our licensors might not have been the first to make the inventions covered by each of our pending patent applications and issued patents;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">our licensors might not have been the first to file patent applications for these inventions;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">others may independently develop similar or alternative technologies or duplicate our products or our current or future product candidates\u2019 technologies;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">it is possible that none of the pending patent applications licensed to us will result in issued patents;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the issued patents covering our products or any current or future product candidates may not provide a basis for commercially viable active products, may not provide us with any competitive advantages, or may be challenged and defeated by third parties;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">we may not develop additional proprietary technologies that are patentable; or</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">patent rights of others may have an adverse effect on our business.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">diversion of management\u2019s attention from our core business;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">substantial damages for past infringement;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">injunctions prohibiting us from selling or licensing our product unless the patent holder licenses the patent to us, which it would not be required to do;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">requirements that we pay substantial royalties or grant cross licenses under our patents;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">redesigning our processes so they do not infringe, which may not be possible or could require substantial funds and time; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">harm to our reputation and subsequent adverse effect on the valuation of our securities and revenue.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">our current or any future product candidates are approved for commercial sale, due to our ability to establish the necessary commercial infrastructure to launch this product candidate without substantial delays, including hiring sales and marketing personnel and contracting with third parties for warehousing, distribution, cash collection and related commercial activities;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">we acquire or in-license new products for development and/or sale;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">we are required by the FDA, or foreign regulatory authorities, to perform studies in addition to those currently expected;</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">there are any delays in completing our clinical trials or the development of our current or any future product candidates;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">we execute other collaborative, licensing or similar arrangements that require us to make payments and/ or expend funds;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">there are variations in the level of expenses related to our future development programs;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">there are any product liability or intellectual property infringement lawsuits in which we may become involved;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">there are any regulatory developments affecting our products, current or future product candidates, or the product candidates of our competitors; or</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the level of underlying demand for our products and wholesalers\u2019 buying patterns.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">obtain and maintain regulatory approval for our products, or any other current or future product candidates that we may license or acquire;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">manufacture commercial quantities of our current products or current or future product candidates, if approved, at acceptable cost levels; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">maintain and/or expand our commercial organization and the supporting infrastructure required to successfully market and sell our products or current or future product candidates, if approved.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">fund our operations and continue our efforts to hire additional personnel;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">qualify and outsource the commercial-scale manufacturing of our products under cGMP; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">acquire, in-license and/ or develop additional product candidates.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the potential for delays in our efforts to seek regulatory approval for any current or future product candidates, and any costs associated with such delays;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the costs of maintaining and/or establishing a commercial organization to sell, market and distribute our products and/or current or future product candidates;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the rate of progress and costs of our efforts to prepare for the submission of NDA or BLA for any product candidates that we may in-license or acquire in the future, and the potential that we may need to conduct additional clinical trials to support applications for regulatory approval;</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights associated with any current or future product candidates, including any such costs we may be required to expend if licensors are unwilling or unable to do so;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the cost and timing of securing sufficient supplies of our products and current or future product candidates from our contract manufacturers in preparation for commercialization, manufacture, and/or sale;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the effect of competing technological and market developments;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the terms and timing of any collaborative, licensing, co-promotion or other arrangements that we may establish;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the potential that we may be required to file a lawsuit to defend our patent rights or regulatory exclusivities from challenges by companies seeking to market generic versions of our branded products; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the success of sales efforts of our current products and/or the commercialization of any current or future product candidates.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">permit the board of directors to establish the number of directors and fill any vacancies and newly created directorships;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">provide that, after a removal for cause, vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">prohibit cumulative voting in the election of directors;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">require majority voting to amend our certificate of incorporation and bylaws;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">authorize the issuance of \u201cblank check\u201d preferred stock that our board of directors could use to implement a stockholder rights plan;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">restrict the forum for certain litigation against us to Delaware or federal courts;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">establish advance notice requirements for nominations for election to our board of directors or for proposing matters that can be acted upon by stockholders at annual stockholder meetings; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">bestow majority control of the stockholder vote to Fortress by virtue of their exclusive ownership of our Class A Common Stock.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">significant volatility in the market price and trading volume of companies in our industry;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">announcements of new solutions or technologies, commercial relationships, acquisitions, or other events by us or our competitors;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">price and volume fluctuations in the overall stock market from time to time;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">changes in how customers perceive the benefits of our products and future offerings;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">the public\u2019s reaction to our press releases, other public announcements, and filings with the SEC;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">fluctuations in the trading volume of our shares or the size of our public float;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">actual or anticipated changes or fluctuations in our results of operations or financial projections;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">changes in actual or future expectations of investors or securities analysts;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">litigation involving us, our industry, or both;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">governmental or regulatory actions or audits;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">regulatory developments applicable to our business, including those related to privacy in the United States or globally;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">general economic conditions and trends;</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">major catastrophic events in our domestic and foreign markets; and</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">departures of key employees.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:57.96%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.42%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:57.96%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"5\" style=\"vertical-align:bottom;white-space:nowrap;width:22.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">For the Years Ended December 31, </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"4\" style=\"vertical-align:bottom;white-space:nowrap;width:14.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Change</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:57.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><i style=\"font-style:italic;\">($ in thousands, except per share data)</i></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2022</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">%</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:57.96%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Revenue:</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:57.96%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\">Product revenue, net</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 59,662</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 70,995</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (11,333)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.42%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (16)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">%</p></td></tr><tr><td style=\"vertical-align:bottom;width:57.96%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\">Other revenue</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 19,519</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 2,674</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 16,845</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 630</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">%</p></td></tr><tr><td style=\"vertical-align:bottom;width:57.96%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Total revenue</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 79,181</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 73,669</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 5,512</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.42%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 7</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">%</p></td></tr><tr><td style=\"vertical-align:bottom;width:57.96%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\"> <span style=\"margin-left:0pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:57.96%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Operating expenses</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.42%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:57.96%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\">Cost of goods sold - product revenue</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 26,660</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 30,775</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (4,115)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (13)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">%</p></td></tr><tr><td style=\"vertical-align:bottom;width:57.96%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\">Research and development</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 7,541</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 10,943</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (3,402)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.42%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (31)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">%</p></td></tr><tr><td style=\"vertical-align:bottom;width:57.96%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\">Selling, general and administrative</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 43,910</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 59,468</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (15,558)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (26)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">%</p></td></tr><tr><td style=\"vertical-align:bottom;width:57.96%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\">Loss on impairment of intangible assets</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 3,143</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> \u2014</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 3,143</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.42%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 100</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">%</p></td></tr><tr><td style=\"vertical-align:bottom;width:57.96%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Total operating expenses</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 81,254</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 101,186</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (19,932)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (20)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">%</p></td></tr><tr><td style=\"vertical-align:bottom;width:57.96%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Loss from operations</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (2,073)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (27,517)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 25,444</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.42%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (92)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">%</p></td></tr><tr><td style=\"vertical-align:bottom;width:57.96%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\"><span style=\"margin-left:0pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:57.96%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Other expense</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.42%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:57.96%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\">Interest income</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (322)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (60)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (262)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 437</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">%</p></td></tr><tr><td style=\"vertical-align:bottom;width:57.96%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\">Interest expense </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 1,698</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 2,019</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (321)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.42%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (16)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">%</p></td></tr><tr><td style=\"vertical-align:bottom;width:57.96%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\">Foreign exchange transaction losses</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 183</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 89</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 94</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 106</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">%</p></td></tr><tr><td style=\"vertical-align:bottom;width:57.96%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Total other expense</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 1,559</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 2,048</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (489)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.42%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (24)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">%</p></td></tr><tr><td style=\"vertical-align:bottom;width:57.96%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Loss before income taxes</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;white-space:pre-wrap;\"> (3,632)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;white-space:pre-wrap;\"> (29,565)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;white-space:pre-wrap;\"> 25,933</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;white-space:pre-wrap;\"> (88)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">%</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:57.96%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.42%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:57.96%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Income tax expense</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 221</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 63</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 158</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 251</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">%</p></td></tr><tr><td style=\"vertical-align:bottom;width:57.96%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Net Loss</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;white-space:pre-wrap;\"> (3,853)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;white-space:pre-wrap;\"> (29,628)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;white-space:pre-wrap;\"> 25,775</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.42%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;white-space:pre-wrap;\"> (87)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">%</b></p></td></tr></table><table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:49.49%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4.74%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:49.49%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"5\" style=\"vertical-align:bottom;white-space:nowrap;width:28.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">For the Years Ended December 31, </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"4\" style=\"vertical-align:bottom;white-space:nowrap;width:16.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Change</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:49.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><i style=\"font-style:italic;\">($in thousands)</i></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:12.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:12.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2022</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">%</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:49.49%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Qbrexza\u00ae</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 25,410</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 26,715</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (1,305)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4.74%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (5)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">%</p></td></tr><tr><td style=\"vertical-align:bottom;width:49.49%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Accutane\u00ae</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 20,168</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 18,373</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 1,795</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4.74%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 10</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">%</p></td></tr><tr><td style=\"vertical-align:bottom;width:49.49%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Amzeeq</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 6,201</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 7,242</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (1,041)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4.74%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (14)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">%</p></td></tr><tr><td style=\"vertical-align:bottom;width:49.49%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Targadox\u00ae</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 3,204</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 7,972</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (4,768)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4.74%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (60)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">%</p></td></tr><tr><td style=\"vertical-align:bottom;width:49.49%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Exelderm\u00ae</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 2,395</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 3,463</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (1,068)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4.74%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (31)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">%</p></td></tr><tr><td style=\"vertical-align:bottom;width:49.49%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Zilxi</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 1,962</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 2,273</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (311)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4.74%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (14)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">%</p></td></tr><tr><td style=\"vertical-align:bottom;width:49.49%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Ximino\u00ae</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 287</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 4,957</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (4,670)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4.74%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (94)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">%</p></td></tr><tr><td style=\"vertical-align:bottom;width:49.49%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Luxamend\u00ae</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 35</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> \u2014</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 35</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4.74%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 100</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">%</p></td></tr><tr><td style=\"vertical-align:bottom;width:49.49%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\"><b style=\"font-weight:bold;\">Total net product revenue</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;white-space:pre-wrap;\"> 59,662</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;white-space:pre-wrap;\"> 70,995</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;white-space:pre-wrap;\"> (11,333)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:4.74%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;white-space:pre-wrap;\"> (16)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">%</b></p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"5\" style=\"vertical-align:bottom;white-space:nowrap;width:18.4%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">For the Years Ended</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"5\" style=\"vertical-align:bottom;white-space:nowrap;width:18.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">December 31,</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"4\" style=\"vertical-align:bottom;white-space:nowrap;width:17.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Change</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><i style=\"font-style:italic;\">($in thousands)</i></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2022</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:8.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">%</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Non-refundable upfront payment from Maruho</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 19,000</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> \u2014</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 19,000</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 100</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">%</p></td></tr><tr><td style=\"vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Net milestone payment from Maruho</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> \u2014</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 2,500</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (2,500)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (100)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">%</p></td></tr><tr><td style=\"vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Royalties on sales of Rapifort\u00ae Wipes 2.5% </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 519</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 174</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 345</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 198</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">%</p></td></tr><tr><td style=\"vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\"><b style=\"font-weight:bold;\">Total other revenue</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;white-space:pre-wrap;\"> 19,519</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;white-space:pre-wrap;\"> 2,674</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;white-space:pre-wrap;\"> 16,845</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;white-space:pre-wrap;\"> 630</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">%</b></p></td></tr></table><table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:27.25%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.17%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:27.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Chargebacks</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Distributor</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Prompt</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Managed</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:27.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">and other</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Service</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Pay</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Care</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Gov\u2019t </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:27.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">($\u2019s in thousands)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">allowances</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Fees</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Discounts</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Returns</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:8.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Coupons</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Rebates</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Rebates</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:8.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Total</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:27.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Balance as of December 31, 2021</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.16%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;white-space:pre-wrap;\"> 622</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.17%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;white-space:pre-wrap;\"> 791</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;white-space:pre-wrap;\"> 197</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;white-space:pre-wrap;\"> 3,240</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;white-space:pre-wrap;\"> 4,992</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;white-space:pre-wrap;\"> 3,492</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;white-space:pre-wrap;\"> 690</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;white-space:pre-wrap;\"> 14,024</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:27.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Current provision related to sales in the current period</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 2,663</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.17%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 5,868</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 1,104</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 5,387</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 117,883</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 22,654</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 3,651</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 159,210</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:27.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Checks/credits issued to third parties</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (3,032)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (5,730)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (1,094)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (4,938)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (121,179)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (22,552)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (3,331)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (161,856)</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:27.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Balance as of December 31, 2022</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;white-space:pre-wrap;\"> 253</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.17%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;white-space:pre-wrap;\"> 929</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;white-space:pre-wrap;\"> 207</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;white-space:pre-wrap;\"> 3,689</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;white-space:pre-wrap;\"> 1,696</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;white-space:pre-wrap;\"> 3,594</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;white-space:pre-wrap;\"> 1,010</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;white-space:pre-wrap;\"> 11,378</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:27.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Current provision related to sales in the current period</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.16%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 1,856</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.17%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 5,439</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 976</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 5,483</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 94,822</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 22,934</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 5,191</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 136,701</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:27.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Checks/credits issued to third parties</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (2,016)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (5,470)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (1,041)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (5,095)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (93,074)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (21,318)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (5,948)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (133,962)</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:27.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Balance as of December 31, 2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;white-space:pre-wrap;\"> 93</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;white-space:pre-wrap;\"> 898</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;white-space:pre-wrap;\"> 142</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;white-space:pre-wrap;\"> 4,077</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;white-space:pre-wrap;\"> 3,444</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;white-space:pre-wrap;\"> 5,210</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;white-space:pre-wrap;\"> 253</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;white-space:pre-wrap;\"> 14,117</b></p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;white-space:nowrap;width:58.81%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:58.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"5\" style=\"vertical-align:bottom;white-space:nowrap;width:27.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">For the Years ended December 31, </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Increase</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:58.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\">($\u2019s in thousands)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2022</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">(Decrease)</b></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:58.81%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Net cash provided by (used in) operating activities </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 5,240</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (13,534)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 18,774</span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:58.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Net cash used in investing activities</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (5,000)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (20,000)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 15,000</span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:58.81%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Net cash provided by (used in) financing activities </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (4,804)</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 16,456</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> (21,260)</span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:58.81%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Net change in cash and cash equivalents </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;white-space:pre-wrap;\"> (4,564)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;white-space:pre-wrap;\"> (17,078)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;white-space:pre-wrap;\"> (12,514)</b></p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">We are required to make regular payments under the SWK Credit Facility. Based on the amount currently outstanding under the SWK facility and current interest rates, and assuming we do not make further draws under the SWK facility, we expect to make the following payments:</span></td></tr></table><table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:50.23%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:50.23%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"14\" style=\"vertical-align:bottom;white-space:nowrap;width:47.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Payments by Period</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:50.23%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Total</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2024</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2025</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2026</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2027</b></p></td></tr><tr style=\"height:0pt;visibility:hidden;\"><td colspan=\"16\" style=\"padding:0pt;\"></td></tr><tr><td style=\"vertical-align:bottom;width:50.23%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"14\" style=\"vertical-align:bottom;white-space:nowrap;width:47.91%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">($\u2019s in thousands)</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:50.23%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Interest </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 6,770</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 1,998</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 1,993</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 1,693</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 1,086</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:50.23%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Principal</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 15,000</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> \u2014</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> \u2014</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 4,500</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 10,500</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:50.23%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Exit fee</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 750</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> \u2014</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> \u2014</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> \u2014</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><span style=\"white-space:pre-wrap;\"> 750</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:50.23%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Total </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;white-space:pre-wrap;\"> 22,520</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;white-space:pre-wrap;\"> 1,998</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;white-space:pre-wrap;\"> 1,993</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;white-space:pre-wrap;\"> 6,193</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;white-space:pre-wrap;\"> 12,336</b></p></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">Pursuant to the Vyne Product Acquisition Agreement, upon the achievement of net sales milestones with respect to the products purchased in the Vyne Product Acquisition, we are also required to pay contingent consideration consisting of a one-time payment, per product, of $10.0 million and $20.0 million upon each product reaching annual net sales of $100 million and $200 million, respectively. Each required payment must only be paid one time following the first achievement of the applicable annual net sales milestone amount.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">On June 29, 2021, we entered into the DFD-29 Agreement to obtain the global rights for the development and commercialization of DFD-29 with DRL. Based on the development and commercialization of DFD-29, additional contingent regulatory and commercial milestone payments totaling up to $158.0 million may also become payable. Royalties ranging from ten percent to twenty percent are payable on net sales of the product. Additionally, the Company was required to fund and </span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\"></td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">oversee the Phase 3 clinical trials beginning upon the license of DFD-29 in 2021. The two Phase 3 clinical trials substantially concluded in July 2023 upon the receipt of positive topline results from the trials. In January 2024, the Company paid a $4.0 million filing fee to the FDA upon filing of an NDA for DFD-29. The Company is obligated to make a $3.0 million milestone payment to DRL in April 2024 based on the FDA\u2019s acceptance of the NDA filed in January 2024.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">We are contractually obligated to make installment milestone payments of $3.0 million on Ximino, all of which is classified as current as it is due within a year of December 31, 2023.</span></td></tr></table><table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"width:18pt;\"></td><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">\u25cf</td><td style=\"padding:0pt;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;\">We are contractually obligated to make sales-based royalty payments to Dermira (for Qbrexza), Sun Pharmaceutical Industries (for Exelderm) and PuraCap Caribe (for Targadox). Due to the contingent nature of these obligations, the amounts of these payments cannot be reasonably predicted as of the date of this Annual Report on Form 10-K.</span></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:95%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"></div></div></td><td style=\"vertical-align:bottom;width:5%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:95%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\"><a href=\"#ReportofIndependentRegisteredPublicAccou\"><span style=\"font-style:normal;font-weight:normal;letter-spacing:0.2pt;\">Report of Independent Registered Public Accounting Firm</span></a><span style=\"letter-spacing:0.2pt;\"> (KPMG LLP, Short Hills, New Jersey; PCAOB# 185)</span></p></td><td style=\"vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;\">F-2</p></td></tr><tr><td style=\"vertical-align:bottom;width:95%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\"><a href=\"#CONSOLIDATEDBALANCESHEETS_981334\"><span style=\"font-style:normal;font-weight:normal;letter-spacing:0.2pt;\">Consolidated Balance Sheets as of December 31, 2023 and 2022</span></a></p></td><td style=\"vertical-align:bottom;width:5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;\">F-3 </p></td></tr><tr><td style=\"vertical-align:bottom;width:95%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\"><a href=\"#CONSOLIDATEDSTATEMENTSOFOPERATIONS_12697\"><span style=\"font-style:normal;font-weight:normal;letter-spacing:0.2pt;\">Consolidated Statements of Operations for the years ended December 31, 2023 and 2022 </span></a></p></td><td style=\"vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;\">F-4</p></td></tr><tr style=\"height:11.7pt;\"><td style=\"vertical-align:bottom;width:95%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\"><a href=\"#CONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOL\"><span style=\"font-style:normal;font-weight:normal;letter-spacing:0.2pt;\">Consolidated Statement of Changes in Stockholders\u2019 Equity for the years ended December 31, 2023 and 2022 </span></a></p></td><td style=\"vertical-align:bottom;width:5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;\">F-5 </p></td></tr><tr><td style=\"vertical-align:bottom;width:95%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\"><a href=\"#CONSOLIDATEDSTATEMENTSOFCASHFLOWS_859125\"><span style=\"font-style:normal;font-weight:normal;letter-spacing:0.2pt;\">Consolidated Statements of Cash Flows for the years ended December 31, 2023 and 2022 </span></a></p></td><td style=\"vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;\">F-6 </p></td></tr><tr><td style=\"vertical-align:bottom;width:95%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\"><a href=\"#NOTE1ORGANIZATIONANDPLANOFBUSINESSOPERAT\"><span style=\"font-style:normal;font-weight:normal;letter-spacing:0.2pt;\">Notes to Consolidated Financial Statements </span></a></p></td><td style=\"vertical-align:bottom;width:5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;\">F-7</p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;\"><tr><td style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;\">(b)</td><td style=\"padding:0pt;\"><b style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;\">Exhibits.</b></td></tr></table><table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;table-layout:auto;width:100%;\"><tr><td style=\"vertical-align:bottom;white-space:normal;width:7.5%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:9.0pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Exhibit </b><b style=\"font-weight:bold;\"><br/></b><b style=\"font-weight:bold;\">Number</b></p></td><td style=\"vertical-align:top;width:2.5%;margin:0pt;padding:0.25pt 0pt 0pt 0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:9.0pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:normal;width:90%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:9.0pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Description </b></p></td></tr><tr><td style=\"vertical-align:top;white-space:normal;width:7.5%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\">3.1 </p></td><td style=\"vertical-align:top;width:2.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:90%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1867066/000141057822000558/derm-20211231xex3d1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Third Amended and Restated Certificate of Incorporation of Journey Medical Corporation, filed on March 28, 2022 and incorporated herein by reference.</span></a></p></td></tr><tr><td style=\"vertical-align:top;white-space:normal;width:7.5%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\">3.2 </p></td><td style=\"vertical-align:top;width:2.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;white-space:normal;width:90%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1867066/000141057822000558/derm-20211231xex3d2.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Amended and Restated Bylaws of Journey Medical Corporation, filed as Exhibit 3.2 to Form 10-K, filed on March 28, 2022 and incorporated herein by reference.</span></a> </p></td></tr><tr><td style=\"vertical-align:top;white-space:normal;width:7.5%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\">4.1 </p></td><td style=\"vertical-align:top;width:2.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;white-space:normal;width:90%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1867066/000110465921128950/tm2122275d9_ex4-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Form of Common Stock Certificate, filed as Exhibit 4.1 to Form S-1, filed on October 22, 2021 and incorporated herein by reference.</span></a></p></td></tr><tr><td style=\"vertical-align:top;white-space:normal;width:7.5%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\">4.2</p></td><td style=\"vertical-align:top;width:2.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;white-space:normal;width:90%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1867066/000141057822000558/derm-20211231xex4d2.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Description of Securities of Journey Medical Corporation, filed as Exhibit 4.2 to Form 10-K, filed on March 28, 2022 and incorporated herein by reference.</span></a> </p></td></tr><tr><td style=\"vertical-align:top;white-space:normal;width:7.5%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\">10.1 </p></td><td style=\"vertical-align:top;width:2.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;white-space:normal;width:90%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1867066/000110465921128950/tm2122275d9_ex10-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Journey Medical Corporation 2015 Stock Plan, filed as Exhibit 10.1 to Form S-1, filed on October 22, 2021 and incorporated herein by reference.#</span></a></p></td></tr><tr><td style=\"vertical-align:top;white-space:normal;width:7.5%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\">10.2</p></td><td style=\"vertical-align:top;width:2.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;white-space:normal;width:90%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1867066/000110465922072953/tm2219018d1_ex10-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Amendment to Journey Medical Corporation 2015 Stock Plan, filed as Exhibit 10.1 to Form 8-K filed on June 21, 2022 and incorporated herein by reference.#</span></a></p></td></tr><tr><td style=\"vertical-align:top;white-space:normal;width:7.5%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\">10.3 </p></td><td style=\"vertical-align:top;width:2.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;white-space:normal;width:90%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1867066/000110465921128950/tm2122275d9_ex10-2.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Executive Employment Agreement with Claude Maraoui, dated September 22, 2014, filed as Exhibit 10.2 to Form S-1, filed on October 22, 2021 and incorporated herein by reference.#</span></a></p></td></tr><tr><td style=\"vertical-align:top;white-space:normal;width:7.5%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\">10.4</p></td><td style=\"vertical-align:top;width:2.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;white-space:normal;width:90%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1867066/000110465921128950/tm2122275d9_ex10-4.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Non-Employee Director Compensation Plan, filed as Exhibit 10.4 to Form S-1, filed on October 22, 2021 and incorporated herein by reference.#</span></a></p></td></tr><tr><td style=\"vertical-align:top;white-space:normal;width:7.5%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\">10.5</p></td><td style=\"vertical-align:top;width:2.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:90%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1867066/000110465923074239/tm2319590d1_ex10-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Journey Medical Corporation 2023 Employee Stock Purchase Plan, filed as Exhibit 10.1 to Form 8-K filed on June 23, 2023 and incorporated herein by reference.#</span></a></p></td></tr><tr><td style=\"vertical-align:top;white-space:normal;width:7.5%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\">10.6</p></td><td style=\"vertical-align:top;width:2.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:90%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1867066/000110465921128950/tm2122275d9_ex10-6.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Asset Purchase Agreement for Qbrexza, entered into by and between Journey Medical Corporation and Dermira, Inc., a subsidiary of Eli Lilly and Company, dated as of March 31, 2021, filed as Exhibit 10.6 to Form S-1, filed on October 22, 2021 and incorporated herein by reference.**</span></a></p></td></tr><tr><td style=\"vertical-align:top;white-space:normal;width:7.5%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\">10.7</p></td><td style=\"vertical-align:top;width:2.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:90%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1867066/000110465922003789/tm222871d1_ex10-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Asset Purchase Agreement between VYNE Therapeutics Inc. and Journey Medical Corporation, dated as of January 12, 2022, filed as Exhibit 10.1 to Form 8-K filed on January 13, 2022 and incorporated herein by reference.**</span></a></p></td></tr><tr><td style=\"vertical-align:top;white-space:normal;width:7.5%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\">10.8</p></td><td style=\"vertical-align:top;width:2.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:90%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1867066/000110465921128950/tm2122275d9_ex10-7.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">License and Supply Agreement for Accutane, entered into by and between Journey Medical Corporation and Dr. Reddy\u2019s Laboratories Ltd., dated as of July 29, 2020, filed as Exhibit 10.7 to Form S-1, filed on October 22, 2021 and incorporated herein by reference.**</span></a></p></td></tr><tr><td style=\"vertical-align:top;white-space:normal;width:7.5%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\">10.9</p></td><td style=\"vertical-align:top;width:2.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:90%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1867066/000110465921128950/tm2122275d9_ex10-8.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">License and Supply Agreement for Targadox, entered into by and between Journey Medical Corporation and Blu Caribe Inc., dated as of March 10, 2015, filed as Exhibit 10.8 to Form S-1, filed on October 22, 2021 and incorporated herein by reference.**</span></a></p></td></tr><tr><td style=\"vertical-align:top;white-space:normal;width:7.5%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\">10.10</p></td><td style=\"vertical-align:top;width:2.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:90%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1867066/000110465921128950/tm2122275d9_ex10-9.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">First Amendment to the License and Supply Agreement for Targadox, entered into by and between Journey Medical Corporation and Blu Caribe Inc., dated as of August 26, 2015, filed as Exhibit 10.9 to Form S-1, filed on October 22, 2021 and incorporated herein by reference.**</span></a></p></td></tr><tr><td style=\"vertical-align:top;white-space:normal;width:7.5%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\">10.11</p></td><td style=\"vertical-align:top;width:2.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:90%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1867066/000110465921128950/tm2122275d9_ex10-10.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Asset Purchase Agreement for Exelderm, entered into by and between Journey Medical Corporation and Sun Pharmaceutical Industries, Inc., dated as of August 31, 2018, filed as Exhibit 10.10 to Form S-1, filed on October 22, 2021 and incorporated herein by reference.**</span></a></p></td></tr><tr><td style=\"vertical-align:top;white-space:normal;width:7.5%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\">10.12</p></td><td style=\"vertical-align:top;width:2.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:90%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1867066/000110465921128950/tm2122275d9_ex10-11.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Amendment 1 to the Asset Purchase Agreement for Exelderm, entered into by and between Journey Medical Corporation and Sun Pharmaceutical Industries, Inc., dated as of September 5, 2018, filed as Exhibit 10.11 to Form S-1, filed on October 22, 2021 and incorporated herein by reference. **</span></a></p></td></tr><tr><td style=\"vertical-align:top;white-space:normal;width:7.5%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\">10.13</p></td><td style=\"vertical-align:top;width:2.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:90%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1867066/000110465921128950/tm2122275d9_ex10-12.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Asset Purchase Agreement for Ximino, entered into by and between Journey Medical Corporation and Sun Pharmaceutical Industries, Inc., dated as of July 22, 2019, filed as Exhibit 10.12 to Form S-1, filed on October 22, 2021 and incorporated herein by reference.**</span></a></p></td></tr><tr><td style=\"vertical-align:top;white-space:normal;width:7.5%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\">10.14</p></td><td style=\"vertical-align:top;width:2.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:90%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1867066/000110465921128950/tm2122275d9_ex10-13.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Asset Purchase Agreement for the Anti-itch Product, entered into by and between Journey Medical Corporation and Sun Pharmaceutical Industries, Inc., dated as of December 18, 2020, filed as Exhibit 10.13 to Form S-1, filed on October 22, 2021 and incorporated herein by reference.**</span></a></p></td></tr><tr><td style=\"vertical-align:top;white-space:normal;width:7.5%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\">10.15</p></td><td style=\"vertical-align:top;width:2.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:90%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1867066/000110465921128950/tm2122275d9_ex10-14.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">License, Collaboration, and Assignment Agreement for DFD-29, entered into by and between Journey Medical Corporation and Dr. Reddy\u2019s Laboratories Ltd., dated as of June 29, 2021, filed as Exhibit 10.14 to Form S-1, filed on October 22, 2021 and incorporated herein by reference.**</span></a></p></td></tr><tr><td style=\"vertical-align:top;white-space:normal;width:7.5%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\">10.16</p></td><td style=\"vertical-align:top;width:2.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:90%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1867066/000110465922003789/tm222871d1_ex10-1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Asset Purchase Agreement between Journey Medical Corporation and VYNE Therapeutics Inc., dated as of January 12, 2022, filed as Exhibit 10.1 to the Form 8-K filed on January 13, 2022 and incorporated herein by reference. **</span></a></p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;table-layout:auto;width:100%;\"><tr><td style=\"vertical-align:top;white-space:normal;width:7.5%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\">10.17</p></td><td style=\"vertical-align:top;width:2.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:90%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1867066/000110465921128950/tm2122275d9_ex10-16.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Fortress Promissory Note, dated as of June 6, 2015, filed as Exhibit 10.16 to Form S-1, filed on October 22, 2021 and incorporated herein by reference.</span></a></p></td></tr><tr><td style=\"vertical-align:top;white-space:normal;width:7.5%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\">10.18</p></td><td style=\"vertical-align:top;width:2.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:90%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1867066/000110465922131336/tm2233626d1_ex1-2.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">At Market Issuance Sales Agreement, dated as of December 30, 2022, by and between Journey Medical Corporation and B. Riley Securities, Inc., filed as Exhibit 1.2 to Form S-3, filed on December 30, 2022 and incorporated herein by reference.</span></a></p></td></tr><tr><td style=\"vertical-align:top;white-space:normal;width:7.5%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\">10.19</p></td><td style=\"vertical-align:top;width:2.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:90%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1867066/000141057823002335/derm-20230930xex10d1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">License Agreement, dated as of August 31, 2023, between Journey Medical Corporation and Maruho Co., Ltd. filed as Exhibit 10.1 to Form 10 - Q filed on November 13, 2023.**</span></a></p></td></tr><tr><td style=\"vertical-align:top;white-space:normal;width:7.5%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\">10.20</p></td><td style=\"vertical-align:top;width:2.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:90%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1867066/000141057823002335/derm-20230930xex10d2.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Second Amended and Restated License Agreement, dated as of August 31, 2023, between Journey Medical Corporation and Maruho Co., Ltd. filed as Exhibit 10.2 to Form 10 - Q filed on November 13, 2023.**</span></a></p></td></tr><tr><td style=\"vertical-align:top;white-space:normal;width:7.5%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\">10.21</p></td><td style=\"vertical-align:top;width:2.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:90%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1867066/000141057824000347/derm-20231231xex10d21.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Credit Agreement, dated as of December 27, 2023, between Journey Medical Corporation with SWK Funding LLC. ***</span></a></p></td></tr><tr><td style=\"vertical-align:top;white-space:normal;width:7.5%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\">21.1</p></td><td style=\"vertical-align:top;width:2.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:90%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1867066/000141057824000347/derm-20231231xex21d1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">List of Subsidiaries of Journey Medical Corporation.*</span></a></p></td></tr><tr><td style=\"vertical-align:top;white-space:normal;width:7.5%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\">23.1</p></td><td style=\"vertical-align:top;width:2.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:90%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1867066/000141057824000347/derm-20231231xex23d1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Consent of KPMG LLP.*</span></a></p></td></tr><tr><td style=\"vertical-align:top;white-space:normal;width:7.5%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\">31.1</p></td><td style=\"vertical-align:top;width:2.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:90%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1867066/000141057824000347/derm-20231231xex31d1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. *</span></a></p></td></tr><tr><td style=\"vertical-align:top;white-space:normal;width:7.5%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\">31.2</p></td><td style=\"vertical-align:top;width:2.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:90%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1867066/000141057824000347/derm-20231231xex31d2.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. *</span></a></p></td></tr><tr><td style=\"vertical-align:top;white-space:normal;width:7.5%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\">32.1</p></td><td style=\"vertical-align:top;width:2.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:90%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1867066/000141057824000347/derm-20231231xex32d1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. *</span><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">*</span><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">*</span></a></p></td></tr><tr><td style=\"vertical-align:top;white-space:normal;width:7.5%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\">32.2</p></td><td style=\"vertical-align:top;width:2.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:90%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1867066/000141057824000347/derm-20231231xex32d2.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. **</span><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">*</span></a></p></td></tr><tr><td style=\"vertical-align:top;white-space:normal;width:7.5%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\">97.1</p></td><td style=\"vertical-align:top;width:2.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:90%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;\"><a href=\"https://www.sec.gov/Archives/edgar/data/1867066/000141057824000347/derm-20231231xex97d1.htm\" style=\"-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;\"><span style=\"font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;\">Clawback Policy of Journey Medical Corporation*</span></a></p></td></tr><tr><td style=\"vertical-align:top;white-space:normal;width:7.5%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\">101</p></td><td style=\"vertical-align:top;width:2.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:90%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;\">The following financial information from the Company\u2019s Quarterly Report on Form 10-K for the period ended December 31, 2023, formatted in Extensible Business Reporting Language (XBRL): (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements of Operations, (iii) the Consolidated Statement of Stockholders\u2019 Equity, (iv) the Consolidated Statements of Cash Flows, and (v) Notes to the Consolidated Financial Statements.</p></td></tr><tr><td style=\"vertical-align:top;white-space:normal;width:7.5%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\">104</p></td><td style=\"vertical-align:top;width:2.5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:90%;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;\">Cover page from the Company\u2019s Annual Report on Form 10-K for the year ended December 31, 2023, formatted in Inline XBRL.</p></td></tr></table><table style=\"border-collapse:collapse;border:0;\"><tr><td style=\"width:1pt;padding:0pt;\"></td><td style=\"vertical-align:text-top;white-space:nowrap;width:53.45pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;\"><b style=\"font-weight:bold;\">Item 16.</b></p></td><td style=\"padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;\"><b style=\"font-weight:bold;\">Form 10-K Summary</b></p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:95%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"></div></div></td><td style=\"vertical-align:bottom;width:5%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:95%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><a href=\"#ReportofIndependentRegisteredPublicAccou\"><span style=\"font-style:normal;font-weight:normal;letter-spacing:0.2pt;\">Report of Independent Registered Public Accounting Firm </span></a><span style=\"letter-spacing:0.2pt;\">(</span> <span style=\"letter-spacing:0.2pt;\">KPMG LLP</span> <span style=\"letter-spacing:0.2pt;\">, </span> <span style=\"letter-spacing:0.2pt;\">Short Hills, New Jersey</span> <span style=\"letter-spacing:0.2pt;\">; PCAOB# </span> <span style=\"letter-spacing:0.2pt;\">185</span> <span style=\"letter-spacing:0.2pt;\">)</span></p></td><td style=\"vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;\">F-2</p></td></tr><tr><td style=\"vertical-align:bottom;width:95%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><a href=\"#CONSOLIDATEDBALANCESHEETS_981334\"><span style=\"font-style:normal;font-weight:normal;letter-spacing:0.2pt;\">Consolidated Balance Sheets as of December 31, 2023 and 2022</span></a></p></td><td style=\"vertical-align:bottom;width:5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;\">F-3 </p></td></tr><tr><td style=\"vertical-align:bottom;width:95%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><a href=\"#CONSOLIDATEDSTATEMENTSOFOPERATIONS_12697\"><span style=\"font-style:normal;font-weight:normal;letter-spacing:0.2pt;\">Consolidated Statements of Operations for the years ended December 31, 2023 and 2022</span></a></p></td><td style=\"vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;\">F-4</p></td></tr><tr><td style=\"vertical-align:bottom;width:95%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><a href=\"#CONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOL\"><span style=\"font-style:normal;font-weight:normal;letter-spacing:0.2pt;\">Consolidated Statement of Changes in Stockholders\u2019 Equity for the years ended December 31, 2023 and 2022</span></a></p></td><td style=\"vertical-align:bottom;width:5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;\">F-5 </p></td></tr><tr><td style=\"vertical-align:bottom;width:95%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><a href=\"#CONSOLIDATEDSTATEMENTSOFCASHFLOWS_859125\"><span style=\"font-style:normal;font-weight:normal;letter-spacing:0.2pt;\">Consolidated Statements of Cash Flows for the years ended December 31, 2023 and 2022</span></a></p></td><td style=\"vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;\">F-6 </p></td></tr><tr><td style=\"vertical-align:bottom;width:95%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><a href=\"#NOTE1ORGANIZATIONANDPLANOFBUSINESSOPERAT\"><span style=\"font-style:normal;font-weight:normal;letter-spacing:0.2pt;\">Notes to Consolidated Financial Statements </span></a></p></td><td style=\"vertical-align:bottom;width:5%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;\">F-7</p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"5\" style=\"vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">December 31, </b></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2022</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">ASSETS</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Current assets</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;\">Cash and cash equivalents</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  27,439 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  32,003 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;\">Accounts receivable, net of reserves</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  15,222 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  28,208 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;\">Inventory</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  10,206 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  14,159 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;\">Prepaid expenses and other current assets</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  3,588 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  3,309 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Total current assets</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  56,455 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  77,679 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;\">Intangible assets, net</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  20,287 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  27,197 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;\">Operating lease right-of-use asset, net</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  101 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  189 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;\">Other assets</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  6 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  95 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Total assets</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  76,849 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  105,160 </b></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">LIABILITIES AND STOCKHOLDERS\u2019 EQUITY</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Current liabilities</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;\">Accounts payable</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  18,149 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  36,570 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;\"><span style=\"-sec-ix-hidden:Hidden_KcnowGjCYUCLzAfxEbp_tg;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;\">Due to related party</span></span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  195 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  413 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;\">Accrued expenses</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  20,350 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  19,388 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;\">Accrued interest</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  22 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  160 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;\">Income taxes payable</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  53 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  35 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;\">Line of credit</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  2,948 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;\">Deferred cash payment, net of discount</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  4,991 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;\">Installment payments \u2013 licenses, short-term</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  3,000 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  2,244 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;\">Operating lease liability, short-term</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  99 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  83 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Total current liabilities</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  41,868 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  66,832 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Term loan, net of discount</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  14,622 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  19,826 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Installment payments \u2013 licenses, long-term</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  1,412 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Operating lease liability, long-term</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  9 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  108 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Total liabilities</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  56,499 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  88,178 </b></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Commitments and contingencies (Note 14)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Stockholders\u2019 equity </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;\"><span style=\"font-size:9pt;\">Common stock, </span><span style=\"font-size:9pt;\">$  .0001  </span><span style=\"font-size:9pt;\"> par value, </span><span style=\"font-size:9pt;\">  50,000,000  </span><span style=\"font-size:9pt;\"> shares authorized, </span><span style=\"font-size:9pt;\"> 13,323,952 </span><span style=\"font-size:9pt;\"> and </span><span style=\"font-size:9pt;\"> 11,765,700 </span><span style=\"font-size:9pt;\"> shares </span><span style=\"-sec-ix-hidden:Hidden_m2FjlSHkEUCwZhjSnlAjMg;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;\">issued</span></span><span style=\"font-size:9pt;\"> and </span><span style=\"-sec-ix-hidden:Hidden_x6DMvBdT00GPccCqOE4XtA;\"><span style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;\">outstanding</span></span><span style=\"font-size:9pt;\"> as of December 31, 2023 and December 31, 2022, respectively</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  1 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  1 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;\">Common stock - Class A, $  .0001   par value,   50,000,000   shares authorized,   6,000,000   shares issued and outstanding as of December 31, 2023 and December 31, 2022</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  1 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  1 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;\">Additional paid-in capital</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  92,703 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  85,482 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;\">Accumulated deficit</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 72,355 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 68,502 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;\">Total stockholders\u2019 equity</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  20,350 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  16,982 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Total liabilities and stockholders\u2019 equity</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  76,849 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:9pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  105,160 </b></p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"5\" style=\"vertical-align:bottom;white-space:nowrap;width:23.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Year Ended December 31, </b></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2022</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Revenue:</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\">Product revenue, net</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  59,662 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  70,995 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\">Other revenue</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  19,519 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  2,674 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Total revenue</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  79,181 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  73,669 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Operating expenses</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\">Cost of goods sold\u2009\u2013\u2009product revenue </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  26,660 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  30,775 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\">Research and development</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  7,541 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  10,943 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\">Selling, general and administrative</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  43,910 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  59,468 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\">Loss on impairment of intangible assets</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  3,143 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td></tr><tr><td style=\"vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Total operating expenses</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  81,254 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  101,186 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Loss from operations</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 2,073 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 27,517 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Other expense (income)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\">Interest income </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 322 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 60 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\">Interest expense </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  1,698 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  2,019 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\">Foreign exchange transaction losses</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  183 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  89 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Total other expense (income)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  1,559 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  2,048 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Loss before income taxes</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\"> ( 3,632 )</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\"> ( 29,565 )</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Income tax expense</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  221 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  63 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Net Loss</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\"> ( 3,853 )</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\"> ( 29,628 )</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Net loss per common share:</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;\">Basic and diluted</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> (  0.21  )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> (  1.69  )</p></td></tr><tr><td style=\"vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Weighted average number of common shares:</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;\">Basic and diluted</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">   18,232,422  </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">   17,531,274  </p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:35.49%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;width:7.59%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.61%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.85%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.47%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:35.49%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"4\" style=\"vertical-align:bottom;white-space:nowrap;width:16.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"4\" style=\"vertical-align:bottom;white-space:nowrap;width:15.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Additional</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Total</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:35.49%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td colspan=\"4\" style=\"vertical-align:bottom;white-space:nowrap;width:16.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Common Stock</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td colspan=\"4\" style=\"vertical-align:bottom;white-space:nowrap;width:15.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Common Stock A</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Paid-in</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">(Accumulated</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Shareholders\u2019</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:35.49%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Shares</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Amount</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Shares</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Amount</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Capital</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Deficit)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Equity</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:35.49%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Balance as of December 31, 2021</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  11,316,344 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.61%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  1 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  6,000,000 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.38%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  1 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.47%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  80,915 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\"> ( 38,874 )</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  42,043 </b></p></td></tr><tr><td style=\"vertical-align:bottom;width:35.49%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Share-based compensation</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.61%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  \u2014 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  4,425 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  4,425 </p></td></tr><tr><td style=\"vertical-align:bottom;width:35.49%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Exercise of stock options for cash</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  155,649 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.61%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  \u2014 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.38%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.47%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  142 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  142 </p></td></tr><tr><td style=\"vertical-align:bottom;width:35.49%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Issuance of common stock for vested restricted stock units</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  293,707 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.61%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  \u2014 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td></tr><tr><td style=\"vertical-align:bottom;width:35.49%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Net loss</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  \u2014 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 29,628 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 29,628 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:35.49%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Balance as of December 31, 2022</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  11,765,700 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.61%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  1 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  6,000,000 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  1 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  85,482 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\"> ( 68,502 )</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  16,982 </b></p></td></tr><tr><td style=\"vertical-align:bottom;width:35.49%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Share-based compensation </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.61%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  \u2014 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.38%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.47%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  2,606 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  2,606 </p></td></tr><tr><td style=\"vertical-align:bottom;width:35.49%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Exercise of stock options for cash</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  82,300 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.61%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  \u2014 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  121 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  121 </p></td></tr><tr><td style=\"vertical-align:bottom;width:35.49%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Issuance of common stock for vested restricted stock units</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  727,249 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.61%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  \u2014 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.38%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.47%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td></tr><tr><td style=\"vertical-align:bottom;width:35.49%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Issuance of common stock, ATM offering, net of issuance costs of $ 140 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  748,703 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.61%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  \u2014 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  4,494 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  4,494 </p></td></tr><tr><td style=\"vertical-align:bottom;width:35.49%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Net loss</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  \u2014 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 3,853 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 3,853 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:35.49%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Balance as of December 31, 2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  13,323,952 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  1 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  6,000,000 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  1 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:6.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  92,703 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\"> ( 72,355 )</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  20,350 </b></p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;\"><span style=\"font-size:6.5pt;margin-left:0pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-size:6.5pt;font-weight:bold;\">\u00a0</b></p></td><td colspan=\"5\" style=\"vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-size:6.5pt;font-weight:bold;\"> Year Ended</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;\"><span style=\"font-size:6.5pt;margin-left:0pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"5\" style=\"vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-size:6.5pt;font-weight:bold;\">December 31, </b></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-size:6.5pt;font-weight:bold;\">2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-size:6.5pt;font-weight:bold;\">2022</b></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-size:6.5pt;font-weight:bold;\">Cash flows from operating activities</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">Net loss</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">$</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\"> ( 3,853 )</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">$</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\"> ( 29,628 )</span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 6pt;\"><span style=\"font-size:6.5pt;\">Bad debt expense</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">  435 </span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">  284 </span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 6pt;\"><span style=\"font-size:6.5pt;\">Non-cash interest expense</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">  353 </span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">  770 </span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 6pt;\"><span style=\"font-size:6.5pt;\">Amortization of debt discount</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">  356 </span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">  63 </span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 6pt;\"><span style=\"font-size:6.5pt;\">Amortization of acquired intangible assets</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">  3,767 </span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">  4,277 </span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 6pt;\"><span style=\"font-size:6.5pt;\">Amortization of operating lease right-of-use assets</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">  88 </span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">  88 </span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 6pt;\"><span style=\"font-size:6.5pt;\">Share-based compensation</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">  2,606 </span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">  4,425 </span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 6pt;\"><span style=\"font-size:6.5pt;\">Loss on impairment of intangible assets</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">  3,143 </span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">-</span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 6pt;\"><span style=\"font-size:6.5pt;\">Changes in operating assets and liabilities:</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 12pt;\"><span style=\"font-size:6.5pt;\">Accounts receivable</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">  12,551 </span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\"> ( 5,380 )</span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 12pt;\"><span style=\"font-size:6.5pt;\">Inventory</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">  3,953 </span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">  1,744 </span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 12pt;\"><span style=\"font-size:6.5pt;\">Prepaid expenses and other current assets</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\"> ( 279 )</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\"> ( 871 )</span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 12pt;\"><span style=\"font-size:6.5pt;\">Other assets</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\"> \u2014</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">  55 </span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 12pt;\"><span style=\"font-size:6.5pt;\">Accounts payable</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\"> ( 18,421 )</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">  14,343 </span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 12pt;\"><span style=\"font-size:6.5pt;\">Related party expenses</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\"> ( 218 )</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\"> ( 228 )</span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 12pt;\"><span style=\"font-size:6.5pt;\">Accrued expenses</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">  962 </span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\"> ( 3,568 )</span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 12pt;\"><span style=\"font-size:6.5pt;\">Accrued interest</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\"> ( 138 )</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">  160 </span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 12pt;\"><span style=\"font-size:6.5pt;\">Income tax payable</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">  18 </span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">  27 </span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 12pt;\"><span style=\"font-size:6.5pt;\">Lease liabilities</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\"> ( 83 )</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\"> ( 95 )</span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">Net cash provided by (used in) operating activities</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">  5,240 </span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\"> ( 13,534 )</span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-size:6.5pt;font-weight:bold;\">Cash flows from investing activities</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 12pt;\"><span style=\"font-size:6.5pt;\">Acquired intangible assets</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\"> ( 5,000 )</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\"> ( 20,000 )</span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">Net cash (used in) investing activities</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\"> ( 5,000 )</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\"> ( 20,000 )</span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-size:6.5pt;font-weight:bold;\">Cash flows from financing activities</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 12pt;\"><span style=\"font-size:6.5pt;\">Proceeds from the exercise of stock options</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">  121 </span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">  142 </span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 12pt;\"><span style=\"font-size:6.5pt;\">Payment of license installment note payable</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\"> ( 1,000 )</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\"> ( 5,000 )</span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 12pt;\"><span style=\"font-size:6.5pt;\">Payment of debt issuance costs associated with convertible preferred shares</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\"> \u2014</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\"> ( 214 )</span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 12pt;\"><span style=\"font-size:6.5pt;\">Proceeds from line of credit</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">  28,000 </span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">  5,000 </span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 12pt;\"><span style=\"font-size:6.5pt;\">Repayment of line of credit</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\"> ( 30,948 )</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">( 2,864 )</span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 12pt;\"><span style=\"font-size:6.5pt;\">Proceeds from term-loan</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\"> 15,000 </span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">  19,763 </span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 12pt;\"><span style=\"font-size:6.5pt;\">Repayment of EWB term-loan</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\"> ( 20,000 )</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\"> \u2014</span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 12pt;\"><span style=\"font-size:6.5pt;\">Payment of issuance costs associated with EWB term-loan modification</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\"> ( 91 )</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\"> \u2014</span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 12pt;\"><span style=\"font-size:6.5pt;\">Payment of issuance costs associated with issuance of SWK term-loan</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\"> ( 380 )</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\"> \u2014</span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 12pt;\"><span style=\"font-size:6.5pt;\">Proceeds from issuance of common stock, ATM offering, net of issuance costs</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">  4,494 </span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\"> \u2014</span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 12pt;\"><span style=\"font-size:6.5pt;\">Offering costs for the issuance of common stock - initial public offering</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\"> \u2014</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\"> ( 371 )</span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">Net cash (used in) provided by financing activities</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\"> ( 4,804 )</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">  16,456 </span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;\"><span style=\"font-size:6.5pt;margin-left:0pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">Net change in cash</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\"> ( 4,564 )</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\"> ( 17,078 )</span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">Cash at the beginning of the period</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">  32,003 </span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">  49,081 </span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-size:6.5pt;font-weight:bold;\">Cash at the end of the period</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-size:6.5pt;font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;\"><b style=\"font-size:6.5pt;font-weight:bold;\">  27,439 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-size:6.5pt;font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;\"><b style=\"font-size:6.5pt;font-weight:bold;\">  32,003 </b></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-size:6.5pt;font-weight:bold;\">Supplemental disclosure of cash flow information:</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">\u00a0</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">Cash paid for interest</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">$</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">  1,127 </span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">$</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">  993 </span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">Cash paid for income taxes</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">$</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">  181 </span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">$</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\"> 168 </span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-size:6.5pt;font-weight:bold;\">Supplemental disclosure of non-cash financing and investing activities:</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 6pt;\"><span style=\"font-size:6.5pt;\">Deferred payment for asset acquisition</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">$</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\"> \u2014</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">$</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">  4,740 </span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 6pt;\"><span style=\"font-size:6.5pt;\">ROU assets obtained in exchange for lease liabilities</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">$</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\"> \u2014</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">$</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;\"><span style=\"font-size:6.5pt;\">  188 </span></p></td></tr></table>",
        "<table style=\"border-collapse:collapse;border:0;\"><tr><td style=\"width:36pt;padding:0pt;\"></td><td style=\"vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;\"><i style=\"font-style:italic;\">Level 1</i>: </p></td><td style=\"padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;\">Quoted prices in active markets for identical assets or liabilities.</p></td></tr></table><table style=\"border-collapse:collapse;border:0;\"><tr><td style=\"width:36pt;padding:0pt;\"></td><td style=\"vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;\"><i style=\"font-style:italic;\">Level 2</i>:</p></td><td style=\"padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;\">Observable inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.</p></td></tr></table><table style=\"border-collapse:collapse;border:0;\"><tr><td style=\"width:36pt;padding:0pt;\"></td><td style=\"vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;\"><i style=\"font-style:italic;\">Level 3</i>:</p></td><td style=\"padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;\">Unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.</p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;white-space:nowrap;width:73.9%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"5\" style=\"vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">December 31, </b></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><i style=\"font-style:italic;\">($\u2019s in thousands)</i></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2022</b></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Raw materials</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  4,640 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  6,454 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Work-in-process</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  884 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  395 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Finished goods</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  4,987 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  7,739 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Inventory at cost</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  10,511 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  14,588 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Inventory reserves</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 305 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 429 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Total Inventories</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  10,206 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  14,159 </b></p></td></tr></table><table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:83.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:14.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Aggregate </b></p></td></tr><tr><td style=\"vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-style:italic;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:14.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Consideration </b></p></td></tr><tr><td style=\"vertical-align:bottom;width:83.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><i style=\"font-style:italic;\">($\u2019s in thousands)</i></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:14.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Transferred</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Consideration transferred to Vyne at closing</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  20,000 </p></td></tr><tr><td style=\"vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Fair Value of deferred cash payment due January 2023</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  4,740 </p></td></tr><tr><td style=\"vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Transaction costs</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  223 </p></td></tr><tr><td style=\"vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Total consideration transferred at closing</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  24,963 </b></p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:83.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:14.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Assets </b></p></td></tr><tr><td style=\"vertical-align:bottom;width:83.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><i style=\"font-style:italic;\">($\u2019s in thousands)</i></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:14.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Recognized</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Inventory</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  6,041 </p></td></tr><tr><td style=\"vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Identifiable intangibles:</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">Amzeeq intangible</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  15,162 </p></td></tr><tr><td style=\"vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">Zilxi intangible</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  3,760 </p></td></tr><tr><td style=\"vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><b style=\"font-weight:bold;\">Fair value of net identifiable assets acquired</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><b style=\"font-weight:bold;\">  24,963 </b></p></td></tr></table><table style=\"border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:63.62%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:63.62%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Estimated</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"5\" style=\"vertical-align:bottom;white-space:nowrap;width:19.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">December 31,</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:63.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><i style=\"font-style:italic;\">($\u2019s in thousands)</i></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Useful Lives (Years)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2022</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:63.62%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Intangible assets - product licenses</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">  3  -  9  </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  37,925 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  37,925 </p></td></tr><tr><td style=\"vertical-align:bottom;width:63.62%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\">Accumulated amortization</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 14,495 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 10,728 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:63.62%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\">Accumulated impairment loss</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 3,143 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td></tr><tr><td style=\"vertical-align:bottom;width:63.62%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Total intangible assets</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  20,287 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  27,197 </b></p></td></tr></table><table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Total</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:84.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><i style=\"font-style:italic;\">For the years ended</i></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Amortization</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">December 31, 2024</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  3,257 </p></td></tr><tr><td style=\"vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">December 31, 2025</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  3,257 </p></td></tr><tr><td style=\"vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">December 31, 2026</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  2,471 </p></td></tr><tr><td style=\"vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">December 31, 2027</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  1,775 </p></td></tr><tr><td style=\"vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Thereafter</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  5,585 </p></td></tr><tr><td style=\"vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Subtotal</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  16,345 </p></td></tr><tr><td style=\"vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Asset not yet placed in service</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  3,942 </p></td></tr><tr><td style=\"vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Total</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  20,287 </b></p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:54.01%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:54.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"11\" style=\"vertical-align:bottom;white-space:nowrap;width:44.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\"> December 31, 2023</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:54.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><i style=\"font-style:italic;\">($\u2019s in thousands)</i></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Level 1</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Level 2</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Level 3</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Total</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:54.01%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><b style=\"font-weight:bold;\">Assets</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:54.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Cash and cash equivalents</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  27,439 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  27,439 </p></td></tr><tr><td style=\"vertical-align:bottom;width:54.01%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><b style=\"font-weight:bold;\">Total</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><b style=\"font-weight:bold;\">  27,439 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><b style=\"font-weight:bold;\"> \u2014</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><b style=\"font-weight:bold;\"> \u2014</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><b style=\"font-weight:bold;\">  27,439 </b></p></td></tr></table><table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.01%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:54.01%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:54.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"11\" style=\"vertical-align:bottom;white-space:nowrap;width:44.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">December 31, 2022</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:54.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><i style=\"font-style:italic;\">($\u2019s in thousands)</i></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Level 1</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Level 2</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Level 3</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Total</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:54.01%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Assets</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:54.01%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Cash and cash equivalents</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  32,003 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  32,003 </p></td></tr><tr><td style=\"vertical-align:bottom;width:54.01%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Total</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  32,003 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\"> \u2014</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\"> \u2014</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  32,003 </b></p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"5\" style=\"vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">December 31, </b></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><i style=\"font-style:italic;\">($\u2019s in thousands)</i></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">2022</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Accrued expenses and other short-term liabilities:</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;\">Accrued coupons and rebates</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  9,987 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  7,604 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;\">Accrued compensation</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  3,374 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  2,586 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;\">Accrued royalties payable</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  2,015 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  2,627 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;\">Return reserve</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  4,077 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  3,689 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;\">Accrued inventory</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  352 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  112 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;\">Accrued research and development</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  20 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  1,404 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;\">Accrued legal, accounting and tax</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  185 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  334 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;\">Accrued iPledge program</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  174 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  447 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;\">Other</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  166 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  585 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\"><b style=\"font-weight:bold;\">Total accrued expenses</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><b style=\"font-weight:bold;\">  20,350 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><b style=\"font-weight:bold;\">  19,388 </b></p></td></tr></table><table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:65.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td colspan=\"8\" style=\"vertical-align:bottom;white-space:nowrap;width:32.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">December 31, 2023</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:65.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><i style=\"font-style:italic;\">($\u2019s in thousands)</i></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Short-Term</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Long-Term</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Total</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:65.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Installment payments - licenses</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  3,000 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  3,000 </p></td></tr><tr><td style=\"vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Less: imputed interest</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td></tr><tr><td style=\"vertical-align:bottom;width:65.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Sub-total installment payments - licenses</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  3,000 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\"> \u2014</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  3,000 </b></p></td></tr></table><table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:65.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td colspan=\"8\" style=\"vertical-align:bottom;white-space:nowrap;width:32.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">December 31, 2022</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:65.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><i style=\"font-style:italic;\">($\u2019s in thousands)</i></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Short-Term</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Long-Term</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Total</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:65.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Installment payments - licenses</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  2,500 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  1,500 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  4,000 </p></td></tr><tr><td style=\"vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Less: imputed interest</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 256 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 88 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 344 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:65.35%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Sub-total installment payments - licenses</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  2,244 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  1,412 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  3,656 </b></p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:69.9%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:69.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"5\" style=\"vertical-align:bottom;white-space:nowrap;width:28.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">For the Years Ended December 31, </b></p></td></tr><tr><td style=\"vertical-align:bottom;width:69.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:12.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">2022</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:69.9%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Operating lease cost</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  97 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  93 </p></td></tr><tr><td style=\"vertical-align:bottom;width:69.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Variable lease cost</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  5 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  4 </p></td></tr><tr><td style=\"vertical-align:bottom;width:69.9%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><b style=\"font-weight:bold;\">Total lease cost</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><b style=\"font-weight:bold;\">  102 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><b style=\"font-weight:bold;\">  97 </b></p></td></tr></table><table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:67.67%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:67.67%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"5\" style=\"vertical-align:bottom;white-space:nowrap;width:28.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">For the Years Ended December 31, </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:67.67%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2022</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:67.67%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Cash paid for amounts included in the measurement of lease liabilities</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  92 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  100 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:67.67%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Right-of-use assets exchanged for new operating lease liabilities</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  188 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:67.67%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Weighted-average remaining lease term - operating leases </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  1.1 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  2.1 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:67.67%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Weighted-average discount rate - operating leases </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  6.25 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">% </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  6.25 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">%</p></td></tr></table><table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:80.98%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:80.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:16.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:80.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">For the year ended December 31,</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:16.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><i style=\"font-style:italic;\">($\u2019s in thousands)</i></p></td></tr><tr><td style=\"vertical-align:bottom;width:80.98%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">2024</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  102 </p></td></tr><tr><td style=\"vertical-align:bottom;width:80.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">2025</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  9 </p></td></tr><tr><td style=\"vertical-align:bottom;width:80.98%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Total lease payments</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  111 </p></td></tr><tr><td style=\"vertical-align:bottom;width:80.98%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Less: present value discount</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 3 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:80.98%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Total operating lease liabilities</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  108 </b></p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">December 31,</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:84.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><i style=\"font-style:italic;\">($\u2019s in thousands)</i></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2023</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-style:italic;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Principal balance</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  15,000 </p></td></tr><tr><td style=\"vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Plus: Exit fee</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  750 </p></td></tr><tr><td style=\"vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Less: Debt discount and fees</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 1,128 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Net carry amount (Long-term)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  14,622 </b></p></td></tr></table><table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:63.86%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td colspan=\"10\" style=\"vertical-align:bottom;white-space:nowrap;width:100%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">December 31, 2022</b>\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:63.86%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Net</b>\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:63.86%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Principal</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Unamortized</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Carry</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:63.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><i style=\"font-style:italic;\">($\u2019s in thousands)</i></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Balance</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Discount &amp; Fees</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Amount</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:63.86%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-style:italic;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:63.86%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Deferred cash payment</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  5,000 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  9 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  4,991 </p></td></tr><tr><td style=\"vertical-align:bottom;width:63.86%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">EWB Revolving LOC</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  2,948 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  2,948 </p></td></tr><tr><td style=\"vertical-align:bottom;width:63.86%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Total Short-Term Debt</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  7,948 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  9 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  7,939 </b></p></td></tr><tr><td style=\"vertical-align:bottom;width:63.86%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">EWB Term Loan (Long-term)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  20,000 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  174 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  19,826 </p></td></tr><tr><td style=\"vertical-align:bottom;width:63.86%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Total Debt &amp; Obligations</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  27,948 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  183 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  27,765 </b></p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:84.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Years ending December 31,</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Term Loan</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:84.97%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">2024</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td></tr><tr><td style=\"vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">2025</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td></tr><tr><td style=\"vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">2026</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  4,500 </p></td></tr><tr><td style=\"vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">2027</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  11,250 </p></td></tr><tr><td style=\"vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Total</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  15,750 </p></td></tr><tr><td style=\"vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Debt discount</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 1,128 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Total, net</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  14,622 </p></td></tr><tr><td style=\"vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Current portion</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td></tr><tr><td style=\"vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Term-loan (long-term)</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  14,622 </b></p></td></tr></table><table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"5\" style=\"vertical-align:bottom;white-space:nowrap;width:28.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Year Ended December 31, </b></p></td></tr><tr><td style=\"vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2022</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Interest payments on term loans and LOC</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  989 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  1,153 </p></td></tr><tr><td style=\"vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Amortization/accretion</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  356 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  347 </p></td></tr><tr><td style=\"vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Imputed interest on acquired intangible assets </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  353 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  519 </p></td></tr><tr><td style=\"vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Total interest expense and financing fees</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  1,698 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  2,019 </b></p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"5\" style=\"vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Year Ended December 31,</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;\"><i style=\"font-style:italic;\">($\u2019s in thousands)</i></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">2022</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;\">Research and development</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  110 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  73 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;\">Selling, general and administrative</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  2,496 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  4,352 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;\"><b style=\"font-weight:bold;\">Total non-cash compensation expense related to share-based compensation included in operating expense</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><b style=\"font-weight:bold;\">  2,606 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><b style=\"font-weight:bold;\">  4,425 </b></p></td></tr></table><table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:80.77%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:17.36%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:80.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:17.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2023</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:80.77%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Risk-free interest rate</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:17.36%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"> 3.45 % -  4.44 %</p></td></tr><tr><td style=\"vertical-align:bottom;width:80.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Expected volatility</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:17.36%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"> 89.09 % -  101.75 %</p></td></tr><tr><td style=\"vertical-align:bottom;width:80.77%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Weighted average expected volatility</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:17.36%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"> 91.08 %</p></td></tr><tr><td style=\"vertical-align:bottom;width:80.77%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Expected term (years)</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:17.36%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"> 5.37  -  6.25 </p></td></tr><tr><td style=\"vertical-align:bottom;width:80.77%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Expected dividend yield</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:17.36%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"> 0 %</p></td></tr></table><table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:middle;width:52.66%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"position:absolute;top:50%;transform:translate(0,-50%);width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Weighted</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Weighted</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\"> average</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Number</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\"> average</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Aggregate</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">remaining</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">of</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">exercise</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">intrinsic</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">contractual </b></p></td></tr><tr><td style=\"vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Shares</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\"> price</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\"> value</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">life (years)</b></p></td></tr><tr><td style=\"vertical-align:middle;width:52.66%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Outstanding options at December 31, 2022</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  2,960,000 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  1.76 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  2,217,815 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  5.65 </p></td></tr><tr><td style=\"vertical-align:middle;width:52.66%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Granted</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  430,756 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  1.64 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td></tr><tr><td style=\"vertical-align:middle;width:52.66%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Exercised</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 82,300 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  1.46 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td></tr><tr><td style=\"vertical-align:middle;width:52.66%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Forfeited</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 504,687 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  3.06 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td></tr><tr><td style=\"vertical-align:bottom;width:52.66%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Expired</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 33,900 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  3.58 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td></tr><tr><td style=\"vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Outstanding options at December 31, 2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  2,769,869 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  1.49 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:middle;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  3,441,146 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> <b style=\"font-weight:bold;\"> 4.53</b> </p></td></tr><tr><td style=\"vertical-align:bottom;width:52.66%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Options vested and exercisable at December 31, 2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  1,984,475 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  0.96 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:middle;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  1,758,134 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> <b style=\"font-weight:bold;\"> 2.83</b> </p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;white-space:nowrap;width:72.45%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:72.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Weighted</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:72.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">average</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:72.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Number of</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">grant date</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:72.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\"> units</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Fair value</b></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:72.45%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\">Unvested balance at December 31, 2022</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  2,261,048 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  4.05 </p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:72.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;\">Granted</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  119,888 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  1.82 </p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:72.45%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;\">Vested</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 727,249 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  3.96 </p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:72.45%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;\">Forfeited</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;\"> ( 346,764 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  4.10 </p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:72.45%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Unvested balance at December 31, 2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  1,306,923 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  3.88 </b></p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"5\" style=\"vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Year Ended December 31, </b></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:73.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\"><i style=\"font-style:italic;\">($ in thousands)</i></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2022</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Qbrexza\u00ae</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  25,410 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> 26,715 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Accutane\u00ae</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  20,168 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> 18,373 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Amzeeq</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  6,201 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> 7,242 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Targadox\u00ae</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  3,204 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  7,972 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Exelderm\u00ae</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  2,395 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  3,463 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Zilxi</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  1,962 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  2,273 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Ximino\u00ae</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  287 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  4,957 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Luxamend\u00ae</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  35 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"> \u2014</p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\"><b style=\"font-weight:bold;\">Total product revenues</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  59,662 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  70,995 </b></p></td></tr></table><table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"5\" style=\"vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Year Ended December 31,</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><i style=\"font-style:italic;\">($in thousands)</i></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">\u00a0</b></p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">2022</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Non-refundable upfront payment from Maruho</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  19,000 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Net milestone payment from Maruho</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  2,500 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Royalties on sales of Rapifort\u00ae Wipes  2.5 %</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  519 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  174 </p></td></tr><tr><td style=\"vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\"><b style=\"font-weight:bold;\">Total other revenue</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><b style=\"font-weight:bold;\">  19,519 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><b style=\"font-weight:bold;\">  2,674 </b></p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"5\" style=\"vertical-align:bottom;white-space:nowrap;width:26.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"color:#231f20;font-weight:bold;\">Years Ended December 31, </b></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:71.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><i style=\"font-style:italic;\">($\u2019s in thousands)</i></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">2022</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><b style=\"font-weight:bold;\">Current:</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">Federal</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  34 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td></tr><tr><td style=\"vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">State</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  187 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  63 </p></td></tr><tr><td style=\"vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Total current</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  221 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  63 </p></td></tr><tr><td style=\"vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><b style=\"font-weight:bold;\">Deferred:</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">Federal</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 753 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 6,701 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">State</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 94 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 1,737 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Total deferred</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 847 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 8,438 )</p></td></tr><tr><td style=\"vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Valuation allowance </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  847 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  8,438 </p></td></tr><tr><td style=\"vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><b style=\"font-weight:bold;\">Total income tax expense</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><b style=\"font-weight:bold;\">  221 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><b style=\"font-weight:bold;\">  63 </b></p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;white-space:nowrap;width:71.44%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"5\" style=\"vertical-align:bottom;white-space:nowrap;width:26.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">December 31, </b></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:71.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\"><i style=\"font-style:italic;\">($\u2019s in thousands)</i></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td colspan=\"2\" style=\"vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">2022</b></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><b style=\"font-weight:bold;\">Deferred tax assets:</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:71.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">Net operating loss carryforwards</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  4,376 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">$</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  6,553 </p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">Amortization of license fees</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  5,603 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  4,951 </p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:71.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">R&amp;D capitalization</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  3,312 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  2,462 </p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">Stock compensation</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  1,081 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  1,293 </p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:71.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">Lease liability</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  27 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  48 </p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">Reserve on sales return, discount and bad debt</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  3,566 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  2,988 </p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:71.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">Accruals and reserves</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  723 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  574 </p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">Tax credits</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  1,491 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  1,152 </p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:71.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">Business interest expense deduction limit</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  322 </p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">State taxes</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  13 </p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:71.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Total deferred tax assets</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  20,179 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  20,356 </p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Less: valuation allowance</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 20,154 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 19,307 )</p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:71.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><b style=\"font-weight:bold;\">Deferred tax assets, net</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><b style=\"font-weight:bold;\">  25 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><b style=\"font-weight:bold;\">  1,049 </b></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:71.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><b style=\"font-weight:bold;\">Deferred tax liability:</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">Section 481(a) adjustment on reserve on sales return, discount and bad debt</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"> \u2014</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 1,001 )</p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:71.44%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">Right-of-use asset</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 25 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 48 )</p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><b style=\"font-weight:bold;\">Deferred tax assets, net</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><b style=\"font-weight:bold;\"> \u2014</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><b style=\"font-weight:bold;\">$</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\"><b style=\"font-weight:bold;\"> \u2014</b></p></td></tr></table><table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:72.27%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:72.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td colspan=\"3\" style=\"vertical-align:bottom;white-space:nowrap;width:23.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Years Ended December 31, </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:72.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">2022</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;\">\u00a0</p></td></tr><tr><td style=\"vertical-align:bottom;width:72.27%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><b style=\"font-weight:bold;\">Percentage of pre-tax income:</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:72.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">U.S. federal statutory income tax rate</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  21 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">% </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  21 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">%</p></td></tr><tr><td style=\"vertical-align:bottom;width:72.27%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">State taxes, net of federal benefit</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 1 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">% </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  4 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">%</p></td></tr><tr><td style=\"vertical-align:bottom;width:72.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">Non-deductible items</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 4 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">% </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">( 0 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">%</p></td></tr><tr><td style=\"vertical-align:bottom;width:72.27%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">Provision to return</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 1 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">% </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  0 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">%</p></td></tr><tr><td style=\"vertical-align:bottom;width:72.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">State tax adjustments</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 1 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">% </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  0 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">%</p></td></tr><tr><td style=\"vertical-align:bottom;width:72.27%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">Change in valuation allowance</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 23 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">% </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 28 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">%</p></td></tr><tr><td style=\"vertical-align:bottom;width:72.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">Share-based compensation</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\"> ( 10 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">% </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  0 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">% </p></td></tr><tr><td style=\"vertical-align:bottom;width:72.27%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;\">Tax credits</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  13 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">% </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;\">  3 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">%</p></td></tr><tr><td style=\"vertical-align:bottom;width:72.27%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Effective income tax rate</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">( 6 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">% </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;\">( 0 )</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">%</p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:74.23%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:1pt;visibility:hidden;\">\u200b</span></p></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:74.23%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td colspan=\"3\" style=\"vertical-align:bottom;white-space:nowrap;width:25.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Year ended December 31,</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:74.23%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-size:8pt;font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2023</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">2022</b></p></td></tr><tr><td style=\"vertical-align:bottom;width:74.23%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Basic and diluted</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  18,232,422 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  17,531,274 </p></td></tr><tr><td style=\"vertical-align:bottom;width:74.23%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\">Potentially dilutive securities:</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:bottom;width:74.23%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\">Unvested restricted stock units</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  1,306,923 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  2,261,048 </p></td></tr><tr><td style=\"vertical-align:bottom;white-space:nowrap;width:74.23%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;\">Stock options</p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  1,345,193 </p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\">  1,566,131 </p></td></tr><tr><td style=\"vertical-align:bottom;width:74.23%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">Total potentially dilutive securities</b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  20,884,538 </b></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;\"><span style=\"font-weight:bold;visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;\"><b style=\"font-weight:bold;\">  21,358,453 </b></p></td></tr></table>",
        "<table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;\"><tr><td style=\"vertical-align:top;width:50%;margin:0pt;padding:0.25pt;\"></td><td colspan=\"2\" style=\"vertical-align:top;width:50%;margin:0pt;padding:0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\"><b style=\"font-weight:bold;\">Journey Medical Corporation</b></p></td></tr><tr><td style=\"vertical-align:top;width:50%;margin:0pt;padding:0.25pt;\"></td><td style=\"vertical-align:top;width:3.34%;margin:0pt;padding:0.25pt;\"></td><td style=\"vertical-align:top;width:46.65%;margin:0pt;padding:0.25pt;\"></td></tr><tr><td style=\"vertical-align:top;width:50%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;\"></td><td style=\"vertical-align:top;width:3.34%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">By:</p></td><td style=\"vertical-align:top;width:46.65%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">/s/ Claude Maraoui</p></td></tr><tr><td style=\"vertical-align:top;width:50%;margin:0pt;padding:0.25pt;\"></td><td style=\"vertical-align:top;width:3.34%;margin:0pt;padding:0.25pt;\"></td><td style=\"vertical-align:top;width:46.65%;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Name: Claude Maraoui</p></td></tr><tr><td style=\"vertical-align:top;width:50%;margin:0pt;padding:0.25pt;\"></td><td style=\"vertical-align:top;width:3.34%;margin:0pt;padding:0.25pt;\"></td><td style=\"vertical-align:top;width:46.65%;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">Title: President, Chief Executive Officer, and Director</p></td></tr><tr><td style=\"vertical-align:top;width:50%;margin:0pt;padding:0.25pt;\"></td><td style=\"vertical-align:top;width:3.34%;margin:0pt;padding:0.25pt;\"></td><td style=\"vertical-align:top;width:46.65%;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;\">March 28, 2024</p></td></tr></table><table style=\"border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;\"><tr style=\"height:1pt;\"><td style=\"vertical-align:bottom;width:30%;margin:0pt;padding:0.25pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"></div></div></td><td style=\"vertical-align:top;width:2%;margin:0pt;padding:0.25pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"position:absolute;top:0pt;width:100%;\"></div></div></td><td style=\"vertical-align:bottom;width:43%;margin:0pt;padding:0.25pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"></div></div></td><td style=\"vertical-align:top;width:2%;margin:0pt;padding:0.25pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"position:absolute;top:0pt;width:100%;\"></div></div></td><td style=\"vertical-align:bottom;width:22.99%;margin:0pt;padding:0.25pt;\"><div style=\"height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;\"><div style=\"bottom:0pt;position:absolute;width:100%;\"></div></div></td></tr><tr><td style=\"vertical-align:bottom;width:30%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Signature</b></p></td><td style=\"vertical-align:top;width:2%;margin:0pt;padding:0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;width:43%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Title</b></p></td><td style=\"vertical-align:top;width:2%;margin:0pt;padding:0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">\u00a0</p></td><td style=\"vertical-align:bottom;width:22.99%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><b style=\"font-weight:bold;\">Date</b></p></td></tr><tr><td style=\"vertical-align:top;width:30%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\">/s/ Claude Maraoui</p></td><td style=\"vertical-align:top;width:2%;margin:0pt;padding:0.25pt;\"></td><td style=\"vertical-align:middle;width:43%;margin:0pt;padding:0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">President, Chief Executive Officer and Director</p></td><td style=\"vertical-align:top;width:2%;margin:0pt;padding:0.25pt;\"></td><td style=\"vertical-align:top;width:22.99%;margin:0pt;padding:0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">March 28, 2024</p></td></tr><tr><td style=\"vertical-align:top;width:30%;border-top:1px solid #000000;margin:0pt;padding:0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\">Claude Maraoui</p></td><td style=\"vertical-align:top;width:2%;margin:0pt;padding:0.25pt;\"></td><td style=\"vertical-align:middle;width:43%;margin:0pt;padding:0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">(Principal Executive Officer) </p></td><td style=\"vertical-align:top;width:2%;margin:0pt;padding:0.25pt;\"></td><td style=\"vertical-align:top;width:22.99%;margin:0pt;padding:0.25pt;\"></td></tr><tr><td style=\"vertical-align:top;width:30%;margin:0pt;padding:0.25pt;\"></td><td style=\"vertical-align:top;width:2%;margin:0pt;padding:0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:middle;width:43%;margin:0pt;padding:0.25pt;\"></td><td style=\"vertical-align:top;width:2%;margin:0pt;padding:0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:middle;width:22.99%;margin:0pt;padding:0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:30%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\">/s/ Lindsay A. Rosenwald, M.D.</p></td><td style=\"vertical-align:top;width:2%;margin:0pt;padding:0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:middle;width:43%;margin:0pt;padding:0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">Executive Chairman</p></td><td style=\"vertical-align:top;width:2%;margin:0pt;padding:0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:middle;width:22.99%;margin:0pt;padding:0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">March 28, 2024</p></td></tr><tr><td style=\"vertical-align:top;width:30%;border-top:1px solid #000000;margin:0pt;padding:0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\">Lindsay A. Rosenwald, M.D. </p></td><td style=\"vertical-align:top;width:2%;margin:0pt;padding:0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:middle;width:43%;margin:0pt;padding:0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:2%;margin:0pt;padding:0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:22.99%;margin:0pt;padding:0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:30%;margin:0pt;padding:0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:2%;margin:0pt;padding:0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:middle;width:43%;margin:0pt;padding:0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:2%;margin:0pt;padding:0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:22.99%;margin:0pt;padding:0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:30%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\">/s/ Joseph Benesch</p></td><td style=\"vertical-align:top;width:2%;margin:0pt;padding:0.25pt;\"></td><td style=\"vertical-align:middle;width:43%;margin:0pt;padding:0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">Interim Chief Financial Officer</p></td><td style=\"vertical-align:top;width:2%;margin:0pt;padding:0.25pt;\"></td><td style=\"vertical-align:top;width:22.99%;margin:0pt;padding:0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">March 28, 2024</p></td></tr><tr><td style=\"vertical-align:top;width:30%;border-top:1px solid #000000;margin:0pt;padding:0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\">Joseph Benesch</p></td><td style=\"vertical-align:top;width:2%;margin:0pt;padding:0.25pt;\"></td><td style=\"vertical-align:middle;width:43%;margin:0pt;padding:0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">(Principal Financial Officer)</p></td><td style=\"vertical-align:top;width:2%;margin:0pt;padding:0.25pt;\"></td><td style=\"vertical-align:top;width:22.99%;margin:0pt;padding:0.25pt;\"></td></tr><tr><td style=\"vertical-align:top;width:30%;margin:0pt;padding:0.25pt;\"></td><td style=\"vertical-align:top;width:2%;margin:0pt;padding:0.25pt;\"></td><td style=\"vertical-align:middle;width:43%;margin:0pt;padding:0.25pt;\"></td><td style=\"vertical-align:top;width:2%;margin:0pt;padding:0.25pt;\"></td><td style=\"vertical-align:top;width:22.99%;margin:0pt;padding:0.25pt;\"></td></tr><tr><td style=\"vertical-align:top;width:30%;margin:0pt;padding:0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:2%;margin:0pt;padding:0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:middle;width:43%;margin:0pt;padding:0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:2%;margin:0pt;padding:0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:22.99%;margin:0pt;padding:0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:30%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\">/s/ Neil Herskowitz</p></td><td style=\"vertical-align:top;width:2%;margin:0pt;padding:0.25pt;\"></td><td style=\"vertical-align:middle;width:43%;margin:0pt;padding:0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">Director</p></td><td style=\"vertical-align:top;width:2%;margin:0pt;padding:0.25pt;\"></td><td style=\"vertical-align:top;width:22.99%;margin:0pt;padding:0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">March 28, 2024</p></td></tr><tr><td style=\"vertical-align:top;width:30%;border-top:1px solid #000000;margin:0pt;padding:0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\">Neil Herskowitz</p></td><td style=\"vertical-align:top;width:2%;margin:0pt;padding:0.25pt;\"></td><td style=\"vertical-align:middle;width:43%;margin:0pt;padding:0.25pt;\"></td><td style=\"vertical-align:top;width:2%;margin:0pt;padding:0.25pt;\"></td><td style=\"vertical-align:top;width:22.99%;margin:0pt;padding:0.25pt;\"></td></tr><tr><td style=\"vertical-align:top;width:30%;margin:0pt;padding:0.25pt;\"></td><td style=\"vertical-align:top;width:2%;margin:0pt;padding:0.25pt;\"></td><td style=\"vertical-align:middle;width:43%;margin:0pt;padding:0.25pt;\"></td><td style=\"vertical-align:top;width:2%;margin:0pt;padding:0.25pt;\"></td><td style=\"vertical-align:top;width:22.99%;margin:0pt;padding:0.25pt;\"></td></tr><tr><td style=\"vertical-align:top;width:30%;margin:0pt;padding:0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:2%;margin:0pt;padding:0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:middle;width:43%;margin:0pt;padding:0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:2%;margin:0pt;padding:0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td><td style=\"vertical-align:top;width:22.99%;margin:0pt;padding:0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\"><span style=\"visibility:hidden;\">\u200b</span></p></td></tr><tr><td style=\"vertical-align:top;width:30%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\">/s/ Justin Smith</p></td><td style=\"vertical-align:top;width:2%;margin:0pt;padding:0.25pt;\"></td><td style=\"vertical-align:middle;width:43%;margin:0pt;padding:0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">Director</p></td><td style=\"vertical-align:top;width:2%;margin:0pt;padding:0.25pt;\"></td><td style=\"vertical-align:top;width:22.99%;margin:0pt;padding:0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;\">March 28, 2024</p></td></tr><tr><td style=\"vertical-align:top;width:30%;border-top:1px solid #000000;margin:0pt;padding:0.25pt;\"><p style=\"font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;\">Justin Smith</p></td><td style=\"vertical-align:top;width:2%;margin:0pt;padding:0.25pt;\"></td><td style=\"vertical-align:middle;width:43%;margin:0pt;padding:0.25pt;\"></td><td style=\"vertical-align:top;width:2%;margin:0pt;padding:0.25pt;\"></td><td style=\"vertical-align:top;width:22.99%;margin:0pt;padding:0.25pt;\"></td></tr><tr><td style=\"vertical-align:top;width:30%;margin:0pt;padding:0.25pt;\"></td><td style=\"vertical-align:top;width:2%;margin:0pt;padding:0.25pt;\"></td><td style=\"vertical-align:middle;width:43%;margin:0pt;padding:0.25pt;\"></td><td style=\"vertical-align:top;width:2%;margin:0pt;padding:0.25pt;\"></td><td style=\"vertical-align:top;width:22.99%;margin:0pt;padding:0.25pt;\"></td></tr></table>"
    ]
}